{ "version": "2.2", "instance": { "revb-20230930.htm": { "nsprefix": "revb", "nsuri": "http://revbiosciences.com/20230930", "dts": { "inline": { "local": [ "revb-20230930.htm" ] }, "schema": { "local": [ "revb-20230930.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "calculationLink": { "local": [ "revb-20230930_cal.xml" ] }, "definitionLink": { "local": [ "revb-20230930_def.xml" ] }, "labelLink": { "local": [ "revb-20230930_lab.xml" ] }, "presentationLink": { "local": [ "revb-20230930_pre.xml" ] } }, "keyStandard": 191, "keyCustom": 81, "axisStandard": 13, "axisCustom": 1, "memberStandard": 20, "memberCustom": 33, "hidden": { "total": 10, "http://xbrl.sec.gov/dei/2023": 4, "http://fasb.org/us-gaap/2023": 6 }, "contextCount": 235, "entityCount": 1, "segmentCount": 54, "elementCount": 499, "unitCount": 8, "baseTaxonomies": { "http://fasb.org/us-gaap/2023": 525, "http://xbrl.sec.gov/dei/2023": 31 }, "report": { "R1": { "role": "http://revbiosciences.com/20230930/taxonomy/role/DocumentAndEntityInformation", "longName": "100000 - Document - Document And Entity Information", "shortName": "Document And Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "C_a2ffd6bb-9ae3-4806-847e-03d3069d41f2", "name": "dei:EntityRegistrantName", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "revb-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_a2ffd6bb-9ae3-4806-847e-03d3069d41f2", "name": "dei:EntityRegistrantName", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "revb-20230930.htm", "first": true, "unique": true } }, "R2": { "role": "http://revbiosciences.com/20230930/taxonomy/role/StatementConsolidatedBalanceSheets1", "longName": "100010 - Statement - Consolidated Balance Sheets", "shortName": "Consolidated Balance Sheets", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "C_381d79b2-8505-4100-916f-6aa520de5404", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "revb-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_ab107eb2-e7c0-4ed9-90f0-c32fb25259b5", "name": "us-gaap:DeferredOfferingCosts", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "revb-20230930.htm", "unique": true } }, "R3": { "role": "http://revbiosciences.com/20230930/taxonomy/role/StatementConsolidatedBalanceSheetsParentheticals", "longName": "100020 - Statement - Consolidated Balance Sheets (Parentheticals)", "shortName": "Consolidated Balance Sheets (Parentheticals)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "C_381d79b2-8505-4100-916f-6aa520de5404", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "unitRef": "U_UnitedStatesOfAmericaDollarsShare", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "us-gaap:PreferredStockTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "revb-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_65dfc1f4-4ddf-4e3e-862e-8adfe9ed38e6", "name": "us-gaap:PreferredStockSharesOutstanding", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "revb-20230930.htm", "unique": true } }, "R4": { "role": "http://revbiosciences.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfOperations", "longName": "100030 - Statement - Consolidated Statements of Operations", "shortName": "Consolidated Statements of Operations", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "C_3ece7038-93c4-42c6-a2b7-7fd74d30629a", "name": "us-gaap:ResearchAndDevelopmentExpense", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "revb-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_3ece7038-93c4-42c6-a2b7-7fd74d30629a", "name": "us-gaap:ResearchAndDevelopmentExpense", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "revb-20230930.htm", "first": true, "unique": true } }, "R5": { "role": "http://revbiosciences.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquityDeficit", "longName": "100040 - Statement - Consolidated Statements of Changes in Stockholders' Equity (Deficit)", "shortName": "Consolidated Statements of Changes in Stockholders' Equity (Deficit)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "C_ab8862f3-e7ea-46f0-a1df-947fc4ff0c55", "name": "us-gaap:StockholdersEquity", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "revb-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_1e85016c-7969-41d3-abf4-6788883dcc02", "name": "revb:IssuanceOfCommonStockInConnectionWithTheBusinessCombinationNet", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "revb-20230930.htm", "unique": true } }, "R6": { "role": "http://revbiosciences.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfCashFlows", "longName": "100050 - Statement - Consolidated Statements of Cash Flows", "shortName": "Consolidated Statements of Cash Flows", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "C_a2ffd6bb-9ae3-4806-847e-03d3069d41f2", "name": "us-gaap:NetIncomeLoss", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "revb-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_a2ffd6bb-9ae3-4806-847e-03d3069d41f2", "name": "us-gaap:ShareBasedCompensation", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "revb-20230930.htm", "unique": true } }, "R7": { "role": "http://revbiosciences.com/20230930/taxonomy/role/DisclosureOrganizationAndBasisOfPresentation", "longName": "100060 - Disclosure - Organization and Basis of Presentation", "shortName": "Organization and Basis of Presentation", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "7", "firstAnchor": { "contextRef": "C_a2ffd6bb-9ae3-4806-847e-03d3069d41f2", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "revb-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_a2ffd6bb-9ae3-4806-847e-03d3069d41f2", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "revb-20230930.htm", "first": true, "unique": true } }, "R8": { "role": "http://revbiosciences.com/20230930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies1", "longName": "100070 - Disclosure - Summary of Significant Accounting Policies", "shortName": "Summary of Significant Accounting Policies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "C_a2ffd6bb-9ae3-4806-847e-03d3069d41f2", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "revb-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_a2ffd6bb-9ae3-4806-847e-03d3069d41f2", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "revb-20230930.htm", "first": true, "unique": true } }, "R9": { "role": "http://revbiosciences.com/20230930/taxonomy/role/DisclosureBalanceSheetDetails", "longName": "100090 - Disclosure - Balance Sheet Details", "shortName": "Balance Sheet Details", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "C_a2ffd6bb-9ae3-4806-847e-03d3069d41f2", "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "revb-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_a2ffd6bb-9ae3-4806-847e-03d3069d41f2", "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "revb-20230930.htm", "first": true, "unique": true } }, "R10": { "role": "http://revbiosciences.com/20230930/taxonomy/role/revb_r_CommitmentsandContingencies", "longName": "100100 - Disclosure - Commitments and Contingencies", "shortName": "Commitments and Contingencies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "C_a2ffd6bb-9ae3-4806-847e-03d3069d41f2", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "revb-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_a2ffd6bb-9ae3-4806-847e-03d3069d41f2", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "revb-20230930.htm", "first": true, "unique": true } }, "R11": { "role": "http://revbiosciences.com/20230930/taxonomy/role/DisclosurePipeInvestment1", "longName": "100110 - Disclosure - PIPE Investment", "shortName": "PIPE Investment", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "C_a2ffd6bb-9ae3-4806-847e-03d3069d41f2", "name": "revb:PIPEInvestmentOrSecuritiesPurchaseAgreementTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "revb-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_a2ffd6bb-9ae3-4806-847e-03d3069d41f2", "name": "revb:PIPEInvestmentOrSecuritiesPurchaseAgreementTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "revb-20230930.htm", "first": true, "unique": true } }, "R12": { "role": "http://revbiosciences.com/20230930/taxonomy/role/Disclosure2022PublicOffering1", "longName": "100120 - Disclosure - 2022 Public Offering", "shortName": "2022 Public Offering", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "C_a2ffd6bb-9ae3-4806-847e-03d3069d41f2", "name": "revb:ProposedPublicOfferingTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "revb-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_a2ffd6bb-9ae3-4806-847e-03d3069d41f2", "name": "revb:ProposedPublicOfferingTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "revb-20230930.htm", "first": true, "unique": true } }, "R13": { "role": "http://revbiosciences.com/20230930/taxonomy/role/Disclosure2023PublicOffering", "longName": "100130 - Disclosure - 2023 Public Offering", "shortName": "2023 Public Offering", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "C_a2ffd6bb-9ae3-4806-847e-03d3069d41f2", "name": "revb:TwoThousandTwentyThreePublicOfferingTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "revb-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_a2ffd6bb-9ae3-4806-847e-03d3069d41f2", "name": "revb:TwoThousandTwentyThreePublicOfferingTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "revb-20230930.htm", "first": true, "unique": true } }, "R14": { "role": "http://revbiosciences.com/20230930/taxonomy/role/DisclosurePreferredStock1", "longName": "100140 - Disclosure - Preferred Stock", "shortName": "Preferred Stock", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "C_a2ffd6bb-9ae3-4806-847e-03d3069d41f2", "name": "us-gaap:PreferredStockTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "revb-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_a2ffd6bb-9ae3-4806-847e-03d3069d41f2", "name": "us-gaap:PreferredStockTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "revb-20230930.htm", "first": true, "unique": true } }, "R15": { "role": "http://revbiosciences.com/20230930/taxonomy/role/DisclosureUnits1", "longName": "100150 - Disclosure - Units", "shortName": "Units", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "C_a2ffd6bb-9ae3-4806-847e-03d3069d41f2", "name": "revb:UnitsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "revb-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_a2ffd6bb-9ae3-4806-847e-03d3069d41f2", "name": "revb:UnitsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "revb-20230930.htm", "first": true, "unique": true } }, "R16": { "role": "http://revbiosciences.com/20230930/taxonomy/role/DisclosureCommonStock1", "longName": "100160 - Disclosure - Common Stock", "shortName": "Common Stock", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "C_a2ffd6bb-9ae3-4806-847e-03d3069d41f2", "name": "revb:CommonStockTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "revb-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_a2ffd6bb-9ae3-4806-847e-03d3069d41f2", "name": "revb:CommonStockTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "revb-20230930.htm", "first": true, "unique": true } }, "R17": { "role": "http://revbiosciences.com/20230930/taxonomy/role/DisclosureStockbasedCompensation", "longName": "100170 - Disclosure - Stock-Based Compensation", "shortName": "Stock-Based Compensation", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "C_a2ffd6bb-9ae3-4806-847e-03d3069d41f2", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "revb-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_a2ffd6bb-9ae3-4806-847e-03d3069d41f2", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "revb-20230930.htm", "first": true, "unique": true } }, "R18": { "role": "http://revbiosciences.com/20230930/taxonomy/role/DisclosureWarrants1", "longName": "100180 - Disclosure - Warrants", "shortName": "Warrants", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "C_a2ffd6bb-9ae3-4806-847e-03d3069d41f2", "name": "revb:WarrantsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "revb-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_a2ffd6bb-9ae3-4806-847e-03d3069d41f2", "name": "revb:WarrantsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "revb-20230930.htm", "first": true, "unique": true } }, "R19": { "role": "http://revbiosciences.com/20230930/taxonomy/role/revb_r_IncomeTaxes", "longName": "100190 - Disclosure - Income Taxes", "shortName": "Income Taxes", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "C_a2ffd6bb-9ae3-4806-847e-03d3069d41f2", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "revb-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_a2ffd6bb-9ae3-4806-847e-03d3069d41f2", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "revb-20230930.htm", "first": true, "unique": true } }, "R20": { "role": "http://revbiosciences.com/20230930/taxonomy/role/revb_r_SubsequentEvents", "longName": "100200 - Disclosure - Subsequent Events", "shortName": "Subsequent Events", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "20", "firstAnchor": { "contextRef": "C_a2ffd6bb-9ae3-4806-847e-03d3069d41f2", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "revb-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_a2ffd6bb-9ae3-4806-847e-03d3069d41f2", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "revb-20230930.htm", "first": true, "unique": true } }, "R21": { "role": "http://revbiosciences.com/20230930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies", "longName": "100210 - Disclosure - Summary of Significant Accounting Policies (Policies)", "shortName": "Summary of Significant Accounting Policies (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "21", "firstAnchor": { "contextRef": "C_a2ffd6bb-9ae3-4806-847e-03d3069d41f2", "name": "us-gaap:UseOfEstimates", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "revb-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_a2ffd6bb-9ae3-4806-847e-03d3069d41f2", "name": "us-gaap:UseOfEstimates", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "revb-20230930.htm", "first": true, "unique": true } }, "R22": { "role": "http://revbiosciences.com/20230930/taxonomy/role/DisclosureBalanceSheetDetailsTables", "longName": "100220 - Disclosure - Balance Sheet Details (Tables)", "shortName": "Balance Sheet Details (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "22", "firstAnchor": { "contextRef": "C_a2ffd6bb-9ae3-4806-847e-03d3069d41f2", "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "revb-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_a2ffd6bb-9ae3-4806-847e-03d3069d41f2", "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "revb-20230930.htm", "first": true, "unique": true } }, "R23": { "role": "http://revbiosciences.com/20230930/taxonomy/role/DisclosureCommonStockTables", "longName": "100230 - Disclosure - Common Stock (Tables)", "shortName": "Common Stock (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "23", "firstAnchor": { "contextRef": "C_a2ffd6bb-9ae3-4806-847e-03d3069d41f2", "name": "revb:CommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "revb:CommonStockTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "revb-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_a2ffd6bb-9ae3-4806-847e-03d3069d41f2", "name": "revb:CommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "revb:CommonStockTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "revb-20230930.htm", "first": true, "unique": true } }, "R24": { "role": "http://revbiosciences.com/20230930/taxonomy/role/DisclosureStockbasedCompensationTables", "longName": "100240 - Disclosure - Stock-Based Compensation (Tables)", "shortName": "Stock-Based Compensation (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "24", "firstAnchor": { "contextRef": "C_a2ffd6bb-9ae3-4806-847e-03d3069d41f2", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "revb-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_a2ffd6bb-9ae3-4806-847e-03d3069d41f2", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "revb-20230930.htm", "first": true, "unique": true } }, "R25": { "role": "http://revbiosciences.com/20230930/taxonomy/role/DisclosureWarrantsTables", "longName": "100250 - Disclosure - Warrants (Tables)", "shortName": "Warrants (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "25", "firstAnchor": { "contextRef": "C_a2ffd6bb-9ae3-4806-847e-03d3069d41f2", "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "revb-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_529090e1-57ee-448e-af89-eb2967ac406c", "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "revb:WarrantsTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "revb-20230930.htm", "unique": true } }, "R26": { "role": "http://revbiosciences.com/20230930/taxonomy/role/DisclosureOrganizationAndBasisOfPresentationDetails", "longName": "100270 - Disclosure - Organization and Basis of Presentation (Details)", "shortName": "Organization and Basis of Presentation (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "26", "firstAnchor": { "contextRef": "C_a2ffd6bb-9ae3-4806-847e-03d3069d41f2", "name": "revb:UnitsSeparatedIntoCommonStockAndPublicWarrantDescription", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "revb-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_a2ffd6bb-9ae3-4806-847e-03d3069d41f2", "name": "revb:UnitsSeparatedIntoCommonStockAndPublicWarrantDescription", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "revb-20230930.htm", "first": true, "unique": true } }, "R27": { "role": "http://revbiosciences.com/20230930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails", "longName": "100280 - Disclosure - Summary of Significant Accounting Policies (Details)", "shortName": "Summary of Significant Accounting Policies (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "27", "firstAnchor": { "contextRef": "C_381d79b2-8505-4100-916f-6aa520de5404", "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "div", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "revb-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_3ece7038-93c4-42c6-a2b7-7fd74d30629a", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "us-gaap:EarningsPerSharePolicyTextBlock", "div", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "revb-20230930.htm", "unique": true } }, "R28": { "role": "http://revbiosciences.com/20230930/taxonomy/role/DisclosureBusinessCombinationDetails", "longName": "100290 - Disclosure - Business Combination (Details)", "shortName": "Business Combination (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "28", "firstAnchor": { "contextRef": "C_381d79b2-8505-4100-916f-6aa520de5404", "name": "us-gaap:CommonStockParOrStatedValuePerShare", "unitRef": "U_UnitedStatesOfAmericaDollarsShare", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "revb-20230930.htm", "first": true }, "uniqueAnchor": null }, "R29": { "role": "http://revbiosciences.com/20230930/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails", "longName": "100300 - Disclosure - Balance Sheet Details - Schedule of Prepaid Expenses and Other Current Assets (Details)", "shortName": "Balance Sheet Details - Schedule of Prepaid Expenses and Other Current Assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "29", "firstAnchor": { "contextRef": "C_381d79b2-8505-4100-916f-6aa520de5404", "name": "revb:PrepaidClinicalCostsCurrent", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "div", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "revb-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_381d79b2-8505-4100-916f-6aa520de5404", "name": "revb:PrepaidClinicalCostsCurrent", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "div", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "revb-20230930.htm", "first": true, "unique": true } }, "R30": { "role": "http://revbiosciences.com/20230930/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfPropertyAndEquipmentNetDetails", "longName": "100310 - Disclosure - Balance Sheet Details - Schedule of Property and Equipment, Net (Details)", "shortName": "Balance Sheet Details - Schedule of Property and Equipment, Net (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "30", "firstAnchor": { "contextRef": "C_381d79b2-8505-4100-916f-6aa520de5404", "name": "us-gaap:MachineryAndEquipmentGross", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "div", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "revb-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_381d79b2-8505-4100-916f-6aa520de5404", "name": "us-gaap:MachineryAndEquipmentGross", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "div", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "revb-20230930.htm", "first": true, "unique": true } }, "R31": { "role": "http://revbiosciences.com/20230930/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfAccruedExpensesDetails", "longName": "100320 - Disclosure - Balance Sheet Details - Schedule of Accrued Expenses (Details)", "shortName": "Balance Sheet Details - Schedule of Accrued Expenses (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "31", "firstAnchor": { "contextRef": "C_381d79b2-8505-4100-916f-6aa520de5404", "name": "us-gaap:EmployeeRelatedLiabilitiesCurrentAndNoncurrent", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "div", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "revb-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_381d79b2-8505-4100-916f-6aa520de5404", "name": "us-gaap:EmployeeRelatedLiabilitiesCurrentAndNoncurrent", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "div", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "revb-20230930.htm", "first": true, "unique": true } }, "R32": { "role": "http://revbiosciences.com/20230930/taxonomy/role/DisclosureBalanceSheetDetailsDetails", "longName": "100330 - Disclosure - Balance Sheet Details (Details)", "shortName": "Balance Sheet Details (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "32", "firstAnchor": { "contextRef": "C_3ece7038-93c4-42c6-a2b7-7fd74d30629a", "name": "us-gaap:Depreciation", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "revb-20230930.htm", "first": true }, "uniqueAnchor": null }, "R33": { "role": "http://revbiosciences.com/20230930/taxonomy/role/revb_r_CommitmentsandContingenciesDetails", "longName": "100340 - Disclosure - Commitments and Contingencies (Details)", "shortName": "Commitments and Contingencies (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "33", "firstAnchor": { "contextRef": "C_60f4a6ac-3d14-4325-8407-1d4eb4ece0ba", "name": "revb:LesseeOperatingLeaseLiabilityBaseMonthlyRent", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "revb-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_60f4a6ac-3d14-4325-8407-1d4eb4ece0ba", "name": "revb:LesseeOperatingLeaseLiabilityBaseMonthlyRent", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "revb-20230930.htm", "first": true, "unique": true } }, "R34": { "role": "http://revbiosciences.com/20230930/taxonomy/role/DisclosurePipeInvestmentDetails", "longName": "100350 - Disclosure - PIPE Investment (Details)", "shortName": "PIPE Investment (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "34", "firstAnchor": { "contextRef": "C_381d79b2-8505-4100-916f-6aa520de5404", "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "td", "tr", "table", "revb:CommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock", "div", "revb:CommonStockTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "revb-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_ad50ba6d-67a0-46d0-8067-f18c34c53588", "name": "revb:WarrantsAndRightExpirationDate", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "revb:PIPEInvestmentOrSecuritiesPurchaseAgreementTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "revb-20230930.htm", "unique": true } }, "R35": { "role": "http://revbiosciences.com/20230930/taxonomy/role/Disclosure2022PublicOfferingDetails", "longName": "100360 - Disclosure - 2022 Public Offering (Details)", "shortName": "2022 Public Offering (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "35", "firstAnchor": { "contextRef": "C_0a223f09-41c9-4eab-832c-0aa879a9fbd6", "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "revb:TwoThousandTwentyThreePublicOfferingTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "revb-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_7a2deae8-a4cd-4e06-98c7-69281aabcc83", "name": "revb:ClassOfWarrantOrRightIssued", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "revb:ProposedPublicOfferingTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "revb-20230930.htm", "unique": true } }, "R36": { "role": "http://revbiosciences.com/20230930/taxonomy/role/Disclosure2023PublicOfferingDetails", "longName": "100370 - Disclosure - 2023 Public Offering (Details)", "shortName": "2023 Public Offering (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "36", "firstAnchor": { "contextRef": "C_0a223f09-41c9-4eab-832c-0aa879a9fbd6", "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "revb:TwoThousandTwentyThreePublicOfferingTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "revb-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_9314ba57-b228-4c7d-88c9-3ad9fdc27912", "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "revb:TwoThousandTwentyThreePublicOfferingTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "revb-20230930.htm", "unique": true } }, "R37": { "role": "http://revbiosciences.com/20230930/taxonomy/role/DisclosurePreferredStockDetails", "longName": "100380 - Disclosure - Preferred Stock (Details)", "shortName": "Preferred Stock (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "37", "firstAnchor": { "contextRef": "C_381d79b2-8505-4100-916f-6aa520de5404", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "unitRef": "U_UnitedStatesOfAmericaDollarsShare", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "us-gaap:PreferredStockTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "revb-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_d2060c3f-f3ae-42b0-89f4-5b56c8c2ac82", "name": "us-gaap:PreferredStockSharesAuthorized", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "us-gaap:PreferredStockTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "revb-20230930.htm", "unique": true } }, "R38": { "role": "http://revbiosciences.com/20230930/taxonomy/role/DisclosureUnitsDetails", "longName": "100390 - Disclosure - Units (Details)", "shortName": "Units (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "38", "firstAnchor": { "contextRef": "C_a2ffd6bb-9ae3-4806-847e-03d3069d41f2", "name": "revb:ClassOfWarrantOrRightForIssuingDescription", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "revb:UnitsTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "revb-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_a2ffd6bb-9ae3-4806-847e-03d3069d41f2", "name": "revb:ClassOfWarrantOrRightForIssuingDescription", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "revb:UnitsTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "revb-20230930.htm", "first": true, "unique": true } }, "R39": { "role": "http://revbiosciences.com/20230930/taxonomy/role/DisclosureCommonStockDetails", "longName": "100400 - Disclosure - Common Stock (Details)", "shortName": "Common Stock (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "39", "firstAnchor": { "contextRef": "C_f1f09818-5016-445d-a97e-035a78515339", "name": "us-gaap:CommonStockSharesAuthorized", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "revb:CommonStockTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "revb-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_e15d53e1-8eed-412f-884f-53d27f2ee689", "name": "us-gaap:StockholdersEquityReverseStockSplit", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "revb:CommonStockTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "revb-20230930.htm", "unique": true } }, "R40": { "role": "http://revbiosciences.com/20230930/taxonomy/role/DisclosureCommonStockSummaryOfTotalSharesOfCommonStockReservedForIssuanceDetails", "longName": "100410 - Disclosure - Common Stock - Summary of Total Shares of Common Stock Reserved for Issuance (Details)", "shortName": "Common Stock - Summary of Total Shares of Common Stock Reserved for Issuance (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "40", "firstAnchor": { "contextRef": "C_381d79b2-8505-4100-916f-6aa520de5404", "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "td", "tr", "table", "revb:CommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock", "div", "revb:CommonStockTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "revb-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_b680c7ed-4a2c-4140-805e-2c09c9fcb914", "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "td", "tr", "table", "revb:CommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock", "div", "revb:CommonStockTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "revb-20230930.htm", "unique": true } }, "R41": { "role": "http://revbiosciences.com/20230930/taxonomy/role/DisclosureCommonStockSummaryOfTotalSharesOfCommonStockReservedForIssuanceParentheticalDetails", "longName": "100420 - Disclosure - Common Stock - Summary of Total Shares of Common Stock Reserved for Issuance (Parenthetical) (Details)", "shortName": "Common Stock - Summary of Total Shares of Common Stock Reserved for Issuance (Parenthetical) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "parenthetical", "menuCat": "Details", "order": "41", "firstAnchor": { "contextRef": "C_5738da7e-3dbe-4fca-b8fc-e53f80cbc8e7", "name": "us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "unitRef": "U_UnitedStatesOfAmericaDollarsShare", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "span", "p", "td", "tr", "table", "revb:CommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock", "div", "revb:CommonStockTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "revb-20230930.htm", "first": true }, "uniqueAnchor": null }, "R42": { "role": "http://revbiosciences.com/20230930/taxonomy/role/DisclosureStockbasedCompensationDetails", "longName": "100430 - Disclosure - Stock-Based Compensation (Details)", "shortName": "Stock-Based Compensation (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "42", "firstAnchor": { "contextRef": "C_83da391f-7423-4ed1-8ac5-56c954a896a8", "name": "revb:PercentageOfAggregateNumberOfOutstandingSharesOfCommonStock", "unitRef": "U_pure", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "span", "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "revb-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_83da391f-7423-4ed1-8ac5-56c954a896a8", "name": "revb:PercentageOfAggregateNumberOfOutstandingSharesOfCommonStock", "unitRef": "U_pure", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "span", "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "revb-20230930.htm", "first": true, "unique": true } }, "R43": { "role": "http://revbiosciences.com/20230930/taxonomy/role/DisclosureStockbasedCompensationScheduleOfStockOptionsActivityDetails", "longName": "100440 - Disclosure - Stock-Based Compensation - Schedule of Stock Options Activity (Details)", "shortName": "Stock-Based Compensation - Schedule of Stock Options Activity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "43", "firstAnchor": { "contextRef": "C_8ff77589-ca53-4c2e-a812-86ee1da6619d", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "revb-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_8ff77589-ca53-4c2e-a812-86ee1da6619d", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "revb-20230930.htm", "first": true, "unique": true } }, "R44": { "role": "http://revbiosciences.com/20230930/taxonomy/role/DisclosureStockbasedCompensationAssumptionsUsedInEstimatingFairValueOfStockOptionsDetails", "longName": "100450 - Disclosure - Stock-Based Compensation - Assumptions used in Estimating Fair Value of Stock Options (Details)", "shortName": "Stock-Based Compensation - Assumptions used in Estimating Fair Value of Stock Options (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "44", "firstAnchor": { "contextRef": "C_bbf65be7-84b3-4a65-a2fd-4ddb3757484a", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "unitRef": "U_pure", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": [ "span", "p", "td", "tr", "table", "ix:continuation", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "revb-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_bbf65be7-84b3-4a65-a2fd-4ddb3757484a", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "unitRef": "U_pure", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": [ "span", "p", "td", "tr", "table", "ix:continuation", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "revb-20230930.htm", "first": true, "unique": true } }, "R45": { "role": "http://revbiosciences.com/20230930/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockbasedCompensationExpenseDetails", "longName": "100460 - Disclosure - Stock-Based Compensation - Summary of Stock-Based Compensation Expense (Details)", "shortName": "Stock-Based Compensation - Summary of Stock-Based Compensation Expense (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "45", "firstAnchor": { "contextRef": "C_3ece7038-93c4-42c6-a2b7-7fd74d30629a", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "revb-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_0b4caec3-2f0f-4304-a4c4-20a9a609f34d", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "revb-20230930.htm", "unique": true } }, "R46": { "role": "http://revbiosciences.com/20230930/taxonomy/role/DisclosureWarrantsDetails", "longName": "100470 - Disclosure - Warrants (Details)", "shortName": "Warrants (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "46", "firstAnchor": { "contextRef": "C_381d79b2-8505-4100-916f-6aa520de5404", "name": "us-gaap:CommonStockSharesIssued", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "revb-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_529090e1-57ee-448e-af89-eb2967ac406c", "name": "us-gaap:ProceedsFromIssuanceOfWarrants", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "revb:WarrantsTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "revb-20230930.htm", "unique": true } }, "R47": { "role": "http://revbiosciences.com/20230930/taxonomy/role/DisclosureWarrantsScheduleOfFairValueOfWarrantsEstimatedUsingBlackscholesOptionPricingModelDetails", "longName": "100480 - Disclosure - Warrants - Schedule of Fair Value of Warrants Estimated Using Black-Scholes Option Pricing Model (Details)", "shortName": "Warrants - Schedule of Fair Value of Warrants Estimated Using Black-Scholes Option Pricing Model (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "47", "firstAnchor": { "contextRef": "C_529090e1-57ee-448e-af89-eb2967ac406c", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "unitRef": "U_pure", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "div", "revb:WarrantsTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "revb-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_529090e1-57ee-448e-af89-eb2967ac406c", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "unitRef": "U_pure", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "div", "revb:WarrantsTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "revb-20230930.htm", "first": true, "unique": true } }, "R48": { "role": "http://revbiosciences.com/20230930/taxonomy/role/revb_r_IncomeTaxesDetails", "longName": "100490 - Disclosure - Income Taxes (Details)", "shortName": "Income Taxes (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "48", "firstAnchor": { "contextRef": "C_3ece7038-93c4-42c6-a2b7-7fd74d30629a", "name": "us-gaap:IncomeTaxExpenseBenefit", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "revb-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_3ece7038-93c4-42c6-a2b7-7fd74d30629a", "name": "us-gaap:IncomeTaxExpenseBenefit", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "revb-20230930.htm", "first": true, "unique": true } } }, "tag": { "us-gaap_WarrantsNotSettleableInCashFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WarrantsNotSettleableInCashFairValueDisclosure", "crdr": "credit", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DisclosureWarrantsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair value of warrants", "label": "Warrants Not Settleable in Cash, Fair Value Disclosure", "documentation": "Fair value portion of warrants not settleable in cash classified as equity." } } }, "auth_ref": [ "r58" ] }, "us-gaap_DividendsCommonStockCash": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DividendsCommonStockCash", "crdr": "debit", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DisclosureCommonStockDetails" ], "lang": { "en-us": { "role": { "label": "Dividends, Common Stock, Cash", "terseLabel": "Cash dividends declared or paid", "documentation": "Amount of paid and unpaid common stock dividends declared with the form of settlement in cash." } } }, "auth_ref": [ "r92" ] }, "revb_ClosingBidPriceOfCommonStockPerShare": { "xbrltype": "perShareItemType", "nsuri": "http://revbiosciences.com/20230930", "localname": "ClosingBidPriceOfCommonStockPerShare", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DisclosureOrganizationAndBasisOfPresentationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Closing bid price of common stock per share", "label": "Closing Bid Price of Common Stock Per Share", "documentation": "Closing bid price of common stock per share." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockbasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]", "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements." } } }, "auth_ref": [ "r53" ] }, "us-gaap_UnrecognizedTaxBenefits": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UnrecognizedTaxBenefits", "crdr": "credit", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Unrecognized Tax Benefits, Beginning Balance", "periodEndLabel": "Unrecognized Tax Benefits, Ending Balance", "label": "Unrecognized Tax Benefits", "terseLabel": "Unrecognized tax benefits", "documentation": "Amount of unrecognized tax benefits." } } }, "auth_ref": [ "r281", "r286" ] }, "us-gaap_LesseeLeasesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeLeasesPolicyTextBlock", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Lessee, Leases [Policy Text Block]", "terseLabel": "Leases", "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee." } } }, "auth_ref": [ "r325" ] }, "revb_NumberOfCalendarDayGracePeriod": { "xbrltype": "durationItemType", "nsuri": "http://revbiosciences.com/20230930", "localname": "NumberOfCalendarDayGracePeriod", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DisclosureOrganizationAndBasisOfPresentationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of calendar day grace period", "label": "Number of Calendar Day Grace Period", "documentation": "Number of calendar day grace period." } } }, "auth_ref": [] }, "revb_CommonStockTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://revbiosciences.com/20230930", "localname": "CommonStockTextBlock", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DisclosureCommonStock1" ], "lang": { "en-us": { "role": { "documentation": "Common stock.", "label": "Common Stock [Text Block}", "terseLabel": "Common Stock" } } }, "auth_ref": [] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "terseLabel": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r480" ] }, "revb_TransactionExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://revbiosciences.com/20230930", "localname": "TransactionExpenses", "crdr": "debit", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/revb_r_CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "documentation": "Transaction expenses", "label": "Transaction Expenses", "terseLabel": "Transaction Expenses", "verboseLabel": "Transaction expenses" } } }, "auth_ref": [] }, "revb_ClassAPlacementAgentCommonStockWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://revbiosciences.com/20230930", "localname": "ClassAPlacementAgentCommonStockWarrantsMember", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DisclosureCommonStockSummaryOfTotalSharesOfCommonStockReservedForIssuanceDetails", "http://revbiosciences.com/20230930/taxonomy/role/DisclosureCommonStockSummaryOfTotalSharesOfCommonStockReservedForIssuanceParentheticalDetails", "http://revbiosciences.com/20230930/taxonomy/role/DisclosurePipeInvestmentDetails", "http://revbiosciences.com/20230930/taxonomy/role/DisclosureWarrantsDetails", "http://revbiosciences.com/20230930/taxonomy/role/DisclosureWarrantsScheduleOfFairValueOfWarrantsEstimatedUsingBlackscholesOptionPricingModelDetails", "http://revbiosciences.com/20230930/taxonomy/role/DisclosureWarrantsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Class A Placement Agent Common Stock Warrants [Member]", "label": "Class A Placement Agent Common Stock Warrants [Member]", "documentation": "Class A placement agent common stock warrants." } } }, "auth_ref": [] }, "us-gaap_AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountingPoliciesAbstract", "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityNoteStockSplitConversionRatio1": { "xbrltype": "pureItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityNoteStockSplitConversionRatio1", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DisclosureCommonStockDetails", "http://revbiosciences.com/20230930/taxonomy/role/DisclosureOrganizationAndBasisOfPresentationDetails" ], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Note, Stock Split, Conversion Ratio", "terseLabel": "Reverse stock split ratio", "documentation": "Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one." } } }, "auth_ref": [ "r13" ] }, "revb_NoncashIssuanceOfPlacementAgentWarrantsWithPipeInvestment": { "xbrltype": "monetaryItemType", "nsuri": "http://revbiosciences.com/20230930", "localname": "NoncashIssuanceOfPlacementAgentWarrantsWithPipeInvestment", "crdr": "debit", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of Class A Placement Agent Common Stock Warrants in connection with the PIPE Investment", "documentation": "Noncash issuance of placement agent warrants with PIPE investment.", "label": "Noncash Issuance of Placement Agent Warrants with PIPE Investment" } } }, "auth_ref": [] }, "revb_OfficersEmployeesAndConsultantsMember": { "xbrltype": "domainItemType", "nsuri": "http://revbiosciences.com/20230930", "localname": "OfficersEmployeesAndConsultantsMember", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DisclosureStockbasedCompensationDetails" ], "lang": { "en-us": { "role": { "documentation": "Officers, employees and consultants.", "label": "Officers, Employees and Consultants [Member]" } } }, "auth_ref": [] }, "revb_NoncashOrPartNonCashAcquisitionCurrentLiabilitiesAssumed": { "xbrltype": "monetaryItemType", "nsuri": "http://revbiosciences.com/20230930", "localname": "NoncashOrPartNonCashAcquisitionCurrentLiabilitiesAssumed", "crdr": "credit", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "Noncash or part non-cash acquisition current liabilities assumed.", "label": "Noncash or Part Non cash Acquisition Current Liabilities Assumed", "terseLabel": "Current liabilities assumed in the Business Combination" } } }, "auth_ref": [] }, "revb_PetraCommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://revbiosciences.com/20230930", "localname": "PetraCommonStockMember", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DisclosureBusinessCombinationDetails", "http://revbiosciences.com/20230930/taxonomy/role/revb_r_CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "label": "PetraCommonStockMember", "terseLabel": "Petra Common Stock [Member]" } } }, "auth_ref": [] }, "us-gaap_Goodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Goodwill", "crdr": "debit", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DisclosureBusinessCombinationDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Goodwill, Total", "periodStartLabel": "Goodwill, Beginning Balance", "periodEndLabel": "Goodwill, Ending Balance", "label": "Goodwill", "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized." } } }, "auth_ref": [ "r123", "r190", "r336", "r452", "r466", "r517", "r518" ] }, "revb_PatentCostsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://revbiosciences.com/20230930", "localname": "PatentCostsPolicyTextBlock", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "documentation": "Patent costs.", "label": "Patent Costs [Policy Text Block]", "terseLabel": "Patent Costs" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationAwardTrancheOneMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationAwardTrancheOneMember", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DisclosureStockbasedCompensationDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Tranche One [Member]", "terseLabel": "25% on One Year Anniversary", "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period." } } }, "auth_ref": [] }, "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SupplementalBalanceSheetDisclosuresTextBlock", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DisclosureBalanceSheetDetails" ], "lang": { "en-us": { "role": { "label": "Supplemental Balance Sheet Disclosures [Text Block]", "terseLabel": "Balance Sheet Details", "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity." } } }, "auth_ref": [ "r497" ] }, "revb_SecondAmendmentMember": { "xbrltype": "domainItemType", "nsuri": "http://revbiosciences.com/20230930", "localname": "SecondAmendmentMember", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DisclosureSubsequentEventsDetails", "http://revbiosciences.com/20230930/taxonomy/role/revb_r_CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "label": "Second Amendment [Member]", "documentation": "Second Amendment." } } }, "auth_ref": [] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockParOrStatedValuePerShare", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DisclosureBusinessCombinationDetails", "http://revbiosciences.com/20230930/taxonomy/role/DisclosureCommonStockDetails", "http://revbiosciences.com/20230930/taxonomy/role/StatementConsolidatedBalanceSheetsParentheticals" ], "lang": { "en-us": { "role": { "label": "Common stock, per share", "netLabel": "Common stock, par value", "verboseLabel": "Common stock par value (in Dollars per share)", "terseLabel": "Common stock, par value (in Dollars per share)", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": [ "r68" ] }, "revb_NoncashIssuanceOfNewPlacementAgentWarrantsWithPublicOffering": { "xbrltype": "monetaryItemType", "nsuri": "http://revbiosciences.com/20230930", "localname": "NoncashIssuanceOfNewPlacementAgentWarrantsWithPublicOffering", "crdr": "debit", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "Noncash issuance of new placement agent warrants with public offering.", "label": "Noncash Issuance of New Placement Agent Warrants with Public Offering", "terseLabel": "Issuance of Class B Placement Agent Common Stock Warrants in connection with the July 2022 Public Offering" } } }, "auth_ref": [] }, "us-gaap_OperatingLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiabilityCurrent", "crdr": "credit", "calculation": { "http://revbiosciences.com/20230930/taxonomy/role/StatementConsolidatedBalanceSheets1": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/StatementConsolidatedBalanceSheets1" ], "lang": { "en-us": { "role": { "label": "Operating Lease, Liability, Current", "terseLabel": "Lease liability", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current." } } }, "auth_ref": [ "r324" ] }, "revb_WarrantLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://revbiosciences.com/20230930", "localname": "WarrantLiability", "crdr": "credit", "calculation": { "http://revbiosciences.com/20230930/taxonomy/role/StatementConsolidatedBalanceSheets1": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/StatementConsolidatedBalanceSheets1" ], "lang": { "en-us": { "role": { "label": "Warrant Liability", "documentation": "Warrant liability.", "terseLabel": "Warrant liability" } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationDisclosureTextBlock", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DisclosureBusinessCombination" ], "lang": { "en-us": { "role": { "label": "Business Combination Disclosure [Text Block]", "terseLabel": "Business Combination", "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable)." } } }, "auth_ref": [ "r98", "r300" ] }, "revb_NewCommonStockWarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://revbiosciences.com/20230930", "localname": "NewCommonStockWarrantMember", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/Disclosure2022PublicOfferingDetails", "http://revbiosciences.com/20230930/taxonomy/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "New Common Stock Warrant [Member]", "documentation": "New Common Stock Warrant Member" } } }, "auth_ref": [] }, "us-gaap_LeaseAndRentalExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LeaseAndRentalExpense", "crdr": "debit", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/revb_r_CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Rent expense", "label": "Operating Leases, Rent Expense", "documentation": "Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line." } } }, "auth_ref": [] }, "revb_SharesAmountRepurchasedEscrowedAndReturned": { "xbrltype": "monetaryItemType", "nsuri": "http://revbiosciences.com/20230930", "localname": "SharesAmountRepurchasedEscrowedAndReturned", "crdr": "debit", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DisclosureBusinessCombinationDetails", "http://revbiosciences.com/20230930/taxonomy/role/DisclosureCommonStockDetails" ], "lang": { "en-us": { "role": { "documentation": "Shares amount repurchased escrowed and returned.", "label": "Shares Amount Repurchased Escrowed and Returned", "terseLabel": "Shares amount repurchased escrowed and returned" } } }, "auth_ref": [] }, "revb_RepurchaseForForwardSharePurchaseAgreementExerciseShares": { "xbrltype": "sharesItemType", "nsuri": "http://revbiosciences.com/20230930", "localname": "RepurchaseForForwardSharePurchaseAgreementExerciseShares", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "negatedLabel": "Repurchase for the Forward Share Purchase Agreement exercise (in Shares)", "label": "Repurchase for Forward Share Purchase Agreement exercise Shares", "terseLabel": "Repurchase for the Forward Share Purchase Agreement exercise (in Shares)", "documentation": "Repurchase for forward share purchase agreement exercise shares." } } }, "auth_ref": [] }, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Liabilities", "crdr": "credit", "calculation": { "http://revbiosciences.com/20230930/taxonomy/role/StatementConsolidatedBalanceSheets1": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/StatementConsolidatedBalanceSheets1" ], "lang": { "en-us": { "role": { "label": "Liabilities", "totalLabel": "Total liabilities", "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future." } } }, "auth_ref": [ "r15", "r140", "r187", "r199", "r200", "r201", "r202", "r203", "r204", "r205", "r206", "r207", "r302", "r303", "r304", "r314", "r387", "r447", "r478", "r521", "r559", "r560" ] }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "crdr": "credit", "calculation": { "http://revbiosciences.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Increase (Decrease) in Prepaid Expense and Other Assets, Total", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "negatedLabel": "Prepaid expenses and other current assets", "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other." } } }, "auth_ref": [ "r3" ] }, "us-gaap_NoninterestExpenseInvestmentAdvisoryFees": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NoninterestExpenseInvestmentAdvisoryFees", "crdr": "debit", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/revb_r_CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "label": "Noninterest Expense Investment Advisory Fees", "terseLabel": "Unpaid banking advisory fees (in Dollars)", "verboseLabel": "Unpaid banking advisory fees (in equity)", "documentation": "This represents the company's cost incurred during an accounting period for managing the money in a fund, which will be billed back to the client and is a component of noninterest expenses." } } }, "auth_ref": [ "r103" ] }, "revb_CashPaidForUpfrontMonthlyAndInterestPaymentsUnderFinanceAgreement": { "xbrltype": "monetaryItemType", "nsuri": "http://revbiosciences.com/20230930", "localname": "CashPaidForUpfrontMonthlyAndInterestPaymentsUnderFinanceAgreement", "crdr": "credit", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/revb_r_CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "documentation": "Cash paid for upfront, monthly and interest payments under finance agreement.", "label": "Cash Paid for Upfront Monthly and Interest Payments under Finance Agreement", "terseLabel": "Total cash paid for upfront, monthly and interest payments under finance agreement" } } }, "auth_ref": [] }, "revb_RolloverWarrantExerciseShares": { "xbrltype": "sharesItemType", "nsuri": "http://revbiosciences.com/20230930", "localname": "RolloverWarrantExerciseShares", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "documentation": "Rollover warrant exercise shares.", "label": "Rollover Warrant Exercise Shares", "terseLabel": "Rollover Warrant Exercise (in Shares)" } } }, "auth_ref": [] }, "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DisclosureBalanceSheetDetailsTables" ], "lang": { "en-us": { "role": { "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]", "terseLabel": "Schedule of Prepaid Expenses and Other Current Assets", "documentation": "Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs." } } }, "auth_ref": [] }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NonoperatingIncomeExpenseAbstract", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Nonoperating Income (Expense) [Abstract]", "verboseLabel": "Other income (expense):" } } }, "auth_ref": [] }, "revb_EscrowedAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://revbiosciences.com/20230930", "localname": "EscrowedAmount", "crdr": "credit", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DisclosureBusinessCombinationDetails", "http://revbiosciences.com/20230930/taxonomy/role/DisclosureCommonStockDetails" ], "lang": { "en-us": { "role": { "label": "EscrowedAmount", "documentation": "Escrowed amount.", "terseLabel": "Escrowed amount (in Dollars)" } } }, "auth_ref": [] }, "revb_AccruedClinicalStudyExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://revbiosciences.com/20230930", "localname": "AccruedClinicalStudyExpenses", "crdr": "credit", "calculation": { "http://revbiosciences.com/20230930/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfAccruedExpensesDetails": { "parentTag": "us-gaap_AccruedLiabilitiesCurrentAndNoncurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfAccruedExpensesDetails" ], "lang": { "en-us": { "role": { "documentation": "Accrued Clinical Study Expenses", "label": "Accrued Clinical Study Expenses", "terseLabel": "Accrued clinical study expenses" } } }, "auth_ref": [] }, "us-gaap_RestrictedStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestrictedStockMember", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DisclosureCommonStockDetails" ], "lang": { "en-us": { "role": { "label": "Restricted Stock [Member]", "terseLabel": "Rollover RSU Awards [Member]", "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met." } } }, "auth_ref": [ "r33" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DisclosureStockbasedCompensationDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period", "terseLabel": "Exercisable period", "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r463" ] }, "us-gaap_StockRepurchasedDuringPeriodShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockRepurchasedDuringPeriodShares", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DisclosureBusinessCombinationDetails", "http://revbiosciences.com/20230930/taxonomy/role/DisclosureCommonStockDetails" ], "lang": { "en-us": { "role": { "label": "Stock Repurchased During Period, Shares", "terseLabel": "Shares repurchased", "documentation": "Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock." } } }, "auth_ref": [ "r6", "r67", "r68", "r92", "r364", "r428", "r439" ] }, "revb_ProceedsFromPipeInvestmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://revbiosciences.com/20230930", "localname": "ProceedsFromPipeInvestmentNet", "crdr": "debit", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "documentation": "Proceeds from pipe investment net.", "label": "Proceeds From Pipe Investment Net", "terseLabel": "Proceeds from the PIPE Investment, net" } } }, "auth_ref": [] }, "us-gaap_OtherIntangibleAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherIntangibleAssetsNet", "crdr": "debit", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DisclosureBusinessCombinationDetails" ], "lang": { "en-us": { "role": { "label": "Other Intangible Assets, Net", "terseLabel": "Other intangible assets", "documentation": "Amount after accumulated amortization of finite-lived and indefinite-lived intangible assets classified as other." } } }, "auth_ref": [] }, "us-gaap_NonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://revbiosciences.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Nonoperating Income (Expense)", "totalLabel": "Total other income (expense), net", "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)." } } }, "auth_ref": [ "r77" ] }, "revb_PercentageOfAggregateNumberOfOutstandingSharesOfCommonStock": { "xbrltype": "percentItemType", "nsuri": "http://revbiosciences.com/20230930", "localname": "PercentageOfAggregateNumberOfOutstandingSharesOfCommonStock", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DisclosureStockbasedCompensationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Percentage of aggregate number of outstanding shares of common stock", "label": "Percentage of Aggregate Number of Outstanding Shares of Common Stock", "documentation": "Percentage of aggregate number of outstanding shares of common stock." } } }, "auth_ref": [] }, "revb_ProceedsFromPipeInvestmentNetShares": { "xbrltype": "sharesItemType", "nsuri": "http://revbiosciences.com/20230930", "localname": "ProceedsFromPipeInvestmentNetShares", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "documentation": "Proceeds from pipe investment net shares.", "label": "Proceeds From Pipe Investment Net Shares", "terseLabel": "Proceeds from the PIPE Investment, net (in Shares)" } } }, "auth_ref": [] }, "revb_RepurchaseForTheForwardSharePurchaseAgreementExercise": { "xbrltype": "monetaryItemType", "nsuri": "http://revbiosciences.com/20230930", "localname": "RepurchaseForTheForwardSharePurchaseAgreementExercise", "crdr": "credit", "calculation": { "http://revbiosciences.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 12.0 } }, "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfCashFlows", "http://revbiosciences.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "negatedLabel": "Repurchase for the Forward Share Purchase Agreement exercise", "label": "Repurchase For The Forward Share Purchase Agreement Exercise", "terseLabel": "Repurchase for the Forward Share Purchase Agreement exercise", "documentation": "Repurchase for the forward share purchase agreement exercise." } } }, "auth_ref": [] }, "us-gaap_BusinessAcquisitionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionAxis", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DisclosureBusinessCombinationDetails", "http://revbiosciences.com/20230930/taxonomy/role/DisclosureCommonStockDetails", "http://revbiosciences.com/20230930/taxonomy/role/DisclosureOrganizationAndBasisOfPresentationDetails", "http://revbiosciences.com/20230930/taxonomy/role/revb_r_CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "label": "Business Acquisition [Axis]", "documentation": "Information by business combination or series of individually immaterial business combinations." } } }, "auth_ref": [ "r56", "r57", "r299", "r459", "r460" ] }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentUsefulLife", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment, Useful Life", "terseLabel": "Estimated useful lives", "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment." } } }, "auth_ref": [] }, "us-gaap_IncomeStatementLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementLocationDomain", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockbasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "label": "Income Statement Location [Domain]", "documentation": "Location in the income statement." } } }, "auth_ref": [ "r192", "r413" ] }, "revb_PublicWarrantsOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://revbiosciences.com/20230930", "localname": "PublicWarrantsOutstanding", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/Disclosure2023PublicOfferingDetails", "http://revbiosciences.com/20230930/taxonomy/role/DisclosureUnitsDetails", "http://revbiosciences.com/20230930/taxonomy/role/DisclosureWarrantsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Warrants outstanding", "documentation": "Public warrants outstanding.", "label": "Public Warrants Outstanding", "terseLabel": "Public warrants outstanding" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DisclosureStockbasedCompensationTables" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]", "terseLabel": "Schedule of Stock Options Activity", "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value." } } }, "auth_ref": [ "r9", "r10", "r52" ] }, "revb_PlacementAgentWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://revbiosciences.com/20230930", "localname": "PlacementAgentWarrantsMember", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/Disclosure2022PublicOfferingDetails" ], "lang": { "en-us": { "role": { "documentation": "Placement agent warrants.", "label": "Placement Agent Warrants [Member]" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DisclosureStockbasedCompensationDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized", "terseLabel": "Shares authorized", "verboseLabel": "Number of shares reserved", "documentation": "Number of shares authorized for issuance under share-based payment arrangement." } } }, "auth_ref": [ "r464" ] }, "us-gaap_AdditionalPaidInCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalPaidInCapital", "crdr": "credit", "calculation": { "http://revbiosciences.com/20230930/taxonomy/role/StatementConsolidatedBalanceSheets1": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/StatementConsolidatedBalanceSheets1" ], "lang": { "en-us": { "role": { "totalLabel": "Additional Paid in Capital, Total", "periodStartLabel": "Additional Paid in Capital, Beginning Balance", "periodEndLabel": "Additional Paid in Capital, Ending Balance", "label": "Additional Paid in Capital", "terseLabel": "Additional paid-in-capital", "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock." } } }, "auth_ref": [ "r69", "r466", "r570" ] }, "us-gaap_SeriesAPreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SeriesAPreferredStockMember", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DisclosureCommonStockSummaryOfTotalSharesOfCommonStockReservedForIssuanceDetails", "http://revbiosciences.com/20230930/taxonomy/role/DisclosurePreferredStockDetails", "http://revbiosciences.com/20230930/taxonomy/role/StatementConsolidatedBalanceSheets1", "http://revbiosciences.com/20230930/taxonomy/role/StatementConsolidatedBalanceSheetsParentheticals", "http://revbiosciences.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfCashFlows", "http://revbiosciences.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Series A Preferred Stock [Member]", "terseLabel": "Series A Preferred Stock [Member]", "verboseLabel": "Series A preferred stock", "documentation": "Series A preferred stock." } } }, "auth_ref": [ "r498", "r499", "r524" ] }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DisclosureStockbasedCompensationTables", "http://revbiosciences.com/20230930/taxonomy/role/DisclosureWarrantsTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]", "verboseLabel": "Assumptions used in Estimating Fair Value of Stock Options", "terseLabel": "Schedule of Fair Value of Warrants Estimated Using Black-Scholes Option Pricing Model", "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions." } } }, "auth_ref": [ "r95" ] }, "revb_CommonStockIssuanceMember": { "xbrltype": "domainItemType", "nsuri": "http://revbiosciences.com/20230930", "localname": "CommonStockIssuanceMember", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DisclosureCommonStockDetails" ], "lang": { "en-us": { "role": { "label": "CommonStockIssuanceMember", "terseLabel": "Common Stock Issuance [Member]" } } }, "auth_ref": [] }, "revb_TwoThousandTwentyThreePublicOfferingTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://revbiosciences.com/20230930", "localname": "TwoThousandTwentyThreePublicOfferingTextBlock", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/Disclosure2023PublicOffering" ], "lang": { "en-us": { "role": { "terseLabel": "2023 Public Offering", "label": "Two Thousand Twenty Three Public Offering [Text Block]", "documentation": "Two thousand twenty three public offering." } } }, "auth_ref": [] }, "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsAbstract", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/StatementConsolidatedBalanceSheets1" ], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "verboseLabel": "Assets:", "terseLabel": "ASSETS" } } }, "auth_ref": [] }, "revb_AggregateSharesOfCommonStock": { "xbrltype": "sharesItemType", "nsuri": "http://revbiosciences.com/20230930", "localname": "AggregateSharesOfCommonStock", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DisclosureBusinessCombinationDetails", "http://revbiosciences.com/20230930/taxonomy/role/DisclosureCommonStockDetails", "http://revbiosciences.com/20230930/taxonomy/role/DisclosureWarrantsDetails" ], "lang": { "en-us": { "role": { "label": "AggregateSharesOfCommonStock", "documentation": "Number of aggregate shares of common stock.", "terseLabel": "Common stock aggregate shares" } } }, "auth_ref": [] }, "revb_ClassOfWarrantOrRightForIssuingDescription": { "xbrltype": "stringItemType", "nsuri": "http://revbiosciences.com/20230930", "localname": "ClassOfWarrantOrRightForIssuingDescription", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DisclosureUnitsDetails" ], "lang": { "en-us": { "role": { "documentation": "Class of warrant or right for issuing description.", "label": "Class Of Warrant Or Right For Issuing Description", "terseLabel": "Warrant for issuing description" } } }, "auth_ref": [] }, "revb_PreFundedWarrantsExerciseShares": { "xbrltype": "sharesItemType", "nsuri": "http://revbiosciences.com/20230930", "localname": "PreFundedWarrantsExerciseShares", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "documentation": "Pre funded warrants exercise shares.", "label": "Pre Funded Warrants Exercise Shares", "terseLabel": "Pre-Funded Warrants Exercise (in Shares)", "verboseLabel": "Pre-Funded Warrants Exercise" } } }, "auth_ref": [] }, "us-gaap_SubsequentEventsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventsAbstract", "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]" } } }, "auth_ref": [] }, "revb_IssuanceOfCommonStockInConnectionWithTheBusinessCombinationNet": { "xbrltype": "monetaryItemType", "nsuri": "http://revbiosciences.com/20230930", "localname": "IssuanceOfCommonStockInConnectionWithTheBusinessCombinationNet", "crdr": "debit", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "documentation": "Issuance of common stock in connection with the business combination net.", "label": "Issuance Of Common Stock In Connection With The Business Combination Net", "terseLabel": "Issuance of common stock in connection with the Business Combination, net" } } }, "auth_ref": [] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementLineItems", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DisclosureOrganizationAndBasisOfPresentationDetails", "http://revbiosciences.com/20230930/taxonomy/role/StatementConsolidatedBalanceSheets1", "http://revbiosciences.com/20230930/taxonomy/role/StatementConsolidatedBalanceSheetsParentheticals", "http://revbiosciences.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfCashFlows", "http://revbiosciences.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r143", "r144", "r145", "r167", "r335", "r359", "r378", "r381", "r382", "r383", "r384", "r385", "r386", "r389", "r392", "r393", "r394", "r395", "r396", "r397", "r398", "r399", "r400", "r402", "r403", "r404", "r405", "r406", "r408", "r411", "r412", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r428", "r471" ] }, "revb_ClassCCommonStockPurchaseWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://revbiosciences.com/20230930", "localname": "ClassCCommonStockPurchaseWarrantsMember", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DisclosureSubsequentEventsDetails", "http://revbiosciences.com/20230930/taxonomy/role/DisclosureWarrantsTables" ], "lang": { "en-us": { "role": { "documentation": "Class C Common Stock Purchase Warrants [Member]", "label": "Class C Common Stock Purchase Warrants [Member]", "terseLabel": "Class C Common Stock Purchase Warrants [Member]" } } }, "auth_ref": [] }, "revb_February2023PublicOfferingMember": { "xbrltype": "domainItemType", "nsuri": "http://revbiosciences.com/20230930", "localname": "February2023PublicOfferingMember", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DisclosureCommonStockDetails", "http://revbiosciences.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfCashFlows", "http://revbiosciences.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "verboseLabel": "February 2023 Public Offering [Member]", "terseLabel": "February 2023 Public Offering", "label": "February 2023 Public Offering [Member]", "documentation": "February 2023 public offering." } } }, "auth_ref": [] }, "revb_PreFundedWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://revbiosciences.com/20230930", "localname": "PreFundedWarrantsMember", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DisclosureCommonStockDetails", "http://revbiosciences.com/20230930/taxonomy/role/DisclosurePipeInvestmentDetails", "http://revbiosciences.com/20230930/taxonomy/role/DisclosureSubsequentEventsDetails", "http://revbiosciences.com/20230930/taxonomy/role/DisclosureWarrantsDetails", "http://revbiosciences.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "PreFundedWarrantsMember", "terseLabel": "Pre-Funded Warrants Exercise [Member]", "verboseLabel": "Pre-Funded Warrants [Member]" } } }, "auth_ref": [] }, "revb_OriginalLeaseMember": { "xbrltype": "domainItemType", "nsuri": "http://revbiosciences.com/20230930", "localname": "OriginalLeaseMember", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/revb_r_CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "documentation": "Original lease.", "label": "Original Lease [Member]" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DisclosureStockbasedCompensationDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized", "terseLabel": "Additional shares available for grant", "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement." } } }, "auth_ref": [] }, "revb_CashlessCommonStockWarrantsExercise": { "xbrltype": "monetaryItemType", "nsuri": "http://revbiosciences.com/20230930", "localname": "CashlessCommonStockWarrantsExercise", "crdr": "credit", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "terseLabel": "Cashless common stock warrants exercise", "label": "Cashless Common Stock Warrants Exercise", "documentation": "Cashless common stock warrants exercise." } } }, "auth_ref": [] }, "us-gaap_PreferredStockRedemptionAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockRedemptionAmount", "crdr": "credit", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DisclosurePreferredStockDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, redemption amount", "label": "Preferred Stock, Redemption Amount", "documentation": "The redemption (or callable) amount of currently redeemable preferred stock. Includes amounts representing dividends not currently declared or paid but which will be payable under the redemption features or for which ultimate payment is solely within the control of the issuer." } } }, "auth_ref": [ "r21", "r44" ] }, "revb_FirstAmendmentMember": { "xbrltype": "domainItemType", "nsuri": "http://revbiosciences.com/20230930", "localname": "FirstAmendmentMember", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DisclosureSubsequentEventsDetails", "http://revbiosciences.com/20230930/taxonomy/role/revb_r_CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "documentation": "First amendment.", "label": "First Amendment [Member]" } } }, "auth_ref": [] }, "revb_IssuanceOfCommonStockForAccruedExpensesInConnectionWithTheBusinessCombination": { "xbrltype": "monetaryItemType", "nsuri": "http://revbiosciences.com/20230930", "localname": "IssuanceOfCommonStockForAccruedExpensesInConnectionWithTheBusinessCombination", "crdr": "debit", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of common stock for Accrued Expenses in connection with the Business Combination", "label": "Issuance of Common Stock for Accrued Expenses In Connection With the Business Combination", "documentation": "Issuance of common stock for accrued expenses in connection with the business combination." } } }, "auth_ref": [] }, "us-gaap_PreferredStockLiquidationPreferenceValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockLiquidationPreferenceValue", "crdr": "credit", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DisclosurePreferredStockDetails", "http://revbiosciences.com/20230930/taxonomy/role/StatementConsolidatedBalanceSheetsParentheticals" ], "lang": { "en-us": { "role": { "verboseLabel": "Cash paid to purchaser", "label": "Preferred Stock, Liquidation Preference, Value", "terseLabel": "Liquidation preference", "documentation": "Value of the difference between preference in liquidation and the par or stated values of the preferred shares." } } }, "auth_ref": [ "r139", "r221" ] }, "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementPolicyPolicyTextBlock", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value", "label": "Fair Value Measurement, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities." } } }, "auth_ref": [] }, "revb_RolloverRestrictedStockUnitsMember": { "xbrltype": "domainItemType", "nsuri": "http://revbiosciences.com/20230930", "localname": "RolloverRestrictedStockUnitsMember", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DisclosureCommonStockSummaryOfTotalSharesOfCommonStockReservedForIssuanceDetails", "http://revbiosciences.com/20230930/taxonomy/role/DisclosureStockbasedCompensationDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Rollover RSU Awards Outstanding [Member]", "documentation": "Rollover restricted stock units member.", "label": "Rollover Restricted Stock Units Member", "terseLabel": "Rollover Restricted Stock Units [Member]" } } }, "auth_ref": [] }, "revb_PetraMember": { "xbrltype": "domainItemType", "nsuri": "http://revbiosciences.com/20230930", "localname": "PetraMember", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DisclosureBusinessCombinationDetails" ], "lang": { "en-us": { "role": { "documentation": "Petra.", "label": "Petra [Member]" } } }, "auth_ref": [] }, "revb_WarrantsAndRightsExpirationDate": { "xbrltype": "dateItemType", "nsuri": "http://revbiosciences.com/20230930", "localname": "WarrantsAndRightsExpirationDate", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/Disclosure2023PublicOfferingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Warrants and rights expiration date", "label": "Warrants and Rights Expiration Date", "documentation": "Warrants and rights expiration date." } } }, "auth_ref": [] }, "srt_EquityMethodInvesteeNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "EquityMethodInvesteeNameDomain", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DisclosureBusinessCombinationDetails" ], "lang": { "en-us": { "role": { "label": "Investment, Name [Domain]" } } }, "auth_ref": [ "r184", "r185", "r186" ] }, "revb_CommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://revbiosciences.com/20230930", "localname": "CommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DisclosureCommonStockTables" ], "lang": { "en-us": { "role": { "documentation": "Common stock, capital shares reserved for future issuance.", "label": "Common Stock, Capital Shares Reserved for Future Issuance [Table Text Block]", "terseLabel": "Summary of Total Shares of Common Stock Reserved for Issuance" } } }, "auth_ref": [] }, "revb_OtherPrepaidExpenseAndCurrentAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://revbiosciences.com/20230930", "localname": "OtherPrepaidExpenseAndCurrentAssets", "crdr": "debit", "calculation": { "http://revbiosciences.com/20230930/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails": { "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails" ], "lang": { "en-us": { "role": { "documentation": "Other prepaid expense and current assets.", "label": "Other Prepaid Expense and Current Assets", "terseLabel": "Other prepaid expenses & current assets" } } }, "auth_ref": [] }, "revb_InterestIncurred": { "xbrltype": "monetaryItemType", "nsuri": "http://revbiosciences.com/20230930", "localname": "InterestIncurred", "crdr": "debit", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/revb_r_CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "documentation": "Interest incurred.", "label": "Interest Incurred", "terseLabel": "Interest incurred" } } }, "auth_ref": [] }, "revb_ReleasedAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://revbiosciences.com/20230930", "localname": "ReleasedAmount", "crdr": "credit", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DisclosureBusinessCombinationDetails", "http://revbiosciences.com/20230930/taxonomy/role/DisclosureCommonStockDetails" ], "lang": { "en-us": { "role": { "label": "ReleasedAmount", "documentation": "Released amount.", "terseLabel": "Released amount (in Dollars)" } } }, "auth_ref": [] }, "revb_AggregatePurchasePrice": { "xbrltype": "monetaryItemType", "nsuri": "http://revbiosciences.com/20230930", "localname": "AggregatePurchasePrice", "crdr": "credit", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DisclosureBusinessCombinationDetails" ], "lang": { "en-us": { "role": { "label": "AggregatePurchasePrice", "documentation": "Aggregate purchase price.", "terseLabel": "Aggregate purchase price" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DisclosureStockbasedCompensationDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "terseLabel": "Awards, forfeited", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period." } } }, "auth_ref": [ "r253" ] }, "revb_ProceedsFromPipeInvestmentNetIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://revbiosciences.com/20230930", "localname": "ProceedsFromPipeInvestmentNetIssuanceCosts", "crdr": "debit", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DisclosurePipeInvestmentDetails" ], "lang": { "en-us": { "role": { "documentation": "Proceeds from PIPE investment net issuance costs.", "label": "Proceeds From PIPE Investment Net Issuance Costs", "verboseLabel": "Proceeds from PIPE investment, net issuance costs", "terseLabel": "Proceeds from the PIPE Investment, net" } } }, "auth_ref": [] }, "revb_ClassBCommonStockWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://revbiosciences.com/20230930", "localname": "ClassBCommonStockWarrantsMember", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/Disclosure2022PublicOfferingDetails", "http://revbiosciences.com/20230930/taxonomy/role/Disclosure2023PublicOfferingDetails", "http://revbiosciences.com/20230930/taxonomy/role/DisclosureCommonStockSummaryOfTotalSharesOfCommonStockReservedForIssuanceDetails", "http://revbiosciences.com/20230930/taxonomy/role/DisclosureCommonStockSummaryOfTotalSharesOfCommonStockReservedForIssuanceParentheticalDetails", "http://revbiosciences.com/20230930/taxonomy/role/DisclosureWarrantsDetails", "http://revbiosciences.com/20230930/taxonomy/role/DisclosureWarrantsScheduleOfFairValueOfWarrantsEstimatedUsingBlackscholesOptionPricingModelDetails", "http://revbiosciences.com/20230930/taxonomy/role/DisclosureWarrantsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Class B Common Stock Warrants [Member]", "label": "Class B Common Stock Warrants [Member]", "documentation": "Class B common stock warrants." } } }, "auth_ref": [] }, "revb_UnitsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://revbiosciences.com/20230930", "localname": "UnitsTextBlock", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DisclosureUnits1" ], "lang": { "en-us": { "role": { "documentation": "Units.", "label": "Units [Text Block]", "terseLabel": "Units" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DisclosureStockbasedCompensationDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number, Beginning Balance", "periodEndLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number, Ending Balance", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "terseLabel": "Awards, expected to vest", "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date." } } }, "auth_ref": [ "r248", "r249" ] }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DisclosureStockbasedCompensationDetails" ], "lang": { "en-us": { "role": { "label": "Title of Individual [Domain]" } } }, "auth_ref": [] }, "revb_ClassACommonStockWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://revbiosciences.com/20230930", "localname": "ClassACommonStockWarrantsMember", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DisclosureCommonStockSummaryOfTotalSharesOfCommonStockReservedForIssuanceDetails", "http://revbiosciences.com/20230930/taxonomy/role/DisclosureCommonStockSummaryOfTotalSharesOfCommonStockReservedForIssuanceParentheticalDetails", "http://revbiosciences.com/20230930/taxonomy/role/DisclosurePipeInvestmentDetails", "http://revbiosciences.com/20230930/taxonomy/role/DisclosureWarrantsDetails", "http://revbiosciences.com/20230930/taxonomy/role/DisclosureWarrantsScheduleOfFairValueOfWarrantsEstimatedUsingBlackscholesOptionPricingModelDetails", "http://revbiosciences.com/20230930/taxonomy/role/DisclosureWarrantsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Class A Common Stock Warrants [Member]", "label": "Class A Common Stock Warrants [Member]", "documentation": "Class A common stock warrants." } } }, "auth_ref": [] }, "revb_PercentageOfPlacementAgentCashFeeOnGrossProceedsReceived": { "xbrltype": "percentItemType", "nsuri": "http://revbiosciences.com/20230930", "localname": "PercentageOfPlacementAgentCashFeeOnGrossProceedsReceived", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/Disclosure2022PublicOfferingDetails", "http://revbiosciences.com/20230930/taxonomy/role/Disclosure2023PublicOfferingDetails" ], "lang": { "en-us": { "role": { "label": "Percentage of placement agent cash fee on gross proceeds received", "documentation": "Percentage of placement agent cash fee on gross proceeds received." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DisclosureStockbasedCompensationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Awards vested, and unissued", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period." } } }, "auth_ref": [ "r252" ] }, "us-gaap_StatementClassOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementClassOfStockAxis", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DisclosureBusinessCombinationDetails", "http://revbiosciences.com/20230930/taxonomy/role/DisclosureCommonStockDetails", "http://revbiosciences.com/20230930/taxonomy/role/DisclosureCommonStockSummaryOfTotalSharesOfCommonStockReservedForIssuanceDetails", "http://revbiosciences.com/20230930/taxonomy/role/DisclosurePreferredStockDetails", "http://revbiosciences.com/20230930/taxonomy/role/DisclosureWarrantsDetails", "http://revbiosciences.com/20230930/taxonomy/role/StatementConsolidatedBalanceSheets1", "http://revbiosciences.com/20230930/taxonomy/role/StatementConsolidatedBalanceSheetsParentheticals", "http://revbiosciences.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfCashFlows", "http://revbiosciences.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquityDeficit", "http://revbiosciences.com/20230930/taxonomy/role/revb_r_CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]", "documentation": "Information by the different classes of stock of the entity." } } }, "auth_ref": [ "r115", "r125", "r126", "r127", "r140", "r159", "r160", "r162", "r164", "r168", "r169", "r187", "r199", "r201", "r202", "r203", "r206", "r207", "r218", "r219", "r221", "r222", "r225", "r314", "r361", "r362", "r363", "r364", "r367", "r368", "r369", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r378", "r389", "r410", "r428", "r436", "r437", "r438", "r439", "r440", "r490", "r503", "r511" ] }, "revb_SubSeriesA1PreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://revbiosciences.com/20230930", "localname": "SubSeriesA1PreferredStockMember", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DisclosureWarrantsDetails", "http://revbiosciences.com/20230930/taxonomy/role/StatementConsolidatedBalanceSheets1", "http://revbiosciences.com/20230930/taxonomy/role/StatementConsolidatedBalanceSheetsParentheticals" ], "lang": { "en-us": { "role": { "documentation": "Sub series a-1 preferred stock.", "label": "Sub Series A-1 Preferred Stock [Member]", "terseLabel": "Sub Series A-1 Preferred Stock [Member]" } } }, "auth_ref": [] }, "revb_NumberOfEmployees": { "xbrltype": "integerItemType", "nsuri": "http://revbiosciences.com/20230930", "localname": "NumberOfEmployees", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DisclosureStockbasedCompensationDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of employees.", "label": "Number Of Employees", "terseLabel": "Number of employees" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOperatingLeaseLiability", "crdr": "debit", "calculation": { "http://revbiosciences.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Lease Liability", "terseLabel": "Operating lease liability", "documentation": "Amount of increase (decrease) in obligation for operating lease." } } }, "auth_ref": [ "r496", "r502" ] }, "us-gaap_IncomeTaxDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxDisclosureTextBlock", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/revb_r_IncomeTaxes" ], "lang": { "en-us": { "role": { "terseLabel": "Income Taxes", "label": "Income Tax Disclosure [Text Block]", "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information." } } }, "auth_ref": [ "r141", "r280", "r285", "r287", "r290", "r294", "r296", "r297", "r298", "r366" ] }, "us-gaap_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "calculation": { "http://revbiosciences.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "totalLabel": "Research and Development Expense, Total", "label": "Research and Development Expense", "terseLabel": "Research and development", "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use." } } }, "auth_ref": [ "r65", "r279", "r567" ] }, "us-gaap_GeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://revbiosciences.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "General and Administrative Expense", "terseLabel": "General and administrative", "totalLabel": "General and Administrative Expense, Total", "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line." } } }, "auth_ref": [ "r76", "r412" ] }, "revb_NoncashIssuanceOfCommonWarrantsPipeInvestment": { "xbrltype": "monetaryItemType", "nsuri": "http://revbiosciences.com/20230930", "localname": "NoncashIssuanceOfCommonWarrantsPipeInvestment", "crdr": "debit", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of Class A Common Stock Warrants in connection with the PIPE Investment", "documentation": "Noncash issuance of Common warrants PIPE investment.", "label": "Noncash Issuance of Common Warrants PIPE Investment" } } }, "auth_ref": [] }, "revb_NoncashIssuanceOfNewCommonStockWarrantsWithPublicOffering": { "xbrltype": "monetaryItemType", "nsuri": "http://revbiosciences.com/20230930", "localname": "NoncashIssuanceOfNewCommonStockWarrantsWithPublicOffering", "crdr": "debit", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of Common Stock Warrants in connection with Public Offering", "documentation": "Noncash issuance of new common stock warrants with public offering.", "label": "Noncash Issuance of New Common Stock Warrants with Public Offering" } } }, "auth_ref": [] }, "revb_ClassCCommonStockWarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://revbiosciences.com/20230930", "localname": "ClassCCommonStockWarrantMember", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/Disclosure2023PublicOfferingDetails", "http://revbiosciences.com/20230930/taxonomy/role/DisclosureCommonStockSummaryOfTotalSharesOfCommonStockReservedForIssuanceDetails", "http://revbiosciences.com/20230930/taxonomy/role/DisclosureCommonStockSummaryOfTotalSharesOfCommonStockReservedForIssuanceParentheticalDetails", "http://revbiosciences.com/20230930/taxonomy/role/DisclosureSubsequentEventsDetails", "http://revbiosciences.com/20230930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails", "http://revbiosciences.com/20230930/taxonomy/role/DisclosureWarrantsDetails", "http://revbiosciences.com/20230930/taxonomy/role/DisclosureWarrantsScheduleOfFairValueOfWarrantsEstimatedUsingBlackscholesOptionPricingModelDetails", "http://revbiosciences.com/20230930/taxonomy/role/DisclosureWarrantsTables" ], "lang": { "en-us": { "role": { "documentation": "Class c common stock warrant.", "label": "Class C Common Stock Warrant [Member]", "terseLabel": "Class C Common Stock Warrant [Member]" } } }, "auth_ref": [] }, "revb_CommitmentsandContingenciesDetailsTable": { "xbrltype": "stringItemType", "nsuri": "http://revbiosciences.com/20230930", "localname": "CommitmentsandContingenciesDetailsTable", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/revb_r_CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies (Details) [Table]" } } }, "auth_ref": [] }, "revb_RepaymentsOfNotesPayableIncludingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://revbiosciences.com/20230930", "localname": "RepaymentsOfNotesPayableIncludingInterest", "crdr": "credit", "calculation": { "http://revbiosciences.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 10.0 } }, "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "Repayments of notes payable including interest.", "label": "Repayments Of Notes Payable Including Interest", "negatedLabel": "Repayments of Promissory Notes Payable, including interest" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DisclosureStockbasedCompensationDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights", "terseLabel": "Vesting, description", "documentation": "Description of service or performance condition required to be met for earning right to award under share-based payment arrangement. Includes, but is not limited to, combination of market, performance or service condition." } } }, "auth_ref": [ "r51" ] }, "revb_PublicWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://revbiosciences.com/20230930", "localname": "PublicWarrantsMember", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DisclosureCommonStockSummaryOfTotalSharesOfCommonStockReservedForIssuanceDetails", "http://revbiosciences.com/20230930/taxonomy/role/DisclosureCommonStockSummaryOfTotalSharesOfCommonStockReservedForIssuanceParentheticalDetails", "http://revbiosciences.com/20230930/taxonomy/role/DisclosureSubsequentEventsDetails", "http://revbiosciences.com/20230930/taxonomy/role/DisclosureUnitsDetails", "http://revbiosciences.com/20230930/taxonomy/role/DisclosureWarrantsDetails" ], "lang": { "en-us": { "role": { "documentation": "Public warrants.", "label": "Public Warrants [Member]", "terseLabel": "Public Warrants [Member]" } } }, "auth_ref": [] }, "revb_SignificantOfAccountingPoliciesTable": { "xbrltype": "stringItemType", "nsuri": "http://revbiosciences.com/20230930", "localname": "SignificantOfAccountingPoliciesTable", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "label": "Significant of Accounting Policies [Table]", "documentation": "Significant of Accounting Policies [Table]" } } }, "auth_ref": [] }, "revb_SubSeriesAPreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://revbiosciences.com/20230930", "localname": "SubSeriesAPreferredStockMember", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/StatementConsolidatedBalanceSheets1", "http://revbiosciences.com/20230930/taxonomy/role/StatementConsolidatedBalanceSheetsParentheticals" ], "lang": { "en-us": { "role": { "documentation": "Sub series a preferred stock.", "label": "Sub Series A Preferred Stock [Member]", "terseLabel": "Sub Series A Preferred Stock [Member]" } } }, "auth_ref": [] }, "revb_NumberOfConsecutiveBusinessDays": { "xbrltype": "integerItemType", "nsuri": "http://revbiosciences.com/20230930", "localname": "NumberOfConsecutiveBusinessDays", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DisclosureOrganizationAndBasisOfPresentationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of consecutive business days", "label": "Number Of Consecutive Business Days", "documentation": "Number of consecutive business days." } } }, "auth_ref": [] }, "revb_TimeBasedRestrictedStockUnitsMember": { "xbrltype": "domainItemType", "nsuri": "http://revbiosciences.com/20230930", "localname": "TimeBasedRestrictedStockUnitsMember", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DisclosureStockbasedCompensationDetails" ], "lang": { "en-us": { "role": { "documentation": "Time-based restricted stock units.", "label": "Time-based Restricted Stock Units [Member]" } } }, "auth_ref": [] }, "revb_BidPriceOfCommonStockPerShare": { "xbrltype": "perShareItemType", "nsuri": "http://revbiosciences.com/20230930", "localname": "BidPriceOfCommonStockPerShare", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DisclosureOrganizationAndBasisOfPresentationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Bid price of common stock per share", "label": "Bid Price of Common Stock Per Share", "documentation": "Bid price of common stock per share." } } }, "auth_ref": [] }, "revb_WeightedAverageBlackScholesValuePerStockOption": { "xbrltype": "perShareItemType", "nsuri": "http://revbiosciences.com/20230930", "localname": "WeightedAverageBlackScholesValuePerStockOption", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DisclosureStockbasedCompensationDetails" ], "lang": { "en-us": { "role": { "documentation": "weighted-average black-scholes value per stock option.", "label": "weighted-Average Black-Scholes Value Per Stock Option", "terseLabel": "Weighted-average Black-Scholes value per stock option" } } }, "auth_ref": [] }, "revb_NonCashLeaseExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://revbiosciences.com/20230930", "localname": "NonCashLeaseExpense", "crdr": "debit", "calculation": { "http://revbiosciences.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "Non-cash lease expense.", "label": "Non-cash lease expense" } } }, "auth_ref": [] }, "revb_CashFeePercentage": { "xbrltype": "percentItemType", "nsuri": "http://revbiosciences.com/20230930", "localname": "CashFeePercentage", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DisclosurePipeInvestmentDetails" ], "lang": { "en-us": { "role": { "label": "CashFeePercentage", "documentation": "The percentage of cash fee.", "terseLabel": "Cash fee, percentage" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxPolicyTextBlock", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Income Tax, Policy [Policy Text Block]", "terseLabel": "Income Taxes", "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements." } } }, "auth_ref": [ "r131", "r282", "r283", "r287", "r288", "r289", "r291", "r360" ] }, "revb_PreFundedWarrantsExercise": { "xbrltype": "monetaryItemType", "nsuri": "http://revbiosciences.com/20230930", "localname": "PreFundedWarrantsExercise", "crdr": "credit", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "documentation": "Pre-funded warrants exercise.", "label": "Pre Funded Warrants Exercise", "terseLabel": "Pre-Funded Warrants Exercise" } } }, "auth_ref": [] }, "revb_July2022PublicOfferingMember": { "xbrltype": "domainItemType", "nsuri": "http://revbiosciences.com/20230930", "localname": "July2022PublicOfferingMember", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DisclosureCommonStockDetails", "http://revbiosciences.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfCashFlows", "http://revbiosciences.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "July 2022 Public Offering [Member]", "documentation": "July 2022 public offering.", "terseLabel": "July 2022 Public Offering [Member]", "verboseLabel": "July 2022 Public Offering" } } }, "auth_ref": [] }, "revb_RolloverRestrictedStockUnitAwardsMember": { "xbrltype": "domainItemType", "nsuri": "http://revbiosciences.com/20230930", "localname": "RolloverRestrictedStockUnitAwardsMember", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Rollover RSU awards [Member]", "label": "Rollover Restricted Stock Unit Awards [Member]", "documentation": "Rollover Restricted Stock Unit Awards [Member]" } } }, "auth_ref": [] }, "revb_PurchasePrice": { "xbrltype": "perShareItemType", "nsuri": "http://revbiosciences.com/20230930", "localname": "PurchasePrice", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/Disclosure2023PublicOfferingDetails", "http://revbiosciences.com/20230930/taxonomy/role/DisclosureCommonStockDetails", "http://revbiosciences.com/20230930/taxonomy/role/DisclosurePipeInvestmentDetails", "http://revbiosciences.com/20230930/taxonomy/role/DisclosureWarrantsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Purchase price", "label": "PurchasePrice", "documentation": "The per share price.", "terseLabel": "Purchase price (in Dollars per share)" } } }, "auth_ref": [] }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement [Abstract]" } } }, "auth_ref": [] }, "revb_DeferredOfferingCostsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://revbiosciences.com/20230930", "localname": "DeferredOfferingCostsPolicyTextBlock", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "documentation": "Deferred offering costs.", "label": "Deferred Offering Costs [Policy Text Block]", "terseLabel": "Deferred Offering Costs" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DisclosureStockbasedCompensationDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant", "terseLabel": "Shares available for future grant", "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable." } } }, "auth_ref": [ "r50" ] }, "revb_PublicOfferingLineItems": { "xbrltype": "stringItemType", "nsuri": "http://revbiosciences.com/20230930", "localname": "PublicOfferingLineItems", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/Disclosure2022PublicOfferingDetails", "http://revbiosciences.com/20230930/taxonomy/role/Disclosure2023PublicOfferingDetails", "http://revbiosciences.com/20230930/taxonomy/role/DisclosureUnitsDetails" ], "lang": { "en-us": { "role": { "documentation": "Public Offering [Line Items]", "label": "Public Offering [Line Items]" } } }, "auth_ref": [] }, "revb_IssuanceOfCommonStockForFeesInConnectionWithBusinessCombination": { "xbrltype": "monetaryItemType", "nsuri": "http://revbiosciences.com/20230930", "localname": "IssuanceOfCommonStockForFeesInConnectionWithBusinessCombination", "crdr": "credit", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "documentation": "Issuance of common stock for fees in connection with business combination.", "label": "Issuance of Common Stock for Fees In Connection with Business Combination", "terseLabel": "Issuance of common stock for fees in connection with the Business Combination" } } }, "auth_ref": [] }, "revb_ExceedsPercentage": { "xbrltype": "percentItemType", "nsuri": "http://revbiosciences.com/20230930", "localname": "ExceedsPercentage", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DisclosurePipeInvestmentDetails", "http://revbiosciences.com/20230930/taxonomy/role/DisclosureWarrantsDetails" ], "lang": { "en-us": { "role": { "label": "ExceedsPercentage", "documentation": "The percentage of exceeds.", "terseLabel": "Percentage of exceeds" } } }, "auth_ref": [] }, "revb_ProceedsFromPublicOfferingNet": { "xbrltype": "monetaryItemType", "nsuri": "http://revbiosciences.com/20230930", "localname": "ProceedsFromPublicOfferingNet", "crdr": "debit", "calculation": { "http://revbiosciences.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from the Public Offering, net", "documentation": "Proceeds from public offering net.", "label": "Proceeds From Public Offering Net" } } }, "auth_ref": [] }, "revb_ClassCPreFundedWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://revbiosciences.com/20230930", "localname": "ClassCPreFundedWarrantsMember", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/Disclosure2023PublicOfferingDetails", "http://revbiosciences.com/20230930/taxonomy/role/DisclosureCommonStockDetails", "http://revbiosciences.com/20230930/taxonomy/role/DisclosureCommonStockSummaryOfTotalSharesOfCommonStockReservedForIssuanceParentheticalDetails", "http://revbiosciences.com/20230930/taxonomy/role/DisclosureWarrantsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Class C Pre-Funded Warrants [Member]", "label": "Class C Pre-Funded Warrants [Member]", "documentation": "Class c pre-funded warrants." } } }, "auth_ref": [] }, "revb_IncreaseDecreaseInAccruedInterestNotesPayableAndConvertibleNote": { "xbrltype": "monetaryItemType", "nsuri": "http://revbiosciences.com/20230930", "localname": "IncreaseDecreaseInAccruedInterestNotesPayableAndConvertibleNote", "crdr": "debit", "calculation": { "http://revbiosciences.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 11.0 } }, "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "Increase decrease In accrued interest notes payable and convertible note.", "label": "Increase Decrease In Accrued Interest Notes Payable and Convertible Note", "terseLabel": "Accrued interest on Promissory Notes Payable & Convertible Note" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DisclosureStockbasedCompensationScheduleOfStockOptionsActivityDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]", "terseLabel": "Weighted-average Remaining Contractual Term (Years)" } } }, "auth_ref": [] }, "us-gaap_ContractualObligationDueInNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ContractualObligationDueInNextTwelveMonths", "crdr": "credit", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/revb_r_CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Future obligations", "label": "Contractual Obligation, to be Paid, Year One", "documentation": "Amount of contractual obligation to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": { "http://revbiosciences.com/20230930/taxonomy/role/StatementConsolidatedBalanceSheets1": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/StatementConsolidatedBalanceSheets1" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities and stockholders' equity", "label": "Liabilities and Equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": [ "r73", "r101", "r344", "r466", "r505", "r514", "r554" ] }, "revb_SummaryOfSignificantAccountingPoliciesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://revbiosciences.com/20230930", "localname": "SummaryOfSignificantAccountingPoliciesLineItems", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "label": "Summary Of Significant Accounting Policies [Line Items]", "documentation": "Summary Of Significant Accounting Policies." } } }, "auth_ref": [] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "calculation": { "http://revbiosciences.com/20230930/taxonomy/role/StatementConsolidatedBalanceSheets1": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DisclosureOrganizationAndBasisOfPresentationDetails", "http://revbiosciences.com/20230930/taxonomy/role/StatementConsolidatedBalanceSheets1" ], "lang": { "en-us": { "role": { "label": "Retained Earnings (Accumulated Deficit)", "terseLabel": "Accumulated deficit", "totalLabel": "Retained Earnings (Accumulated Deficit), Total", "periodStartLabel": "Retained Earnings (Accumulated Deficit), Beginning Balance", "periodEndLabel": "Retained Earnings (Accumulated Deficit), Ending Balance", "negatedLabel": "Accumulated deficit", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r70", "r92", "r343", "r355", "r356", "r365", "r390", "r466" ] }, "us-gaap_OperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseRightOfUseAsset", "crdr": "debit", "calculation": { "http://revbiosciences.com/20230930/taxonomy/role/StatementConsolidatedBalanceSheets1": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/StatementConsolidatedBalanceSheets1" ], "lang": { "en-us": { "role": { "label": "Operating Lease, Right-of-Use Asset", "terseLabel": "Right-of-use lease asset", "documentation": "Amount of lessee's right to use underlying asset under operating lease." } } }, "auth_ref": [ "r323" ] }, "revb_PetraAcquisitionIncMember": { "xbrltype": "domainItemType", "nsuri": "http://revbiosciences.com/20230930", "localname": "PetraAcquisitionIncMember", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DisclosureBusinessCombinationDetails", "http://revbiosciences.com/20230930/taxonomy/role/DisclosureCommonStockDetails" ], "lang": { "en-us": { "role": { "documentation": "Petra Acquisition, Inc.", "label": "Petra Acquisition, Inc [Member]", "terseLabel": "Petra [Member]" } } }, "auth_ref": [] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "terseLabel": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/StatementConsolidatedBalanceSheets1" ], "lang": { "en-us": { "role": { "terseLabel": "LIABILITIES AND STOCKHOLDERS EQUITY", "label": "Liabilities and Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ProceedsFromWarrantExercises": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromWarrantExercises", "crdr": "debit", "calculation": { "http://revbiosciences.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 9.0 } }, "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Warrant Exercise", "verboseLabel": "Proceeds from Rollover Warrant exercise", "label": "Proceeds from Warrant exercise", "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants." } } }, "auth_ref": [ "r501" ] }, "us-gaap_ClassOfWarrantOrRightOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightOutstanding", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/Disclosure2023PublicOfferingDetails", "http://revbiosciences.com/20230930/taxonomy/role/DisclosureWarrantsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Warrants outstanding", "terseLabel": "Revalued outstanding warrant", "label": "Class of Warrant or Right, Outstanding", "documentation": "Number of warrants or rights outstanding." } } }, "auth_ref": [] }, "revb_ProposedPublicOfferingAbstract": { "xbrltype": "stringItemType", "nsuri": "http://revbiosciences.com/20230930", "localname": "ProposedPublicOfferingAbstract", "lang": { "en-us": { "role": { "label": "Proposed Public Offering [Abstract]" } } }, "auth_ref": [] }, "revb_ProposedPublicOfferingTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://revbiosciences.com/20230930", "localname": "ProposedPublicOfferingTextBlock", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/Disclosure2022PublicOffering1" ], "lang": { "en-us": { "role": { "verboseLabel": "2022 Public Offering", "label": "ProposedPublicOfferingTextBlock", "terseLabel": "PUBLIC OFFERING" } } }, "auth_ref": [] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "terseLabel": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r481" ] }, "revb_PremiumFinanceAgreement": { "xbrltype": "monetaryItemType", "nsuri": "http://revbiosciences.com/20230930", "localname": "PremiumFinanceAgreement", "crdr": "credit", "calculation": { "http://revbiosciences.com/20230930/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfAccruedExpensesDetails": { "parentTag": "us-gaap_AccruedLiabilitiesCurrentAndNoncurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfAccruedExpensesDetails" ], "lang": { "en-us": { "role": { "documentation": "Premium finance agreement.", "label": "Premium Finance Agreement", "terseLabel": "Premium Finance Agreement - D&O Insurance" } } }, "auth_ref": [] }, "revb_DilutiveSharesMember": { "xbrltype": "domainItemType", "nsuri": "http://revbiosciences.com/20230930", "localname": "DilutiveSharesMember", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DisclosureCommonStockSummaryOfTotalSharesOfCommonStockReservedForIssuanceDetails" ], "lang": { "en-us": { "role": { "documentation": "Dilutive shares.", "label": "Dilutive shares [Member]", "terseLabel": "Dilutive Shares Reserved for Issuance [Member]" } } }, "auth_ref": [] }, "revb_ClassCPreFundedWarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://revbiosciences.com/20230930", "localname": "ClassCPreFundedWarrantMember", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DisclosureSubsequentEventsDetails", "http://revbiosciences.com/20230930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Class C Pre-funded Warrant [Member]", "label": "Class C Pre-funded Warrant [Member]", "documentation": "Class c pre-funded warrant." } } }, "auth_ref": [] }, "revb_AlternativeCashlessExerciseOfCommonStockWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://revbiosciences.com/20230930", "localname": "AlternativeCashlessExerciseOfCommonStockWarrants", "crdr": "credit", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "terseLabel": "Alternative cashless exercise of common stock warrants", "label": "Alternative Cashless Exercise of Common Stock Warrants", "documentation": "Alternative cashless exercise of common stock warrants." } } }, "auth_ref": [] }, "revb_NoninterestExpenseInvestmentAdvisoryFeesInFormOfEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://revbiosciences.com/20230930", "localname": "NoninterestExpenseInvestmentAdvisoryFeesInFormOfEquity", "crdr": "debit", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/revb_r_CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "documentation": "Noninterest expense investment advisory fees in form of equity.", "label": "Noninterest Expense Investment Advisory Fees in form of Equity", "terseLabel": "Unpaid banking advisory fees in form of equity" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfStockByClassTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfStockByClassTable", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DisclosureCommonStockDetails", "http://revbiosciences.com/20230930/taxonomy/role/DisclosureCommonStockSummaryOfTotalSharesOfCommonStockReservedForIssuanceDetails", "http://revbiosciences.com/20230930/taxonomy/role/DisclosureCommonStockSummaryOfTotalSharesOfCommonStockReservedForIssuanceParentheticalDetails", "http://revbiosciences.com/20230930/taxonomy/role/DisclosurePreferredStockDetails" ], "lang": { "en-us": { "role": { "label": "Schedule of Stock by Class [Table]", "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity." } } }, "auth_ref": [ "r41", "r42", "r43", "r45", "r46", "r47", "r48", "r89", "r91", "r92", "r125", "r126", "r127", "r168", "r218", "r219", "r220", "r221", "r222", "r224", "r225", "r361", "r362", "r363", "r364", "r458", "r490", "r503" ] }, "us-gaap_ClassOfStockLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfStockLineItems", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DisclosureCommonStockDetails", "http://revbiosciences.com/20230930/taxonomy/role/DisclosureCommonStockSummaryOfTotalSharesOfCommonStockReservedForIssuanceDetails", "http://revbiosciences.com/20230930/taxonomy/role/DisclosureCommonStockSummaryOfTotalSharesOfCommonStockReservedForIssuanceParentheticalDetails", "http://revbiosciences.com/20230930/taxonomy/role/DisclosurePreferredStockDetails" ], "lang": { "en-us": { "role": { "label": "Class of Stock [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r125", "r126", "r127", "r168", "r218", "r219", "r220", "r221", "r222", "r224", "r225", "r361", "r362", "r363", "r364", "r458", "r490", "r503" ] }, "revb_ExpenseIncurredForUpfrontMonthlyAndInterestPayments": { "xbrltype": "monetaryItemType", "nsuri": "http://revbiosciences.com/20230930", "localname": "ExpenseIncurredForUpfrontMonthlyAndInterestPayments", "crdr": "debit", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/revb_r_CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "documentation": "Expense incurred for upfront, monthly and interest payments", "label": "Expense incurred for upfront, monthly and interest payments", "terseLabel": "Total expense incurred for upfront, monthly and interest payments" } } }, "auth_ref": [] }, "revb_NumberOfAdditionalCalendarDayGracePeriod": { "xbrltype": "durationItemType", "nsuri": "http://revbiosciences.com/20230930", "localname": "NumberOfAdditionalCalendarDayGracePeriod", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DisclosureOrganizationAndBasisOfPresentationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of additional calendar day grace period", "label": "Number of Additional Calendar Day Grace Period", "documentation": "Number of additional calendar day grace period." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "terseLabel": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r480" ] }, "us-gaap_FairValueAdjustmentOfWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAdjustmentOfWarrants", "crdr": "debit", "calculation": { "http://revbiosciences.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0, "order": 0.0 }, "http://revbiosciences.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DisclosureWarrantsDetails", "http://revbiosciences.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfCashFlows", "http://revbiosciences.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "negatedLabel": "Change in fair value of warrant liability", "verboseLabel": "Fair value of warrants", "terseLabel": "Change in fair value of warrant liability", "label": "Fair Value Adjustment of Warrants", "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability." } } }, "auth_ref": [ "r0", "r4" ] }, "revb_AlternativeCashlessOfCommonStockWarrantsExercise": { "xbrltype": "monetaryItemType", "nsuri": "http://revbiosciences.com/20230930", "localname": "AlternativeCashlessOfCommonStockWarrantsExercise", "crdr": "credit", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Alternative cashless exercise of Class C Common Stock Warrants", "label": "Alternative Cashless of Common Stock Warrants Exercise", "documentation": "Alternative cashless of common stock warrants exercise." } } }, "auth_ref": [] }, "revb_PreferredStockExchangedToCommonStockConnectionWithBusinessCombination": { "xbrltype": "sharesItemType", "nsuri": "http://revbiosciences.com/20230930", "localname": "PreferredStockExchangedToCommonStockConnectionWithBusinessCombination", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DisclosurePreferredStockDetails" ], "lang": { "en-us": { "role": { "documentation": "Preferred stock exchanged to common stock connection with business combination.", "label": "Preferred Stock Exchanged to Common Stock Connection with Business Combination", "terseLabel": "Preferred stock exchanged to common stock connection with business combination" } } }, "auth_ref": [] }, "revb_ForwardSharePurchaseAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://revbiosciences.com/20230930", "localname": "ForwardSharePurchaseAgreementMember", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DisclosureBusinessCombinationDetails", "http://revbiosciences.com/20230930/taxonomy/role/DisclosureCommonStockDetails" ], "lang": { "en-us": { "role": { "label": "ForwardSharePurchaseAgreementMember", "terseLabel": "Forward Share Purchase agreement [Member]" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityAbstract", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/StatementConsolidatedBalanceSheets1" ], "lang": { "en-us": { "role": { "terseLabel": "Stockholders' equity:", "label": "Equity, Attributable to Parent [Abstract]" } } }, "auth_ref": [] }, "revb_CommonWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://revbiosciences.com/20230930", "localname": "CommonWarrantsMember", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DisclosureCommonStockDetails", "http://revbiosciences.com/20230930/taxonomy/role/DisclosurePipeInvestmentDetails" ], "lang": { "en-us": { "role": { "label": "CommonWarrantsMember", "terseLabel": "Common Warrants [Member]" } } }, "auth_ref": [] }, "revb_UpfrontPaymentDue": { "xbrltype": "monetaryItemType", "nsuri": "http://revbiosciences.com/20230930", "localname": "UpfrontPaymentDue", "crdr": "credit", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/revb_r_CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "documentation": "Upfront payment due.", "label": "Upfront payment due" } } }, "auth_ref": [] }, "revb_DeferredUnderwritingCommissionsAssumedInBusinessCombination": { "xbrltype": "monetaryItemType", "nsuri": "http://revbiosciences.com/20230930", "localname": "DeferredUnderwritingCommissionsAssumedInBusinessCombination", "crdr": "credit", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "Deferred underwriting commissions assumed in business combination.", "label": "Deferred Underwriting Commissions Assumed in Business Combination", "terseLabel": "Deferred underwriting commissions assumed in the Business Combination" } } }, "auth_ref": [] }, "revb_PlacementAgentMember": { "xbrltype": "domainItemType", "nsuri": "http://revbiosciences.com/20230930", "localname": "PlacementAgentMember", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DisclosurePipeInvestmentDetails" ], "lang": { "en-us": { "role": { "label": "PlacementAgentMember", "terseLabel": "Placement Agent [Member]" } } }, "auth_ref": [] }, "us-gaap_PaymentsForRepurchaseOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsForRepurchaseOfCommonStock", "crdr": "credit", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DisclosureBusinessCombinationDetails" ], "lang": { "en-us": { "role": { "label": "Payments for Repurchase of Common Stock", "terseLabel": "Aggregate share value (in Dollars)", "documentation": "The cash outflow to reacquire common stock during the period." } } }, "auth_ref": [ "r26" ] }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DisclosureCommonStockDetails", "http://revbiosciences.com/20230930/taxonomy/role/DisclosureWarrantsDetails" ], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights", "verboseLabel": "Warrants shares", "terseLabel": "Sale of additional private warrants (in Shares)", "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares." } } }, "auth_ref": [ "r226" ] }, "revb_BusinessCombinationMember": { "xbrltype": "domainItemType", "nsuri": "http://revbiosciences.com/20230930", "localname": "BusinessCombinationMember", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DisclosureBusinessCombinationDetails", "http://revbiosciences.com/20230930/taxonomy/role/DisclosureCommonStockDetails", "http://revbiosciences.com/20230930/taxonomy/role/DisclosureOrganizationAndBasisOfPresentationDetails" ], "lang": { "en-us": { "role": { "label": "BusinessCombinationMember", "terseLabel": "Business Combination [Member]" } } }, "auth_ref": [] }, "revb_ConversionOfAccruedExpensesToEquityInConnectionWithTheBusinessCombination": { "xbrltype": "monetaryItemType", "nsuri": "http://revbiosciences.com/20230930", "localname": "ConversionOfAccruedExpensesToEquityInConnectionWithTheBusinessCombination", "crdr": "credit", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Conversion of Accrued Expenses to Equity in connection with the Business Combination", "terseLabel": "Conversion of Accrued Expenses to Equity in connection with the Business Combination", "documentation": "Conversion of accrued expenses to equity in connection with the business combination." } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityNoteAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityNoteAbstract", "lang": { "en-us": { "role": { "label": "Stockholders' Equity Note [Abstract]" } } }, "auth_ref": [] }, "revb_BusinessCombinationSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://revbiosciences.com/20230930", "localname": "BusinessCombinationSharesIssued", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DisclosureBusinessCombinationDetails" ], "lang": { "en-us": { "role": { "documentation": "Business combination shares issued.", "label": "Business Combination Shares Issued", "terseLabel": "Business combination, shares issued (in Shares)" } } }, "auth_ref": [] }, "revb_ScenarioTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://revbiosciences.com/20230930", "localname": "ScenarioTwoMember", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DisclosureStockbasedCompensationDetails" ], "lang": { "en-us": { "role": { "documentation": "Scenario two.", "label": "Scenario Two [Member]", "terseLabel": "Vesting Quarterly over Four Years [Member]" } } }, "auth_ref": [] }, "revb_CommitmentsandContingenciesDetailsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://revbiosciences.com/20230930", "localname": "CommitmentsandContingenciesDetailsLineItems", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/revb_r_CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies (Details) [Line Items]" } } }, "auth_ref": [] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "revb_PetraShareRepurchaseMember": { "xbrltype": "domainItemType", "nsuri": "http://revbiosciences.com/20230930", "localname": "PetraShareRepurchaseMember", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DisclosureBusinessCombinationDetails" ], "lang": { "en-us": { "role": { "documentation": "Petra share repurchase member.", "label": "Petra Share Repurchase [Member]", "terseLabel": "Petra Share Repurchase [Member]" } } }, "auth_ref": [] }, "us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend": { "xbrltype": "booleanItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseExistenceOfOptionToExtend", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/revb_r_CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Existence of Option to Extend [true false]", "terseLabel": "Operating lease, existence of option to extend", "documentation": "Indicates (true false) whether lessee has option to extend operating lease." } } }, "auth_ref": [ "r326" ] }, "revb_NoncashFairValueOfNewCommonStockWarrantsWithPublicOffering": { "xbrltype": "monetaryItemType", "nsuri": "http://revbiosciences.com/20230930", "localname": "NoncashFairValueOfNewCommonStockWarrantsWithPublicOffering", "crdr": "debit", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value of Common Stock Warrants in connection with Public Offering", "label": "Noncash Fair Value of New Common Stock Warrants with Public Offering", "documentation": "Noncash fair value of new common stock warrants with public offering." } } }, "auth_ref": [] }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SaleOfStockNameOfTransactionDomain", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DisclosureCommonStockDetails", "http://revbiosciences.com/20230930/taxonomy/role/DisclosureOrganizationAndBasisOfPresentationDetails", "http://revbiosciences.com/20230930/taxonomy/role/DisclosurePipeInvestmentDetails", "http://revbiosciences.com/20230930/taxonomy/role/DisclosureSubsequentEventsDetails", "http://revbiosciences.com/20230930/taxonomy/role/DisclosureUnitsDetails", "http://revbiosciences.com/20230930/taxonomy/role/DisclosureWarrantsDetails", "http://revbiosciences.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfCashFlows", "http://revbiosciences.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Sale of Stock [Domain]", "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement." } } }, "auth_ref": [] }, "revb_AggregateValueOfWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://revbiosciences.com/20230930", "localname": "AggregateValueOfWarrants", "crdr": "debit", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/Disclosure2022PublicOfferingDetails", "http://revbiosciences.com/20230930/taxonomy/role/Disclosure2023PublicOfferingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate value of warrants", "label": "Aggregate Value Of Warrants", "documentation": "Aggregate value of warrants" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityReverseStockSplit": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityReverseStockSplit", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DisclosureCommonStockDetails" ], "lang": { "en-us": { "role": { "label": "Stockholders' Equity, Reverse Stock Split", "terseLabel": "Reverse stock split term", "documentation": "Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements." } } }, "auth_ref": [ "r93" ] }, "us-gaap_SaleOfStockPricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SaleOfStockPricePerShare", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DisclosureWarrantsDetails" ], "lang": { "en-us": { "role": { "label": "Sale of Stock, Price Per Share", "terseLabel": "Sale of stock price", "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction." } } }, "auth_ref": [] }, "revb_PublicOfferingTable": { "xbrltype": "stringItemType", "nsuri": "http://revbiosciences.com/20230930", "localname": "PublicOfferingTable", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/Disclosure2022PublicOfferingDetails", "http://revbiosciences.com/20230930/taxonomy/role/Disclosure2023PublicOfferingDetails", "http://revbiosciences.com/20230930/taxonomy/role/DisclosureUnitsDetails" ], "lang": { "en-us": { "role": { "documentation": "Public Offering [Table]", "label": "Public Offering [Table]" } } }, "auth_ref": [] }, "us-gaap_BalanceSheetRelatedDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BalanceSheetRelatedDisclosuresAbstract", "lang": { "en-us": { "role": { "label": "Balance Sheet Related Disclosures [Abstract]" } } }, "auth_ref": [] }, "revb_PIPEInvestmentOrSecuritiesPurchaseAgreementTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://revbiosciences.com/20230930", "localname": "PIPEInvestmentOrSecuritiesPurchaseAgreementTextBlock", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DisclosurePipeInvestment1" ], "lang": { "en-us": { "role": { "documentation": "PIPE investment or securities purchase agreement.", "label": "P I P E Investment or Securities Purchase Agreement [Text Block]", "terseLabel": "PIPE Investment" } } }, "auth_ref": [] }, "revb_DeferredOfferingCostsIncludedInAccountsPayableAndAccruedExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://revbiosciences.com/20230930", "localname": "DeferredOfferingCostsIncludedInAccountsPayableAndAccruedExpenses", "crdr": "credit", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "Deferred offering costs included in accounts payable and accrued expenses.", "label": "Deferred Offering Costs Included in Accounts Payable and Accrued Expenses" } } }, "auth_ref": [] }, "revb_DeferredUnderwritingFees": { "xbrltype": "monetaryItemType", "nsuri": "http://revbiosciences.com/20230930", "localname": "DeferredUnderwritingFees", "crdr": "debit", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/revb_r_CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "documentation": "Deferred underwriting fees", "label": "Deferred Underwriting Fees", "verboseLabel": "Deferred underwriting fees" } } }, "auth_ref": [] }, "revb_GrossPurchasePrice": { "xbrltype": "perShareItemType", "nsuri": "http://revbiosciences.com/20230930", "localname": "GrossPurchasePrice", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DisclosurePipeInvestmentDetails" ], "lang": { "en-us": { "role": { "label": "GrossPurchasePrice", "documentation": "The amount of gross purchase price.", "terseLabel": "Gross purchase price (in Dollars per share)" } } }, "auth_ref": [] }, "revb_CommonStockTransferred": { "xbrltype": "sharesItemType", "nsuri": "http://revbiosciences.com/20230930", "localname": "CommonStockTransferred", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/revb_r_CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "documentation": "Common stock transferred.", "label": "Common Stock Transferred", "terseLabel": "Common stocks transferred" } } }, "auth_ref": [] }, "revb_EquityAwardsMember": { "xbrltype": "domainItemType", "nsuri": "http://revbiosciences.com/20230930", "localname": "EquityAwardsMember", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DisclosureStockbasedCompensationDetails" ], "lang": { "en-us": { "role": { "documentation": "Equity awards.", "label": "Equity Awards [Member]" } } }, "auth_ref": [] }, "revb_StockOptionsMaximumTerm": { "xbrltype": "durationItemType", "nsuri": "http://revbiosciences.com/20230930", "localname": "StockOptionsMaximumTerm", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DisclosureStockbasedCompensationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stock options, maximum term", "label": "Stock Options Maximum Term", "documentation": "Stock options maximum term." } } }, "auth_ref": [] }, "revb_SeriesA1PreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://revbiosciences.com/20230930", "localname": "SeriesA1PreferredStockMember", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DisclosureCommonStockSummaryOfTotalSharesOfCommonStockReservedForIssuanceDetails", "http://revbiosciences.com/20230930/taxonomy/role/DisclosurePreferredStockDetails", "http://revbiosciences.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfCashFlows", "http://revbiosciences.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "documentation": "Series A-1 preferred stock", "label": "Series A-1 Preferred Stock [Member]", "terseLabel": "Series A-1 Preferred Stock [Member]", "verboseLabel": "Series A-1 preferred stock" } } }, "auth_ref": [] }, "revb_UnitsSeparatedIntoCommonStockAndPublicWarrantDescription": { "xbrltype": "stringItemType", "nsuri": "http://revbiosciences.com/20230930", "localname": "UnitsSeparatedIntoCommonStockAndPublicWarrantDescription", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DisclosureOrganizationAndBasisOfPresentationDetails" ], "lang": { "en-us": { "role": { "documentation": "Units separated into common stock and public warrant description.", "label": "Units separated into common stock and public warrant description" } } }, "auth_ref": [] }, "revb_NumberOfCalendarDayGracePeriodExtension": { "xbrltype": "durationItemType", "nsuri": "http://revbiosciences.com/20230930", "localname": "NumberOfCalendarDayGracePeriodExtension", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DisclosureOrganizationAndBasisOfPresentationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of calendar day grace period extension", "label": "Number of Calendar Day Grace Period Extension", "documentation": "Number of calendar day grace period extension." } } }, "auth_ref": [] }, "us-gaap_WarrantsAndRightsNoteDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WarrantsAndRightsNoteDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Warrants and Rights Note Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LesseeOperatingLeaseOptionToExtend": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseOptionToExtend", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/revb_r_CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Option to Extend", "terseLabel": "Operating lease option to extend", "documentation": "Description of terms and conditions of option to extend lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability." } } }, "auth_ref": [ "r326" ] }, "revb_AggregateNumberOfSharesSoldPercentage": { "xbrltype": "percentItemType", "nsuri": "http://revbiosciences.com/20230930", "localname": "AggregateNumberOfSharesSoldPercentage", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/Disclosure2022PublicOfferingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Percentage of shares sold in public offering", "label": "Aggregate Number Of Shares Sold, Percentage", "documentation": "Aggregate number of shares sold, percentage" } } }, "auth_ref": [] }, "us-gaap_RepaymentsOfConvertibleDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RepaymentsOfConvertibleDebt", "crdr": "credit", "calculation": { "http://revbiosciences.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Repayments of Convertible Debt", "negatedLabel": "Repayment of the Convertible Note", "documentation": "The cash outflow from the repayment of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder." } } }, "auth_ref": [ "r27" ] }, "revb_IssuanceOfCommonStockInConnectionWithTheBusinessCombinationNetShares": { "xbrltype": "sharesItemType", "nsuri": "http://revbiosciences.com/20230930", "localname": "IssuanceOfCommonStockInConnectionWithTheBusinessCombinationNetShares", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "documentation": "Issuance of common stock in connection with the business combination net shares.", "label": "Issuance Of Common Stock In Connection With The Business Combination Net Shares", "terseLabel": "Issuance of common stock in connection with the Business Combination, net (in shares)" } } }, "auth_ref": [] }, "us-gaap_StockRedeemedOrCalledDuringPeriodShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockRedeemedOrCalledDuringPeriodShares", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DisclosureBusinessCombinationDetails", "http://revbiosciences.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquityDeficit", "http://revbiosciences.com/20230930/taxonomy/role/revb_r_CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Redemption of Preferred Stock ( in shares)", "label": "Stock Redeemed or Called During Period, Shares", "terseLabel": "Aggregate shares purchased (in Shares)", "documentation": "Number of stock bought back by the entity at the exercise price or redemption price." } } }, "auth_ref": [ "r6" ] }, "revb_StockGrantsUnderTwoThousandTwentyOneEquityPlanMember": { "xbrltype": "domainItemType", "nsuri": "http://revbiosciences.com/20230930", "localname": "StockGrantsUnderTwoThousandTwentyOneEquityPlanMember", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DisclosureCommonStockSummaryOfTotalSharesOfCommonStockReservedForIssuanceDetails" ], "lang": { "en-us": { "role": { "documentation": "Stock grants under two thousand twenty one Equity Plan [Member]", "label": "Stock grants under two thousand twenty one Equity Plan [Member]", "terseLabel": "Stock Grants under 2021 Equity Plan [Member]", "verboseLabel": "Shares Available for Future Stock Grants under 2021 Equity Plan [Member]" } } }, "auth_ref": [] }, "revb_NonTaxableIncomeFromFairValueChangeOfWarrantLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://revbiosciences.com/20230930", "localname": "NonTaxableIncomeFromFairValueChangeOfWarrantLiability", "crdr": "credit", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/revb_r_IncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Non-taxable income from fair value change of warrant liability", "label": "Non-taxable Income from Fair Value Change of Warrant Liability", "documentation": "Non-taxable income from fair value change of warrant liability." } } }, "auth_ref": [] }, "revb_WarrantLiabilityPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://revbiosciences.com/20230930", "localname": "WarrantLiabilityPolicyPolicyTextBlock", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Warrant Liability", "label": "Warrant Liability, Policy [Policy Text Block]", "documentation": "Warrant Liability, Policy [Policy Text Block]" } } }, "auth_ref": [] }, "revb_RepaymentsOfNotesPayableIncludingInterestExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://revbiosciences.com/20230930", "localname": "RepaymentsOfNotesPayableIncludingInterestExpenses", "crdr": "credit", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DisclosureBusinessCombinationDetails" ], "lang": { "en-us": { "role": { "documentation": "Repayments of notes payable including interest expenses.", "label": "Repayments of Notes Payable Including Interest Expenses", "terseLabel": "Repayments of Promissory Notes Payable, including interest" } } }, "auth_ref": [] }, "us-gaap_PaymentsForRepurchaseOfRedeemablePreferredStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsForRepurchaseOfRedeemablePreferredStock", "crdr": "credit", "calculation": { "http://revbiosciences.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 8.0 } }, "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Redemption of Series A Preferred Stock", "label": "Payments for Repurchase of Redeemable Preferred Stock", "documentation": "The cash outflow for reacquisition of callable preferred stock." } } }, "auth_ref": [ "r26" ] }, "revb_FebruaryFiveTwoThousandTwentyFourMember": { "xbrltype": "domainItemType", "nsuri": "http://revbiosciences.com/20230930", "localname": "FebruaryFiveTwoThousandTwentyFourMember", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DisclosureOrganizationAndBasisOfPresentationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Until February 5, 2024 [Member]", "label": "February Five Two Thousand Twenty Four [Member]", "documentation": "February 5, 2024" } } }, "auth_ref": [] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Ex Transition Period", "terseLabel": "Entity Ex Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r489" ] }, "us-gaap_PaymentsForRepurchaseOfInitialPublicOffering": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsForRepurchaseOfInitialPublicOffering", "crdr": "credit", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/revb_r_CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "label": "Payments for Repurchase of Initial Public Offering", "terseLabel": "Repayments of initial public offering", "documentation": "The cash outflow associated with the repurchase of amount received from entity's first offering of stock to the public." } } }, "auth_ref": [ "r26" ] }, "revb_ScenarioOneMember": { "xbrltype": "domainItemType", "nsuri": "http://revbiosciences.com/20230930", "localname": "ScenarioOneMember", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DisclosureStockbasedCompensationDetails" ], "lang": { "en-us": { "role": { "documentation": "Scenario one.", "label": "Scenario One [Member]", "terseLabel": "Any Stockholders Holding 10% or More of Equity [Member]" } } }, "auth_ref": [] }, "revb_AgreementDomain": { "xbrltype": "domainItemType", "nsuri": "http://revbiosciences.com/20230930", "localname": "AgreementDomain", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DisclosureBusinessCombinationDetails", "http://revbiosciences.com/20230930/taxonomy/role/DisclosureCommonStockDetails", "http://revbiosciences.com/20230930/taxonomy/role/DisclosurePipeInvestmentDetails" ], "lang": { "en-us": { "role": { "label": "Agreement [Domain]" } } }, "auth_ref": [] }, "revb_CashlessCommonStockWarrantsExerciseShares": { "xbrltype": "sharesItemType", "nsuri": "http://revbiosciences.com/20230930", "localname": "CashlessCommonStockWarrantsExerciseShares", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "terseLabel": "Cashless common stock warrants exercise (in shares)", "label": "Cashless Common Stock Warrants Exercise Shares", "documentation": "Cashless common stock warrants exercise shares." } } }, "auth_ref": [] }, "us-gaap_AllocatedShareBasedCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AllocatedShareBasedCompensationExpense", "crdr": "debit", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DisclosurePipeInvestmentDetails", "http://revbiosciences.com/20230930/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockbasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Expense", "terseLabel": "Aggregate value (in Dollars)", "verboseLabel": "Stock-based compensation expense", "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized." } } }, "auth_ref": [ "r265", "r277" ] }, "revb_RolloverWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://revbiosciences.com/20230930", "localname": "RolloverWarrantsMember", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DisclosureCommonStockSummaryOfTotalSharesOfCommonStockReservedForIssuanceDetails", "http://revbiosciences.com/20230930/taxonomy/role/DisclosureCommonStockSummaryOfTotalSharesOfCommonStockReservedForIssuanceParentheticalDetails", "http://revbiosciences.com/20230930/taxonomy/role/DisclosureWarrantsDetails", "http://revbiosciences.com/20230930/taxonomy/role/DisclosureWarrantsScheduleOfFairValueOfWarrantsEstimatedUsingBlackscholesOptionPricingModelDetails", "http://revbiosciences.com/20230930/taxonomy/role/DisclosureWarrantsTables", "http://revbiosciences.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "Rollover Warrants.", "label": "Rollover Warrants [Member]", "terseLabel": "Rollover Warrants [Member]" } } }, "auth_ref": [] }, "revb_PremiumFinanceAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://revbiosciences.com/20230930", "localname": "PremiumFinanceAgreementMember", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/revb_r_CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "label": "PremiumFinanceAgreementMember", "terseLabel": "Premium Finance Agreement [Member]" } } }, "auth_ref": [] }, "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockbasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "revb_AntidilutiveSecuritiesIncludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://revbiosciences.com/20230930", "localname": "AntidilutiveSecuritiesIncludedFromComputationOfEarningsPerShareAmount", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Potential shares included in common stock", "label": "Antidilutive Securities Included from Computation of Earnings Per Share, Amount", "documentation": "Antidilutive securities included from computation of earnings per share, amount." } } }, "auth_ref": [] }, "revb_RolloverWarrantExercise": { "xbrltype": "monetaryItemType", "nsuri": "http://revbiosciences.com/20230930", "localname": "RolloverWarrantExercise", "crdr": "credit", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "documentation": "Rollover warrant exercise.", "label": "Rollover Warrant Exercise", "terseLabel": "Rollover Warrant Exercise" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "revb_NoncashEquityIssuanceForFeesUponBusinessCombination": { "xbrltype": "monetaryItemType", "nsuri": "http://revbiosciences.com/20230930", "localname": "NoncashEquityIssuanceForFeesUponBusinessCombination", "crdr": "debit", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "Noncash equity issuance for fees upon business combination.", "label": "Noncash Equity Issuance for Fees Upon Business Combination", "terseLabel": "Equity Issuance for fees in connection with the Business Combination" } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingencies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingencies", "crdr": "credit", "calculation": { "http://revbiosciences.com/20230930/taxonomy/role/StatementConsolidatedBalanceSheets1": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/StatementConsolidatedBalanceSheets1" ], "lang": { "en-us": { "role": { "terseLabel": "Commitments and Contingencies (Note 4)", "label": "Commitments and Contingencies", "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur." } } }, "auth_ref": [ "r20", "r62", "r340", "r388" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DisclosureBusinessCombinationDetails", "http://revbiosciences.com/20230930/taxonomy/role/DisclosureStockbasedCompensationDetails", "http://revbiosciences.com/20230930/taxonomy/role/DisclosureStockbasedCompensationScheduleOfStockOptionsActivityDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Common stock reserved for issuance", "terseLabel": "Granted", "label": "Options, granted", "documentation": "Gross number of share options (or share units) granted during the period." } } }, "auth_ref": [ "r244" ] }, "revb_ClassAPreFundedWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://revbiosciences.com/20230930", "localname": "ClassAPreFundedWarrantsMember", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DisclosureCommonStockDetails", "http://revbiosciences.com/20230930/taxonomy/role/DisclosurePipeInvestmentDetails", "http://revbiosciences.com/20230930/taxonomy/role/DisclosureWarrantsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Class A Pre-Funded Warrants [Member]", "label": "Class A Pre-Funded Warrants [Member]", "documentation": "Class a pre-funded warrants." } } }, "auth_ref": [] }, "revb_WarrantsAndRightExpirationDate": { "xbrltype": "dateItemType", "nsuri": "http://revbiosciences.com/20230930", "localname": "WarrantsAndRightExpirationDate", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/Disclosure2022PublicOfferingDetails", "http://revbiosciences.com/20230930/taxonomy/role/Disclosure2023PublicOfferingDetails", "http://revbiosciences.com/20230930/taxonomy/role/DisclosurePipeInvestmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Warrants and rights expiration date", "label": "Warrants and Right Expiration Date", "documentation": "Warrants and right expiration date." } } }, "auth_ref": [] }, "revb_NumberOfNewSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://revbiosciences.com/20230930", "localname": "NumberOfNewSharesIssued", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DisclosureUnitsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of new shares issued", "label": "Number of New Shares Issued", "documentation": "Number of new shares issued." } } }, "auth_ref": [] }, "revb_NumberOfMonthlyInstallments": { "xbrltype": "integerItemType", "nsuri": "http://revbiosciences.com/20230930", "localname": "NumberOfMonthlyInstallments", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/revb_r_CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of monthly installments.", "label": "Number of Monthly Installments", "terseLabel": "Number of monthly installments" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "revb_ProceedsFromBusinessCombinationFinancingActivity": { "xbrltype": "monetaryItemType", "nsuri": "http://revbiosciences.com/20230930", "localname": "ProceedsFromBusinessCombinationFinancingActivity", "crdr": "debit", "calculation": { "http://revbiosciences.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "Proceeds from business combination (Financing activity).", "label": "Proceeds from Business Combination (Financing Activity)", "terseLabel": "Proceeds from the Business Combination, net" } } }, "auth_ref": [] }, "revb_SecuritiesPurchaseAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://revbiosciences.com/20230930", "localname": "SecuritiesPurchaseAgreementMember", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DisclosureCommonStockDetails", "http://revbiosciences.com/20230930/taxonomy/role/DisclosurePipeInvestmentDetails" ], "lang": { "en-us": { "role": { "label": "SecuritiesPurchaseAgreementMember", "terseLabel": "Securities Purchase Agreement [Member]" } } }, "auth_ref": [] }, "revb_ProceedsFromPipeInvestmentFinancingActivity": { "xbrltype": "monetaryItemType", "nsuri": "http://revbiosciences.com/20230930", "localname": "ProceedsFromPipeInvestmentFinancingActivity", "crdr": "debit", "calculation": { "http://revbiosciences.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "Proceeds from PIPE investment (Financing activity).", "label": "Proceeds from PIPE Investment (Financing Activity)", "terseLabel": "Proceeds from the PIPE Investment, net" } } }, "auth_ref": [] }, "us-gaap_CommonClassCMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonClassCMember", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfCashFlows", "http://revbiosciences.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "terseLabel": "Class C Common Stock", "label": "Common Class C [Member]", "documentation": "Classification of common stock that has different rights than provided to Class A or B shares, representing ownership interest in a corporation." } } }, "auth_ref": [] }, "revb_ClassOfWarrantOrRightIssued": { "xbrltype": "sharesItemType", "nsuri": "http://revbiosciences.com/20230930", "localname": "ClassOfWarrantOrRightIssued", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/Disclosure2022PublicOfferingDetails", "http://revbiosciences.com/20230930/taxonomy/role/DisclosureWarrantsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Warrants to purchase an aggregate shares of common stock", "documentation": "Class of warrant or right issued.", "label": "Class Of Warrant Or Right Issued", "terseLabel": "Warrants to purchase an aggregate shares of common stock" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensation", "crdr": "debit", "calculation": { "http://revbiosciences.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Share-based Payment Arrangement, Noncash Expense, Total", "label": "Share-Based Payment Arrangement, Noncash Expense", "terseLabel": "Stock-based compensation expense", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": [ "r3" ] }, "revb_IssuanceOfCommonStockForFeesInConnectionWithBusinessCombinationShares": { "xbrltype": "sharesItemType", "nsuri": "http://revbiosciences.com/20230930", "localname": "IssuanceOfCommonStockForFeesInConnectionWithBusinessCombinationShares", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "documentation": "Issuance of common stock for fees in connection with business combination, shares.", "label": "Issuance of Common Stock for Fees in Connection With Business Combination, Shares", "terseLabel": "Issuance of common stock for fees in connection with the Business Combination (Shares)" } } }, "auth_ref": [] }, "us-gaap_IPOMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IPOMember", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DisclosureOrganizationAndBasisOfPresentationDetails", "http://revbiosciences.com/20230930/taxonomy/role/DisclosureSubsequentEventsDetails", "http://revbiosciences.com/20230930/taxonomy/role/DisclosureUnitsDetails", "http://revbiosciences.com/20230930/taxonomy/role/DisclosureWarrantsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Public Offering [Member]", "label": "IPO [Member]", "terseLabel": "Initial Public Offering [Member]", "documentation": "First sale of stock by a private company to the public." } } }, "auth_ref": [] }, "revb_TwoThousandAndTwentyEquityIncentivePlanMember": { "xbrltype": "domainItemType", "nsuri": "http://revbiosciences.com/20230930", "localname": "TwoThousandAndTwentyEquityIncentivePlanMember", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DisclosureStockbasedCompensationDetails" ], "lang": { "en-us": { "role": { "documentation": "Two thousand and twenty equity incentive plan.", "label": "Two Thousand and Twenty Equity Incentive Plan [Member]", "terseLabel": "2020 Equity Incentive Plan [Member]" } } }, "auth_ref": [] }, "revb_AgreementAxis": { "xbrltype": "stringItemType", "nsuri": "http://revbiosciences.com/20230930", "localname": "AgreementAxis", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DisclosureBusinessCombinationDetails", "http://revbiosciences.com/20230930/taxonomy/role/DisclosureCommonStockDetails", "http://revbiosciences.com/20230930/taxonomy/role/DisclosurePipeInvestmentDetails" ], "lang": { "en-us": { "role": { "documentation": "Agreement [Axis]", "label": "Agreement [Axis]", "terseLabel": "Agreement [Axis]" } } }, "auth_ref": [] }, "revb_StockOptionsMinimumTerm": { "xbrltype": "durationItemType", "nsuri": "http://revbiosciences.com/20230930", "localname": "StockOptionsMinimumTerm", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DisclosureStockbasedCompensationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stock options, minimum term", "label": "Stock Options, Minimum Term", "documentation": "Stock options, minimum term." } } }, "auth_ref": [] }, "revb_PrepaidClinicalCostsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://revbiosciences.com/20230930", "localname": "PrepaidClinicalCostsCurrent", "crdr": "debit", "calculation": { "http://revbiosciences.com/20230930/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails": { "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails" ], "lang": { "en-us": { "role": { "documentation": "Prepaid clinical costs current.", "label": "Prepaid Clinical Costs Current", "terseLabel": "Prepaid clinical costs" } } }, "auth_ref": [] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "terseLabel": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r480" ] }, "srt_CondensedBalanceSheetStatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "CondensedBalanceSheetStatementTable", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfAccruedExpensesDetails" ], "lang": { "en-us": { "role": { "label": "Condensed Balance Sheet Statement [Table]" } } }, "auth_ref": [ "r142", "r492" ] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r480" ] }, "us-gaap_StockRedeemedOrCalledDuringPeriodValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockRedeemedOrCalledDuringPeriodValue", "crdr": "debit", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DisclosureBusinessCombinationDetails", "http://revbiosciences.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Redemption of Preferred Stock", "verboseLabel": "Common stock, redemption value", "terseLabel": "Accretion of common stock to redemption amount", "documentation": "Equity impact of the value of stock bought back by the entity at the exercise price or redemption price." } } }, "auth_ref": [ "r6" ] }, "us-gaap_PlanNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PlanNameAxis", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DisclosureBusinessCombinationDetails", "http://revbiosciences.com/20230930/taxonomy/role/DisclosureStockbasedCompensationDetails" ], "lang": { "en-us": { "role": { "label": "Plan Name [Axis]", "documentation": "Information by plan name for share-based payment arrangement." } } }, "auth_ref": [ "r525", "r526", "r527", "r528", "r529", "r530", "r531", "r532", "r533", "r534", "r535", "r536", "r537", "r538", "r539", "r540", "r541", "r542", "r543", "r544", "r545", "r546", "r547", "r548", "r549", "r550" ] }, "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DisclosureBusinessCombinationDetails" ], "lang": { "en-us": { "role": { "label": "Investment, Name [Axis]" } } }, "auth_ref": [ "r184", "r185", "r186" ] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "calculation": { "http://revbiosciences.com/20230930/taxonomy/role/StatementConsolidatedBalanceSheets1": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DisclosureOrganizationAndBasisOfPresentationDetails", "http://revbiosciences.com/20230930/taxonomy/role/StatementConsolidatedBalanceSheets1" ], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents, at Carrying Value", "terseLabel": "Cash and cash equivalents", "totalLabel": "Cash and Cash Equivalents, at Carrying Value, Total", "periodStartLabel": "Cash and Cash Equivalents, at Carrying Value, Beginning Balance", "periodEndLabel": "Cash and Cash Equivalents, at Carrying Value, Ending Balance", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r28", "r120", "r444" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r480" ] }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "Recent Accounting Pronouncements", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DisclosureStockbasedCompensationDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period", "terseLabel": "Vesting period", "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition." } } }, "auth_ref": [ "r462" ] }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsPolicyTextBlock", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents, Policy [Policy Text Block]", "terseLabel": "Cash and Cash Equivalents", "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value." } } }, "auth_ref": [ "r29" ] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DisclosureStockbasedCompensationDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition", "terseLabel": "Unrecognized stock-based compensation expense, expected period for recognition", "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r268" ] }, "us-gaap_ConversionOfStockSharesConverted1": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConversionOfStockSharesConverted1", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DisclosureOrganizationAndBasisOfPresentationDetails" ], "lang": { "en-us": { "role": { "label": "Conversion of Stock, Shares Converted", "terseLabel": "Conversion of stock, shares converted", "documentation": "The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period." } } }, "auth_ref": [ "r30", "r31", "r32" ] }, "us-gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeStockOptionMember", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DisclosureCommonStockSummaryOfTotalSharesOfCommonStockReservedForIssuanceDetails", "http://revbiosciences.com/20230930/taxonomy/role/DisclosureStockbasedCompensationAssumptionsUsedInEstimatingFairValueOfStockOptionsDetails", "http://revbiosciences.com/20230930/taxonomy/role/DisclosureStockbasedCompensationDetails", "http://revbiosciences.com/20230930/taxonomy/role/DisclosureStockbasedCompensationScheduleOfStockOptionsActivityDetails", "http://revbiosciences.com/20230930/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockbasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "label": "Employee Stock Option [Member]", "terseLabel": "Stock Options [Member]", "verboseLabel": "Stock Options Outstanding [Member]", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r480" ] }, "us-gaap_EquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityAbstract", "lang": { "en-us": { "role": { "label": "Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingIncomeLoss", "crdr": "credit", "calculation": { "http://revbiosciences.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Operating Income (Loss)", "totalLabel": "Loss from operations", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": [ "r170", "r178", "r180", "r182", "r448" ] }, "us-gaap_PlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PlanNameDomain", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DisclosureBusinessCombinationDetails", "http://revbiosciences.com/20230930/taxonomy/role/DisclosureStockbasedCompensationDetails" ], "lang": { "en-us": { "role": { "label": "Plan Name [Domain]", "documentation": "Plan name for share-based payment arrangement." } } }, "auth_ref": [ "r525", "r526", "r527", "r528", "r529", "r530", "r531", "r532", "r533", "r534", "r535", "r536", "r537", "r538", "r539", "r540", "r541", "r542", "r543", "r544", "r545", "r546", "r547", "r548", "r549", "r550" ] }, "us-gaap_SubsequentEventLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventLineItems", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Subsequent Event [Line Items]", "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event." } } }, "auth_ref": [ "r321", "r331" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Securities Act File Number", "terseLabel": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "srt_StatementScenarioAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "StatementScenarioAxis", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DisclosureOrganizationAndBasisOfPresentationDetails", "http://revbiosciences.com/20230930/taxonomy/role/DisclosureStockbasedCompensationDetails" ], "lang": { "en-us": { "role": { "label": "Scenario [Axis]" } } }, "auth_ref": [ "r156", "r230", "r491", "r493", "r510" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "City Area Code", "terseLabel": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AwardTypeAxis", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DisclosureBusinessCombinationDetails", "http://revbiosciences.com/20230930/taxonomy/role/DisclosureCommonStockDetails", "http://revbiosciences.com/20230930/taxonomy/role/DisclosureCommonStockSummaryOfTotalSharesOfCommonStockReservedForIssuanceDetails", "http://revbiosciences.com/20230930/taxonomy/role/DisclosureStockbasedCompensationAssumptionsUsedInEstimatingFairValueOfStockOptionsDetails", "http://revbiosciences.com/20230930/taxonomy/role/DisclosureStockbasedCompensationDetails", "http://revbiosciences.com/20230930/taxonomy/role/DisclosureStockbasedCompensationScheduleOfStockOptionsActivityDetails", "http://revbiosciences.com/20230930/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockbasedCompensationExpenseDetails", "http://revbiosciences.com/20230930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Award Type", "label": "Award Type [Axis]", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": [ "r236", "r237", "r238", "r240", "r241", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r250", "r251", "r252", "r253", "r254", "r255", "r256", "r257", "r260", "r261", "r262", "r263", "r264" ] }, "us-gaap_SubsequentEventTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventTable", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Subsequent Event [Table]", "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued." } } }, "auth_ref": [ "r321", "r331" ] }, "us-gaap_SubsequentEventTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventTypeAxis", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DisclosureCommonStockDetails", "http://revbiosciences.com/20230930/taxonomy/role/DisclosureOrganizationAndBasisOfPresentationDetails", "http://revbiosciences.com/20230930/taxonomy/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Subsequent Event Type [Axis]", "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r321", "r331" ] }, "srt_ScenarioUnspecifiedDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ScenarioUnspecifiedDomain", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DisclosureOrganizationAndBasisOfPresentationDetails", "http://revbiosciences.com/20230930/taxonomy/role/DisclosureStockbasedCompensationDetails" ], "lang": { "en-us": { "role": { "label": "Scenario [Domain]" } } }, "auth_ref": [ "r156", "r230", "r491", "r510" ] }, "revb_DeferredUnderwritingCommissions": { "xbrltype": "monetaryItemType", "nsuri": "http://revbiosciences.com/20230930", "localname": "DeferredUnderwritingCommissions", "crdr": "credit", "calculation": { "http://revbiosciences.com/20230930/taxonomy/role/StatementConsolidatedBalanceSheets1": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/StatementConsolidatedBalanceSheets1" ], "lang": { "en-us": { "role": { "documentation": "Deferred underwriting commissions.", "label": "Deferred Underwriting Commissions", "terseLabel": "Deferred underwriting commissions" } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "terseLabel": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockMember", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DisclosureBusinessCombinationDetails", "http://revbiosciences.com/20230930/taxonomy/role/DisclosureCommonStockDetails", "http://revbiosciences.com/20230930/taxonomy/role/DisclosureSubsequentEventsDetails", "http://revbiosciences.com/20230930/taxonomy/role/DisclosureUnitsDetails", "http://revbiosciences.com/20230930/taxonomy/role/DisclosureWarrantsDetails", "http://revbiosciences.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Common Stock [Member]", "verboseLabel": "Common Stock [Member]", "terseLabel": "Common Stock", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": [ "r468", "r469", "r470", "r472", "r473", "r474", "r475", "r507", "r508", "r552", "r569", "r571" ] }, "us-gaap_ConversionOfStockSharesIssued1": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConversionOfStockSharesIssued1", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DisclosureOrganizationAndBasisOfPresentationDetails", "http://revbiosciences.com/20230930/taxonomy/role/DisclosurePreferredStockDetails" ], "lang": { "en-us": { "role": { "label": "Conversion of Stock, Shares Issued", "terseLabel": "Conversion rate (in Dollars per share)", "documentation": "The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period." } } }, "auth_ref": [ "r30", "r31", "r32" ] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareDiluted", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "terseLabel": "Net earnings per share, diluted", "label": "Earnings Per Share, Diluted", "totalLabel": "Earnings Per Share, Diluted, Total", "verboseLabel": "Net (loss) earnings per share, diluted", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": [ "r135", "r148", "r149", "r150", "r151", "r152", "r159", "r162", "r163", "r164", "r166", "r312", "r313", "r337", "r349", "r446" ] }, "us-gaap_DeferredOfferingCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredOfferingCosts", "crdr": "debit", "calculation": { "http://revbiosciences.com/20230930/taxonomy/role/StatementConsolidatedBalanceSheets1": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/StatementConsolidatedBalanceSheets1" ], "lang": { "en-us": { "role": { "label": "Deferred Offering Costs", "terseLabel": "Deferred offering costs", "documentation": "Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period." } } }, "auth_ref": [ "r516" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r480" ] }, "us-gaap_SubsequentEventTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventTypeDomain", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DisclosureCommonStockDetails", "http://revbiosciences.com/20230930/taxonomy/role/DisclosureOrganizationAndBasisOfPresentationDetails", "http://revbiosciences.com/20230930/taxonomy/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Subsequent Event Type [Domain]", "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r321", "r331" ] }, "us-gaap_LeaseExpirationDate1": { "xbrltype": "dateItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LeaseExpirationDate1", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/revb_r_CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "label": "Lease Expiration Date", "terseLabel": "Operating lease expiration date", "verboseLabel": "Lease expiration date", "documentation": "Date which lease or group of leases is set to expire, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DisclosureStockbasedCompensationScheduleOfStockOptionsActivityDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Total", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period", "negatedLabel": "Expired and foreited", "terseLabel": "Expired and forfeited", "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired." } } }, "auth_ref": [ "r531" ] }, "us-gaap_DirectorsAndOfficersLiabilityInsuranceMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DirectorsAndOfficersLiabilityInsuranceMember", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfAccruedExpensesDetails", "http://revbiosciences.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfCashFlows", "http://revbiosciences.com/20230930/taxonomy/role/revb_r_CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "label": "Directors and Officers Liability Insurance [Member]", "terseLabel": "D&O Insurance [Member]", "documentation": "Professional liability coverage for legal expenses and liability to shareholders, bondholders, creditors or others due to actions or omissions by a director or officer of a corporation or nonprofit organization." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DisclosureStockbasedCompensationScheduleOfStockOptionsActivityDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price", "terseLabel": "Expired and forfeited", "documentation": "Weighted average price of options that were either forfeited or expired." } } }, "auth_ref": [ "r531" ] }, "us-gaap_CommonStockNoParValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockNoParValue", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DisclosureBusinessCombinationDetails" ], "lang": { "en-us": { "role": { "label": "Common Stock, No Par Value", "terseLabel": "Common stock, par value per share (in Dollars per share)", "documentation": "Face amount per share of no-par value common stock." } } }, "auth_ref": [ "r68" ] }, "us-gaap_ConcentrationRiskCreditRisk": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskCreditRisk", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]", "terseLabel": "Concentration of Credit Risk", "documentation": "Disclosure of accounting policy for credit risk." } } }, "auth_ref": [ "r64", "r108" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://revbiosciences.com/20230930/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfPropertyAndEquipmentNetDetails": { "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0, "order": 0.0 } }, "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfPropertyAndEquipmentNetDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total", "periodStartLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance", "periodEndLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "terseLabel": "Accumulated depreciation", "negatedLabel": "Accumulated depreciation", "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services." } } }, "auth_ref": [ "r39", "r122", "r346" ] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r479" ] }, "us-gaap_SubsidiarySaleOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsidiarySaleOfStockAxis", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DisclosureCommonStockDetails", "http://revbiosciences.com/20230930/taxonomy/role/DisclosureOrganizationAndBasisOfPresentationDetails", "http://revbiosciences.com/20230930/taxonomy/role/DisclosurePipeInvestmentDetails", "http://revbiosciences.com/20230930/taxonomy/role/DisclosureSubsequentEventsDetails", "http://revbiosciences.com/20230930/taxonomy/role/DisclosureUnitsDetails", "http://revbiosciences.com/20230930/taxonomy/role/DisclosureWarrantsDetails", "http://revbiosciences.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfCashFlows", "http://revbiosciences.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Sale of Stock [Axis]", "documentation": "Information by type of sale of the entity's stock." } } }, "auth_ref": [] }, "us-gaap_SubsidiarySaleOfStockLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsidiarySaleOfStockLineItems", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DisclosurePipeInvestmentDetails" ], "lang": { "en-us": { "role": { "label": "Subsidiary, Sale of Stock [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DisclosureOrganizationAndBasisOfPresentation" ], "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]", "terseLabel": "Organization and Basis of Presentation", "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure." } } }, "auth_ref": [ "r66", "r99", "r357", "r358" ] }, "us-gaap_IncomeStatementLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementLocationAxis", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockbasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "label": "Income Statement Location [Axis]", "documentation": "Information by location in the income statement." } } }, "auth_ref": [ "r191", "r192", "r413" ] }, "us-gaap_SubsequentEventMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventMember", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DisclosureCommonStockDetails", "http://revbiosciences.com/20230930/taxonomy/role/DisclosureOrganizationAndBasisOfPresentationDetails", "http://revbiosciences.com/20230930/taxonomy/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Subsequent Event [Member]", "terseLabel": "Subsequent Event [Member]", "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r321", "r331" ] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "crdr": "debit", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DisclosureStockbasedCompensationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unrecognized stock-based compensation expense related to stock options", "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount", "documentation": "Amount of cost to be recognized for option under share-based payment arrangement." } } }, "auth_ref": [ "r551" ] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions", "crdr": "debit", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DisclosureStockbasedCompensationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unrecognized stock-based compensation expense related to awards", "label": "Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount", "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options." } } }, "auth_ref": [ "r551" ] }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionAcquireeDomain", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DisclosureBusinessCombinationDetails", "http://revbiosciences.com/20230930/taxonomy/role/DisclosureCommonStockDetails", "http://revbiosciences.com/20230930/taxonomy/role/DisclosureOrganizationAndBasisOfPresentationDetails", "http://revbiosciences.com/20230930/taxonomy/role/revb_r_CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "label": "Business Acquisition, Acquiree [Domain]", "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree." } } }, "auth_ref": [ "r299", "r459", "r460" ] }, "us-gaap_AccountsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsPayableCurrent", "crdr": "credit", "calculation": { "http://revbiosciences.com/20230930/taxonomy/role/StatementConsolidatedBalanceSheets1": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/StatementConsolidatedBalanceSheets1" ], "lang": { "en-us": { "role": { "label": "Accounts Payable, Current", "terseLabel": "Accounts payable", "totalLabel": "Accounts Payable, Current, Total", "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r14", "r466" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Weighted Average Number of Shares Outstanding, Basic", "totalLabel": "Weighted Average Number of Shares Outstanding, Basic, Total", "terseLabel": "Weighted-average shares used to compute net (loss) earnings per share, basic", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": [ "r157", "r164" ] }, "us-gaap_SharePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharePrice", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DisclosureUnitsDetails" ], "lang": { "en-us": { "role": { "label": "Share Price", "terseLabel": "Share price", "documentation": "Price of a single share of a number of saleable stocks of a company." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DisclosureBusinessCombinationDetails" ], "lang": { "en-us": { "role": { "label": "Schedule of Business Acquisitions, by Acquisition [Table]", "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities." } } }, "auth_ref": [ "r56", "r57", "r299" ] }, "us-gaap_BusinessAcquisitionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionLineItems", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DisclosureBusinessCombinationDetails" ], "lang": { "en-us": { "role": { "label": "Business Acquisition [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r299" ] }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/revb_r_CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "label": "Operating Lease, Weighted Average Discount Rate, Percent", "terseLabel": "Operating lease, weighted-average discount rate", "documentation": "Weighted average discount rate for operating lease calculated at point in time." } } }, "auth_ref": [ "r327", "r465" ] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLoss", "crdr": "credit", "calculation": { "http://revbiosciences.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 0.0 }, "http://revbiosciences.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfOperations": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfCashFlows", "http://revbiosciences.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquityDeficit", "http://revbiosciences.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "verboseLabel": "Net income (loss)", "label": "Net Income (Loss)", "terseLabel": "Net loss", "negatedLabel": "Net loss", "totalLabel": "Net (loss) income", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": [ "r74", "r82", "r102", "r117", "r129", "r130", "r134", "r140", "r146", "r148", "r149", "r150", "r151", "r154", "r155", "r161", "r170", "r178", "r180", "r182", "r187", "r199", "r200", "r201", "r202", "r203", "r204", "r205", "r206", "r207", "r313", "r314", "r348", "r409", "r426", "r427", "r448", "r476", "r521" ] }, "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ComprehensiveIncomePolicyPolicyTextBlock", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Comprehensive (Loss) Income", "label": "Comprehensive Income, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for comprehensive income." } } }, "auth_ref": [] }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DisclosureStockbasedCompensation" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement [Text Block]", "terseLabel": "Stock-Based Compensation", "documentation": "The entire disclosure for share-based payment arrangement." } } }, "auth_ref": [ "r231", "r235", "r266", "r267", "r269", "r462" ] }, "us-gaap_AccruedLiabilitiesCurrentAndNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccruedLiabilitiesCurrentAndNoncurrent", "crdr": "credit", "calculation": { "http://revbiosciences.com/20230930/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfAccruedExpensesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfAccruedExpensesDetails" ], "lang": { "en-us": { "role": { "label": "Accrued Liabilities", "totalLabel": "Total accrued expenses", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities." } } }, "auth_ref": [ "r61" ] }, "us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccruedProfessionalFeesCurrentAndNoncurrent", "crdr": "credit", "calculation": { "http://revbiosciences.com/20230930/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfAccruedExpensesDetails": { "parentTag": "us-gaap_AccruedLiabilitiesCurrentAndNoncurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfAccruedExpensesDetails" ], "lang": { "en-us": { "role": { "label": "Accrued Professional Fees", "terseLabel": "Accrued professional fees", "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received." } } }, "auth_ref": [ "r61" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "crdr": "credit", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/revb_r_CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Lessee, Operating Lease, Liability, to be Paid, Total", "label": "Lessee, Operating Lease, Liability, to be Paid", "terseLabel": "Future minimum lease payments", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease." } } }, "auth_ref": [ "r328" ] }, "us-gaap_CommonClassAMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonClassAMember", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfCashFlows", "http://revbiosciences.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "terseLabel": "Class A Common Stock", "label": "Common Class A [Member]", "documentation": "Classification of common stock representing ownership interest in a corporation." } } }, "auth_ref": [ "r571" ] }, "us-gaap_PreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockMember", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Preferred Stock [Member]", "terseLabel": "Preferred Stock", "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company." } } }, "auth_ref": [ "r468", "r469", "r472", "r473", "r474", "r475", "r569", "r571" ] }, "us-gaap_OtherNonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherNonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://revbiosciences.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Other Nonoperating Income (Expense)", "totalLabel": "Other income (expense), net", "terseLabel": "Other income (expense)", "documentation": "Amount of income (expense) related to nonoperating activities, classified as other." } } }, "auth_ref": [ "r78" ] }, "us-gaap_AccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://revbiosciences.com/20230930/taxonomy/role/StatementConsolidatedBalanceSheets1": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/StatementConsolidatedBalanceSheets1", "http://revbiosciences.com/20230930/taxonomy/role/revb_r_CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Accrued Liabilities, Current, Total", "label": "Accrued Liabilities, Current", "terseLabel": "Accrued expenses", "verboseLabel": "Unpaid invoices, plus interest and costs", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r16" ] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquity", "crdr": "credit", "calculation": { "http://revbiosciences.com/20230930/taxonomy/role/StatementConsolidatedBalanceSheets1": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DisclosureOrganizationAndBasisOfPresentationDetails", "http://revbiosciences.com/20230930/taxonomy/role/StatementConsolidatedBalanceSheets1", "http://revbiosciences.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "totalLabel": "Total stockholders' equity", "label": "Equity, Attributable to Parent", "periodStartLabel": "Balance", "periodEndLabel": "Balance", "terseLabel": "Stockholders' equity", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": [ "r68", "r71", "r72", "r84", "r391", "r407", "r429", "r430", "r466", "r478", "r505", "r514", "r554", "r571" ] }, "us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeRelatedLiabilitiesCurrentAndNoncurrent", "crdr": "credit", "calculation": { "http://revbiosciences.com/20230930/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfAccruedExpensesDetails": { "parentTag": "us-gaap_AccruedLiabilitiesCurrentAndNoncurrent", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfAccruedExpensesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Employee-related Liabilities, Total", "label": "Employee-related Liabilities", "terseLabel": "Accrued payroll and related expenses", "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits." } } }, "auth_ref": [ "r61", "r568" ] }, "us-gaap_OperatingLeaseExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseExpense", "crdr": "debit", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/revb_r_CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "label": "Operating Lease, Expense", "terseLabel": "Rent expense", "documentation": "Amount of operating lease expense. Excludes sublease income." } } }, "auth_ref": [ "r555" ] }, "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]", "terseLabel": "Supplemental disclosure of non-cash investing and financing activities:" } } }, "auth_ref": [] }, "us-gaap_LandSubjectToGroundLeases": { "xbrltype": "areaItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LandSubjectToGroundLeases", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/revb_r_CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "label": "Land Subject to Ground Leases", "terseLabel": "Area of laboratory space subject to lease", "documentation": "Area of land subject to a ground lease." } } }, "auth_ref": [ "r556" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DisclosureStockbasedCompensationScheduleOfStockOptionsActivityDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherAccruedLiabilitiesCurrentAndNoncurrent", "crdr": "credit", "calculation": { "http://revbiosciences.com/20230930/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfAccruedExpensesDetails": { "parentTag": "us-gaap_AccruedLiabilitiesCurrentAndNoncurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DisclosureBalanceSheetDetailsDetails", "http://revbiosciences.com/20230930/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfAccruedExpensesDetails" ], "lang": { "en-us": { "role": { "label": "Other Accrued Liabilities", "terseLabel": "Accrued other expenses", "documentation": "Amount of expenses incurred but not yet paid classified as other." } } }, "auth_ref": [ "r61" ] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsCurrent", "crdr": "debit", "calculation": { "http://revbiosciences.com/20230930/taxonomy/role/StatementConsolidatedBalanceSheets1": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/StatementConsolidatedBalanceSheets1" ], "lang": { "en-us": { "role": { "label": "Assets, Current", "totalLabel": "Total current assets", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r118", "r128", "r140", "r187", "r199", "r200", "r201", "r202", "r203", "r204", "r205", "r206", "r207", "r301", "r303", "r314", "r466", "r521", "r522", "r559" ] }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GeneralAndAdministrativeExpenseMember", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockbasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "label": "General and Administrative Expense [Member]", "terseLabel": "General and Administrative [Member]", "documentation": "Primary financial statement caption encompassing general and administrative expense." } } }, "auth_ref": [ "r75" ] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/revb_r_CommitmentsandContingencies" ], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "Commitments and Contingencies", "documentation": "The entire disclosure for commitments and contingencies." } } }, "auth_ref": [ "r86", "r193", "r194", "r441", "r520" ] }, "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardGross", "crdr": "credit", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Value, Restricted Stock Award, Gross", "terseLabel": "RSU awards issued", "documentation": "Aggregate value of stock related to Restricted Stock Awards issued during the period." } } }, "auth_ref": [ "r6", "r67", "r68", "r92" ] }, "us-gaap_DebtInstrumentFaceAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentFaceAmount", "crdr": "credit", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/revb_r_CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "label": "Debt Instrument, Face Amount", "terseLabel": "Debt instrument face amount", "documentation": "Face (par) amount of debt instrument at time of issuance." } } }, "auth_ref": [ "r59", "r60", "r208", "r322", "r454", "r455" ] }, "us-gaap_ProceedsFromPreviousAcquisition": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromPreviousAcquisition", "crdr": "debit", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DisclosureCommonStockDetails" ], "lang": { "en-us": { "role": { "label": "Proceeds from Previous Acquisition", "terseLabel": "Proceeds from business combination", "documentation": "Cash inflow representing an adjustment to the purchase price of a previous acquisition." } } }, "auth_ref": [ "r494" ] }, "us-gaap_DebtInstrumentFrequencyOfPeriodicPayment": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentFrequencyOfPeriodicPayment", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/revb_r_CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "label": "Debt Instrument, Frequency of Periodic Payment", "terseLabel": "Debt instrument, frequency of periodic payment", "documentation": "Description of the frequency of periodic payments (monthly, quarterly, annual)." } } }, "auth_ref": [ "r19", "r63" ] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RangeAxis", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DisclosureCommonStockDetails", "http://revbiosciences.com/20230930/taxonomy/role/DisclosureOrganizationAndBasisOfPresentationDetails", "http://revbiosciences.com/20230930/taxonomy/role/DisclosurePreferredStockDetails", "http://revbiosciences.com/20230930/taxonomy/role/DisclosureStockbasedCompensationDetails", "http://revbiosciences.com/20230930/taxonomy/role/DisclosureSubsequentEventsDetails", "http://revbiosciences.com/20230930/taxonomy/role/DisclosureWarrantsDetails", "http://revbiosciences.com/20230930/taxonomy/role/revb_r_CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]" } } }, "auth_ref": [ "r195", "r196", "r197", "r198", "r228", "r229", "r261", "r262", "r263", "r333", "r334", "r351", "r379", "r380", "r431", "r432", "r433", "r434", "r435", "r442", "r443", "r450", "r458", "r461", "r467", "r470", "r519", "r523", "r562", "r563", "r564", "r565", "r566" ] }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LongtermDebtTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongtermDebtTypeAxis", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/revb_r_CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "label": "Long-Term Debt, Type [Axis]", "documentation": "Information by type of long-term debt." } } }, "auth_ref": [ "r19" ] }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesNewIssues", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/Disclosure2022PublicOfferingDetails", "http://revbiosciences.com/20230930/taxonomy/role/Disclosure2023PublicOfferingDetails", "http://revbiosciences.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "netLabel": "Number of shares consummated (in Shares)", "verboseLabel": "Number of shares sold (in Shares)", "terseLabel": "Number of shares consummated", "label": "Issuance of common stock (Shares)", "documentation": "Number of new stock issued during the period." } } }, "auth_ref": [ "r6", "r67", "r68", "r92", "r361", "r428", "r437" ] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MaximumMember", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DisclosureCommonStockDetails", "http://revbiosciences.com/20230930/taxonomy/role/DisclosureOrganizationAndBasisOfPresentationDetails", "http://revbiosciences.com/20230930/taxonomy/role/DisclosurePreferredStockDetails", "http://revbiosciences.com/20230930/taxonomy/role/DisclosureStockbasedCompensationDetails", "http://revbiosciences.com/20230930/taxonomy/role/DisclosureSubsequentEventsDetails", "http://revbiosciences.com/20230930/taxonomy/role/DisclosureWarrantsDetails", "http://revbiosciences.com/20230930/taxonomy/role/revb_r_CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maximum [Member]", "label": "Maximum [Member]" } } }, "auth_ref": [ "r195", "r196", "r197", "r198", "r229", "r334", "r351", "r379", "r380", "r431", "r432", "r433", "r434", "r435", "r442", "r443", "r450", "r458", "r461", "r467", "r523", "r561", "r562", "r563", "r564", "r565", "r566" ] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RangeMember", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DisclosureCommonStockDetails", "http://revbiosciences.com/20230930/taxonomy/role/DisclosureOrganizationAndBasisOfPresentationDetails", "http://revbiosciences.com/20230930/taxonomy/role/DisclosurePreferredStockDetails", "http://revbiosciences.com/20230930/taxonomy/role/DisclosureStockbasedCompensationDetails", "http://revbiosciences.com/20230930/taxonomy/role/DisclosureSubsequentEventsDetails", "http://revbiosciences.com/20230930/taxonomy/role/DisclosureWarrantsDetails", "http://revbiosciences.com/20230930/taxonomy/role/revb_r_CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]" } } }, "auth_ref": [ "r195", "r196", "r197", "r198", "r228", "r229", "r261", "r262", "r263", "r333", "r334", "r351", "r379", "r380", "r431", "r432", "r433", "r434", "r435", "r442", "r443", "r450", "r458", "r461", "r467", "r470", "r519", "r523", "r562", "r563", "r564", "r565", "r566" ] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementTable", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DisclosureOrganizationAndBasisOfPresentationDetails", "http://revbiosciences.com/20230930/taxonomy/role/StatementConsolidatedBalanceSheets1", "http://revbiosciences.com/20230930/taxonomy/role/StatementConsolidatedBalanceSheetsParentheticals", "http://revbiosciences.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfCashFlows", "http://revbiosciences.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Statement [Table]", "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed." } } }, "auth_ref": [ "r143", "r144", "r145", "r167", "r335", "r359", "r378", "r381", "r382", "r383", "r384", "r385", "r386", "r389", "r392", "r393", "r394", "r395", "r396", "r397", "r398", "r399", "r400", "r402", "r403", "r404", "r405", "r406", "r408", "r411", "r412", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r428", "r471" ] }, "us-gaap_PreferredStockTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockTextBlock", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DisclosurePreferredStock1" ], "lang": { "en-us": { "role": { "label": "Preferred Stock [Text Block]", "terseLabel": "Preferred Stock", "documentation": "The entire disclosure for terms, amounts, nature of changes, rights and privileges, dividends, and other matters related to preferred stock." } } }, "auth_ref": [ "r88" ] }, "revb_AccruedClinicalDevelopmentCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://revbiosciences.com/20230930", "localname": "AccruedClinicalDevelopmentCosts", "crdr": "credit", "calculation": { "http://revbiosciences.com/20230930/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfAccruedExpensesDetails": { "parentTag": "us-gaap_AccruedLiabilitiesCurrentAndNoncurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfAccruedExpensesDetails" ], "lang": { "en-us": { "role": { "documentation": "Accrued Clinical Development Costs", "label": "Accrued Clinical Development Costs", "terseLabel": "Accrued clinical development costs" } } }, "auth_ref": [] }, "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MinimumMember", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DisclosureCommonStockDetails", "http://revbiosciences.com/20230930/taxonomy/role/DisclosureOrganizationAndBasisOfPresentationDetails", "http://revbiosciences.com/20230930/taxonomy/role/DisclosurePreferredStockDetails", "http://revbiosciences.com/20230930/taxonomy/role/DisclosureStockbasedCompensationDetails", "http://revbiosciences.com/20230930/taxonomy/role/DisclosureSubsequentEventsDetails", "http://revbiosciences.com/20230930/taxonomy/role/DisclosureWarrantsDetails" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]", "terseLabel": "Minimum [Member]" } } }, "auth_ref": [ "r195", "r196", "r197", "r198", "r229", "r334", "r351", "r379", "r380", "r431", "r432", "r433", "r434", "r435", "r442", "r443", "r450", "r458", "r461", "r467", "r523", "r561", "r562", "r563", "r564", "r565", "r566" ] }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Changes in operating assets and liabilities:" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInAccountsPayable", "crdr": "debit", "calculation": { "http://revbiosciences.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Increase (Decrease) in Accounts Payable, Total", "label": "Increase (Decrease) in Accounts Payable", "terseLabel": "Accounts payable", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business." } } }, "auth_ref": [ "r3" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DisclosureStockbasedCompensationScheduleOfStockOptionsActivityDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "terseLabel": "Granted", "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options." } } }, "auth_ref": [ "r244" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Type", "terseLabel": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "us-gaap_SecurityDepositLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SecurityDepositLiability", "crdr": "credit", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/revb_r_CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "label": "Security Deposit Liability", "terseLabel": "Security deposit required to maintain", "documentation": "This element represents money paid in advance to protect the provider of a product or service, such as a lessor, against damage or nonpayment by the buyer or tenant (lessee) during the term of the agreement. Such damages may include physical damage to the property, theft of property, and other contractual breaches. Security deposits held may be interest or noninterest bearing." } } }, "auth_ref": [] }, "us-gaap_PrepaidInsurance": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PrepaidInsurance", "crdr": "debit", "calculation": { "http://revbiosciences.com/20230930/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails": { "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Prepaid Insurance", "terseLabel": "Prepaid insurance", "documentation": "Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r445", "r451", "r515" ] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Assets", "crdr": "debit", "calculation": { "http://revbiosciences.com/20230930/taxonomy/role/StatementConsolidatedBalanceSheets1": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/StatementConsolidatedBalanceSheets1" ], "lang": { "en-us": { "role": { "label": "Assets", "totalLabel": "Total assets", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r100", "r124", "r140", "r170", "r179", "r181", "r187", "r199", "r200", "r201", "r202", "r203", "r204", "r205", "r206", "r207", "r301", "r303", "r314", "r339", "r401", "r466", "r478", "r521", "r522", "r559" ] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareBasic", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Basic", "totalLabel": "Earnings Per Share, Basic, Total", "terseLabel": "Net (loss) earnings per share, basic", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": [ "r135", "r148", "r149", "r150", "r151", "r152", "r157", "r159", "r162", "r163", "r164", "r166", "r312", "r313", "r337", "r349", "r446" ] }, "us-gaap_PreferredStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockValue", "crdr": "credit", "calculation": { "http://revbiosciences.com/20230930/taxonomy/role/StatementConsolidatedBalanceSheets1": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/StatementConsolidatedBalanceSheets1" ], "lang": { "en-us": { "role": { "label": "Preferred Stock, Value, Issued", "totalLabel": "Preferred Stock, Value, Issued, Total", "periodStartLabel": "Preferred Stock, Value, Issued, Beginning Balance", "periodEndLabel": "Preferred Stock, Value, Issued, Ending Balance", "verboseLabel": "Preferred stock value", "terseLabel": "Preferred stock value", "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r67", "r341", "r466" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r482", "r484", "r485" ] }, "us-gaap_IncreaseDecreaseInAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInAccruedLiabilities", "crdr": "debit", "calculation": { "http://revbiosciences.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 9.0 } }, "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Increase (Decrease) in Accrued Liabilities, Total", "label": "Increase (Decrease) in Accrued Liabilities", "terseLabel": "Accrued expenses", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid." } } }, "auth_ref": [ "r3" ] }, "us-gaap_MachineryAndEquipmentGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MachineryAndEquipmentGross", "crdr": "debit", "calculation": { "http://revbiosciences.com/20230930/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfPropertyAndEquipmentNetDetails": { "parentTag": "us-gaap_PropertyPlantAndEquipmentGross", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfPropertyAndEquipmentNetDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Machinery and Equipment, Gross, Total", "label": "Machinery and Equipment, Gross", "terseLabel": "Lab equipment", "documentation": "Amount before accumulated depreciation of tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment." } } }, "auth_ref": [ "r85" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DisclosurePipeInvestmentDetails", "http://revbiosciences.com/20230930/taxonomy/role/DisclosureStockbasedCompensationDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent", "terseLabel": "Common stock, percentage", "verboseLabel": "Exercise price based on estimated fair market value of common stock", "documentation": "Purchase price of common stock expressed as a percentage of its fair value." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DisclosureStockbasedCompensationScheduleOfStockOptionsActivityDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price", "terseLabel": "Exercised", "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares." } } }, "auth_ref": [ "r245" ] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r483" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DisclosureStockbasedCompensationScheduleOfStockOptionsActivityDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]", "terseLabel": "Weighted-average Exercise Price" } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DisclosureCommonStockDetails", "http://revbiosciences.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Shares, Restricted Stock Award, Gross", "verboseLabel": "Vested Rollover RSU Awards", "terseLabel": "RSU awards issued, (in Shares)", "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards." } } }, "auth_ref": [ "r6", "r92" ] }, "us-gaap_ConvertibleDebtMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConvertibleDebtMember", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/revb_r_CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "label": "Convertible Debt [Member]", "terseLabel": "Convertible Note [Member]", "documentation": "Borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock." } } }, "auth_ref": [ "r87", "r208", "r209", "r210", "r211", "r212", "r213", "r214", "r215", "r216", "r217", "r453", "r454", "r455", "r456", "r457" ] }, "us-gaap_SharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharesOutstanding", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Shares, Outstanding", "periodEndLabel": "Balance (in Shares)", "periodStartLabel": "Balance (in Shares)", "documentation": "Number of shares issued which are neither cancelled nor held in the treasury." } } }, "auth_ref": [] }, "us-gaap_CommonClassBMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonClassBMember", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Class B Common Stock", "label": "Common Class B [Member]", "documentation": "Classification of common stock that has different rights than Common Class A, representing ownership interest in a corporation." } } }, "auth_ref": [ "r571" ] }, "srt_TitleOfIndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "TitleOfIndividualAxis", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DisclosureStockbasedCompensationDetails" ], "lang": { "en-us": { "role": { "label": "Title of Individual [Axis]" } } }, "auth_ref": [ "r513", "r558" ] }, "us-gaap_LeaseContractualTermDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LeaseContractualTermDomain", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DisclosureSubsequentEventsDetails", "http://revbiosciences.com/20230930/taxonomy/role/revb_r_CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "label": "Lease Contractual Term [Domain]", "documentation": "Contractual term of lease arrangement." } } }, "auth_ref": [ "r495" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "terseLabel": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r486" ] }, "us-gaap_CommonUnitIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonUnitIssued", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DisclosureBusinessCombinationDetails" ], "lang": { "en-us": { "role": { "label": "Common Unit, Issued", "terseLabel": "Common stock shares issued", "documentation": "Number of common units issued of limited liability company (LLC)." } } }, "auth_ref": [ "r92" ] }, "us-gaap_StockIssuedDuringPeriodSharesAcquisitions": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesAcquisitions", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/Disclosure2023PublicOfferingDetails", "http://revbiosciences.com/20230930/taxonomy/role/DisclosureCommonStockDetails", "http://revbiosciences.com/20230930/taxonomy/role/DisclosurePipeInvestmentDetails", "http://revbiosciences.com/20230930/taxonomy/role/DisclosureWarrantsDetails" ], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Shares, Acquisitions", "verboseLabel": "Purchase of shares", "terseLabel": "Purchase of shares (in Shares)", "documentation": "Number of shares of stock issued during the period pursuant to acquisitions." } } }, "auth_ref": [ "r67", "r68", "r92" ] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesIssued", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DisclosureCommonStockDetails", "http://revbiosciences.com/20230930/taxonomy/role/DisclosureWarrantsDetails", "http://revbiosciences.com/20230930/taxonomy/role/StatementConsolidatedBalanceSheetsParentheticals" ], "lang": { "en-us": { "role": { "label": "Common Stock, Shares, Issued", "terseLabel": "Common stock, shares issued", "totalLabel": "Common Stock, Shares, Issued, Total", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": [ "r68" ] }, "us-gaap_IncomeTaxDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentIncreaseAccruedInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentIncreaseAccruedInterest", "crdr": "credit", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DisclosureBusinessCombinationDetails" ], "lang": { "en-us": { "role": { "label": "Debt Instrument, Increase, Accrued Interest", "terseLabel": "Accrued interest", "documentation": "Increase for accrued, but unpaid interest on the debt instrument for the period." } } }, "auth_ref": [ "r504" ] }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentInterestRateStatedPercentage", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/revb_r_CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "label": "Debt Instrument, Interest Rate, Stated Percentage", "terseLabel": "Interest rate", "verboseLabel": "Fixed annual interest rate", "documentation": "Contractual interest rate for funds borrowed, under the debt agreement." } } }, "auth_ref": [ "r18", "r209" ] }, "us-gaap_LeaseContractualTermAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LeaseContractualTermAxis", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DisclosureSubsequentEventsDetails", "http://revbiosciences.com/20230930/taxonomy/role/revb_r_CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "label": "Lease Contractual Term [Axis]", "documentation": "Information by contractual term of lease arrangement." } } }, "auth_ref": [ "r495" ] }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DisclosureStockbasedCompensationScheduleOfStockOptionsActivityDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Options, vested not issued", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period", "terseLabel": "Exercised", "documentation": "Number of share options (or share units) exercised during the current period." } } }, "auth_ref": [ "r6", "r67", "r68", "r92", "r245" ] }, "us-gaap_SubsequentEventsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventsTextBlock", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/revb_r_SubsequentEvents" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Events", "label": "Subsequent Events [Text Block]", "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business." } } }, "auth_ref": [ "r330", "r332" ] }, "us-gaap_CommonUnitAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonUnitAuthorized", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DisclosureBusinessCombinationDetails" ], "lang": { "en-us": { "role": { "label": "Common Unit, Authorized", "terseLabel": "Common stock constituting shares", "documentation": "Maximum number of common units of ownership permitted to be issued by a limited liability company (LLC)." } } }, "auth_ref": [] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockValue", "crdr": "credit", "calculation": { "http://revbiosciences.com/20230930/taxonomy/role/StatementConsolidatedBalanceSheets1": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/StatementConsolidatedBalanceSheets1" ], "lang": { "en-us": { "role": { "terseLabel": "Common Stock, $0.001 par value; 500,000,000 shares authorized at September 30, 2023 and December 31, 2022 and 6,297,303 and 682,882 issued and outstanding at September 30, 2023 and December 31, 2022, respectively", "label": "Common Stock, Value, Issued", "totalLabel": "Common Stock, Value, Issued, Total", "periodStartLabel": "Common Stock, Value, Issued, Beginning Balance", "periodEndLabel": "Common Stock, Value, Issued, Ending Balance", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r68", "r342", "r466" ] }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PrepaidExpenseAndOtherAssetsCurrent", "crdr": "debit", "calculation": { "http://revbiosciences.com/20230930/taxonomy/role/StatementConsolidatedBalanceSheets1": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 2.0 }, "http://revbiosciences.com/20230930/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails", "http://revbiosciences.com/20230930/taxonomy/role/StatementConsolidatedBalanceSheets1" ], "lang": { "en-us": { "role": { "label": "Prepaid Expense and Other Assets, Current", "terseLabel": "Prepaid expenses and other current assets", "totalLabel": "Total prepaid expenses & current assets", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r500" ] }, "us-gaap_DebtInstrumentMaturityDate": { "xbrltype": "dateItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentMaturityDate", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/revb_r_CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "label": "Debt Instrument, Maturity Date", "terseLabel": "Debt instrument maturity date", "documentation": "Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format." } } }, "auth_ref": [ "r114", "r453", "r553" ] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesAuthorized", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DisclosureCommonStockDetails", "http://revbiosciences.com/20230930/taxonomy/role/DisclosureOrganizationAndBasisOfPresentationDetails", "http://revbiosciences.com/20230930/taxonomy/role/StatementConsolidatedBalanceSheetsParentheticals" ], "lang": { "en-us": { "role": { "label": "Common Stock, Shares Authorized", "terseLabel": "Common stock, shares authorized", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r68", "r389" ] }, "us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConvertiblePreferredStockSharesIssuedUponConversion", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DisclosurePreferredStockDetails" ], "lang": { "en-us": { "role": { "label": "Convertible Preferred Stock, Shares Issued upon Conversion", "terseLabel": "Preferred stock converted into shares of common stock", "documentation": "Number of shares issued for each share of convertible preferred stock that is converted." } } }, "auth_ref": [ "r12", "r45", "r67", "r90", "r223" ] }, "us-gaap_CommonUnitOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonUnitOutstanding", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DisclosureBusinessCombinationDetails" ], "lang": { "en-us": { "role": { "label": "Common Unit, Outstanding", "terseLabel": "Common stock shares outstanding", "verboseLabel": "Common stock units outstanding", "documentation": "Number of common units of ownership outstanding of a limited liability company (LLC)." } } }, "auth_ref": [] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesOutstanding", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DisclosureCommonStockDetails", "http://revbiosciences.com/20230930/taxonomy/role/StatementConsolidatedBalanceSheetsParentheticals" ], "lang": { "en-us": { "role": { "label": "Common Stock, Shares, Outstanding", "terseLabel": "Common stock, shares outstanding", "periodStartLabel": "Common Stock, Shares, Outstanding, Beginning Balance", "periodEndLabel": "Common Stock, Shares, Outstanding, Ending Balance", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": [ "r6", "r68", "r389", "r407", "r571", "r572" ] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "crdr": "credit", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "totalLabel": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition, Total", "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition", "terseLabel": "Stock-based compensation expense", "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement." } } }, "auth_ref": [ "r54", "r55", "r233" ] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r487" ] }, "us-gaap_IncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxExpenseBenefit", "crdr": "debit", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/revb_r_IncomeTaxesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Income Tax Expense (Benefit), Total", "label": "Income Tax Expense (Benefit)", "terseLabel": "Provision for income taxes", "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r105", "r113", "r154", "r155", "r171", "r284", "r295", "r350" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "terseLabel": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchAndDevelopmentExpenseMember", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockbasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "label": "Research and Development Expense [Member]", "terseLabel": "Research and Development [Member]", "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included." } } }, "auth_ref": [] }, "srt_BoardOfDirectorsChairmanMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "BoardOfDirectorsChairmanMember", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DisclosureStockbasedCompensationDetails" ], "lang": { "en-us": { "role": { "label": "Board of Directors Chairman [Member]", "terseLabel": "Board of Directors [Member]" } } }, "auth_ref": [ "r513" ] }, "srt_CondensedBalanceSheetStatementsCaptionsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "CondensedBalanceSheetStatementsCaptionsLineItems", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfAccruedExpensesDetails" ], "lang": { "en-us": { "role": { "label": "Condensed Balance Sheet Statements, Captions [Line Items]" } } }, "auth_ref": [ "r142", "r492" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DisclosureStockbasedCompensationScheduleOfStockOptionsActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Outstanding at September 30, 2023", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r94" ] }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueNewIssues", "crdr": "credit", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Value, New Issues", "terseLabel": "Issuance of common stock", "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering." } } }, "auth_ref": [ "r6", "r67", "r68", "r92", "r367", "r428", "r437", "r477" ] }, "us-gaap_SharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharesIssued", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DisclosureBusinessCombinationDetails" ], "lang": { "en-us": { "role": { "label": "Shares, Issued", "verboseLabel": "Shares issued", "terseLabel": "Business combination, shares issued", "periodStartLabel": "Shares, Issued, Beginning Balance", "periodEndLabel": "Shares, Issued, Ending Balance", "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury." } } }, "auth_ref": [ "r6" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DisclosureStockbasedCompensationScheduleOfStockOptionsActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Exercisable at September 30, 2023", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term", "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r50" ] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "terseLabel": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DisclosureStockbasedCompensationScheduleOfStockOptionsActivityDetails" ], "lang": { "en-us": { "role": { "periodEndLabel": "Outstanding at September 30, 2023", "periodStartLabel": "Outstanding at December 31, 2022", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number", "documentation": "Number of options outstanding, including both vested and non-vested options." } } }, "auth_ref": [ "r240", "r241" ] }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://revbiosciences.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 0.0 } }, "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Payments to Acquire Property, Plant, and Equipment, Total", "label": "Payments to Acquire Property, Plant, and Equipment", "negatedLabel": "Purchase of property and equipment", "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets." } } }, "auth_ref": [ "r79" ] }, "dei_IcfrAuditorAttestationFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "IcfrAuditorAttestationFlag", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "ICFR Auditor Attestation Flag" } } }, "auth_ref": [ "r482", "r484", "r485" ] }, "us-gaap_OperatingExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingExpenses", "crdr": "debit", "calculation": { "http://revbiosciences.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 0.0 } }, "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Operating Expenses", "negatedTotalLabel": "Loss from operations", "totalLabel": "Total operating expenses", "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense." } } }, "auth_ref": [] }, "us-gaap_ProceedsFromIssuanceOfWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromIssuanceOfWarrants", "crdr": "debit", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DisclosureWarrantsDetails" ], "lang": { "en-us": { "role": { "label": "Proceeds from Issuance of Warrants", "verboseLabel": "Proceeds from issuance of warrants", "terseLabel": "Issuance of Warrants in connection with the July 2022 Public Offering", "documentation": "The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt)." } } }, "auth_ref": [ "r2" ] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalPaidInCapitalMember", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Additional Paid-in Capital [Member]", "terseLabel": "Additional Paid-in Capital", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": [ "r270", "r271", "r272", "r367", "r507", "r508", "r509", "r552", "r571" ] }, "us-gaap_NumberOfOperatingSegments": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NumberOfOperatingSegments", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "label": "Number of Operating Segments", "terseLabel": "Number of operating segment", "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues." } } }, "auth_ref": [ "r512" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DisclosureStockbasedCompensationScheduleOfStockOptionsActivityDetails" ], "lang": { "en-us": { "role": { "periodEndLabel": "Outstanding at September 30, 2023", "periodStartLabel": "Outstanding at December 31, 2022", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan." } } }, "auth_ref": [ "r240", "r241" ] }, "us-gaap_WarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WarrantMember", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DisclosureCommonStockDetails", "http://revbiosciences.com/20230930/taxonomy/role/DisclosurePipeInvestmentDetails", "http://revbiosciences.com/20230930/taxonomy/role/DisclosureWarrantsDetails" ], "lang": { "en-us": { "role": { "label": "Warrant [Member]", "terseLabel": "Warrant [Member]", "verboseLabel": "Warrants [Member]", "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount." } } }, "auth_ref": [ "r468", "r469", "r472", "r473", "r474", "r475" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DisclosureStockbasedCompensationScheduleOfStockOptionsActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Exercisable at September 30, 2023", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number", "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan." } } }, "auth_ref": [ "r242" ] }, "us-gaap_StockOptionExercisePriceIncrease": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockOptionExercisePriceIncrease", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DisclosureBusinessCombinationDetails" ], "lang": { "en-us": { "role": { "label": "Stock Option, Exercise Price, Increase", "terseLabel": "Cash price per share (in Dollars per share)", "documentation": "Per share increase in exercise price of option. Excludes change due to standard antidilution provision and option granted under share-based payment arrangement." } } }, "auth_ref": [ "r226" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DisclosureStockbasedCompensationScheduleOfStockOptionsActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Exercisable at September 30, 2023", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan." } } }, "auth_ref": [ "r242" ] }, "us-gaap_OperatingExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingExpensesAbstract", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Operating Expenses [Abstract]", "terseLabel": "Operating expenses:" } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "us-gaap_CommonStockConvertibleConversionPriceIncrease": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockConvertibleConversionPriceIncrease", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DisclosureBusinessCombinationDetails" ], "lang": { "en-us": { "role": { "label": "Common Stock, Convertible, Conversion Price, Increase", "verboseLabel": "Share price (in Dollars per share)", "terseLabel": "Conversion rate (in Dollars per share)", "documentation": "Per share increase in conversion price of convertible common stock. Excludes change due to standard antidilution provision." } } }, "auth_ref": [ "r226" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments", "crdr": "debit", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DisclosureWarrantsScheduleOfFairValueOfWarrantsEstimatedUsingBlackscholesOptionPricingModelDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Payments", "verboseLabel": "Expected dividend yield", "documentation": "The estimated amount of dividends to be paid to holders of the underlying shares (expected dividends) over the option's term. Dividends are taken into account because payment of dividends to shareholders reduces the fair value of the underlying shares, and option holders generally do not receive dividends." } } }, "auth_ref": [ "r262" ] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_TypeAndTierIdentifierDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TypeAndTierIdentifierDomain", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfAccruedExpensesDetails", "http://revbiosciences.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfCashFlows", "http://revbiosciences.com/20230930/taxonomy/role/revb_r_CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "label": "Type and Tier Identifier [Domain]", "documentation": "Name of the type of insurance coverage or layer of insurance that covers malpractice claims." } } }, "auth_ref": [ "r104" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DisclosureStockbasedCompensationAssumptionsUsedInEstimatingFairValueOfStockOptionsDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate", "terseLabel": "Expected dividend yield", "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term." } } }, "auth_ref": [ "r262" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DisclosureStockbasedCompensationAssumptionsUsedInEstimatingFairValueOfStockOptionsDetails", "http://revbiosciences.com/20230930/taxonomy/role/DisclosureWarrantsScheduleOfFairValueOfWarrantsEstimatedUsingBlackscholesOptionPricingModelDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate", "terseLabel": "Expected volatility", "verboseLabel": "Volatility", "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period." } } }, "auth_ref": [ "r261" ] }, "us-gaap_ScheduleOfMalpracticeInsuranceTypeAndTierIdentifierAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfMalpracticeInsuranceTypeAndTierIdentifierAxis", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfAccruedExpensesDetails", "http://revbiosciences.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfCashFlows", "http://revbiosciences.com/20230930/taxonomy/role/revb_r_CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "label": "Insurance Type and Tier Identifier [Axis]", "documentation": "Information by type of insurance coverage or layer of insurance that covers malpractice claims." } } }, "auth_ref": [ "r104" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DisclosureStockbasedCompensationAssumptionsUsedInEstimatingFairValueOfStockOptionsDetails", "http://revbiosciences.com/20230930/taxonomy/role/DisclosureWarrantsScheduleOfFairValueOfWarrantsEstimatedUsingBlackscholesOptionPricingModelDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate", "terseLabel": "Risk free interest rate", "verboseLabel": "Risk-free interest rate", "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares." } } }, "auth_ref": [ "r263" ] }, "us-gaap_Depreciation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Depreciation", "crdr": "debit", "calculation": { "http://revbiosciences.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DisclosureBalanceSheetDetailsDetails", "http://revbiosciences.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Depreciation, Total", "label": "Depreciation", "terseLabel": "Depreciation expense", "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation." } } }, "auth_ref": [ "r4", "r38" ] }, "revb_TwoThousandAndTwentyOneEquityIncentivePlanMember": { "xbrltype": "domainItemType", "nsuri": "http://revbiosciences.com/20230930", "localname": "TwoThousandAndTwentyOneEquityIncentivePlanMember", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DisclosureStockbasedCompensationDetails" ], "lang": { "en-us": { "role": { "documentation": "Two thousand and twenty one equity incentive plan.", "label": "Two Thousand and Twenty One Equity Incentive Plan [Member]", "terseLabel": "2021 Equity Incentive Plan [Member]" } } }, "auth_ref": [] }, "us-gaap_LesseeOperatingLeaseTermOfContract": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseTermOfContract", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/revb_r_CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Term of Contract", "terseLabel": "Operating lease term", "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r557" ] }, "us-gaap_WarrantsAndRightsOutstanding": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WarrantsAndRightsOutstanding", "crdr": "credit", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DisclosureCommonStockDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Warrants outstanding", "label": "Warrants, value", "documentation": "Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price." } } }, "auth_ref": [] }, "us-gaap_ResearchAndDevelopmentExpensePolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchAndDevelopmentExpensePolicy", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Research and Development Expense, Policy [Policy Text Block]", "terseLabel": "Research and Development Expenses", "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process." } } }, "auth_ref": [ "r278" ] }, "revb_IncreaseDecreaseInDeferredOfferingCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://revbiosciences.com/20230930", "localname": "IncreaseDecreaseInDeferredOfferingCosts", "crdr": "credit", "calculation": { "http://revbiosciences.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 6.0 } }, "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "IncreaseDecreaseInDeferredOfferingCosts", "documentation": "Amount of changes in deferred offering costs.", "negatedLabel": "Deferred offering costs" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DisclosureBusinessCombinationDetails", "http://revbiosciences.com/20230930/taxonomy/role/DisclosureCommonStockDetails", "http://revbiosciences.com/20230930/taxonomy/role/DisclosureCommonStockSummaryOfTotalSharesOfCommonStockReservedForIssuanceDetails", "http://revbiosciences.com/20230930/taxonomy/role/DisclosureStockbasedCompensationAssumptionsUsedInEstimatingFairValueOfStockOptionsDetails", "http://revbiosciences.com/20230930/taxonomy/role/DisclosureStockbasedCompensationDetails", "http://revbiosciences.com/20230930/taxonomy/role/DisclosureStockbasedCompensationScheduleOfStockOptionsActivityDetails", "http://revbiosciences.com/20230930/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockbasedCompensationExpenseDetails", "http://revbiosciences.com/20230930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "All Award Types", "label": "All Award Types", "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": [ "r236", "r237", "r238", "r240", "r241", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r250", "r251", "r252", "r253", "r254", "r255", "r256", "r257", "r260", "r261", "r262", "r263", "r264" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DisclosureStockbasedCompensationAssumptionsUsedInEstimatingFairValueOfStockOptionsDetails", "http://revbiosciences.com/20230930/taxonomy/role/DisclosureStockbasedCompensationDetails", "http://revbiosciences.com/20230930/taxonomy/role/DisclosureStockbasedCompensationScheduleOfStockOptionsActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r232", "r234", "r236", "r237", "r238", "r240", "r241", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r250", "r251", "r252", "r253", "r254", "r255", "r256", "r257", "r260", "r261", "r262", "r263", "r264" ] }, "us-gaap_DebtInstrumentAnnualPrincipalPayment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentAnnualPrincipalPayment", "crdr": "debit", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DisclosureBusinessCombinationDetails" ], "lang": { "en-us": { "role": { "label": "Debt Instrument, Annual Principal Payment", "verboseLabel": "Monthly payable amount (in Dollars)", "terseLabel": "Aggregate principal amount", "documentation": "Amount of the total principal payments made during the annual reporting period." } } }, "auth_ref": [ "r11" ] }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DisclosureStockbasedCompensationAssumptionsUsedInEstimatingFairValueOfStockOptionsDetails", "http://revbiosciences.com/20230930/taxonomy/role/DisclosureStockbasedCompensationDetails", "http://revbiosciences.com/20230930/taxonomy/role/DisclosureStockbasedCompensationScheduleOfStockOptionsActivityDetails" ], "lang": { "en-us": { "role": { "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]", "documentation": "Disclosure of information about share-based payment arrangement." } } }, "auth_ref": [ "r232", "r234", "r236", "r237", "r238", "r240", "r241", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r250", "r251", "r252", "r253", "r254", "r255", "r256", "r257", "r260", "r261", "r262", "r263", "r264" ] }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromIssuanceOfCommonStock", "crdr": "debit", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DisclosureCommonStockDetails" ], "lang": { "en-us": { "role": { "label": "Proceeds from Issuance of Common Stock", "terseLabel": "Net proceeds from sale and issuance of common stock", "verboseLabel": "Proceeds from issuance of common stock, net", "documentation": "The cash inflow from the additional capital contribution to the entity." } } }, "auth_ref": [ "r2" ] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementEquityComponentsAxis", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/Disclosure2022PublicOfferingDetails", "http://revbiosciences.com/20230930/taxonomy/role/Disclosure2023PublicOfferingDetails", "http://revbiosciences.com/20230930/taxonomy/role/DisclosureBusinessCombinationDetails", "http://revbiosciences.com/20230930/taxonomy/role/DisclosureCommonStockDetails", "http://revbiosciences.com/20230930/taxonomy/role/DisclosureCommonStockSummaryOfTotalSharesOfCommonStockReservedForIssuanceDetails", "http://revbiosciences.com/20230930/taxonomy/role/DisclosureCommonStockSummaryOfTotalSharesOfCommonStockReservedForIssuanceParentheticalDetails", "http://revbiosciences.com/20230930/taxonomy/role/DisclosurePipeInvestmentDetails", "http://revbiosciences.com/20230930/taxonomy/role/DisclosureSubsequentEventsDetails", "http://revbiosciences.com/20230930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails", "http://revbiosciences.com/20230930/taxonomy/role/DisclosureUnitsDetails", "http://revbiosciences.com/20230930/taxonomy/role/DisclosureWarrantsDetails", "http://revbiosciences.com/20230930/taxonomy/role/DisclosureWarrantsScheduleOfFairValueOfWarrantsEstimatedUsingBlackscholesOptionPricingModelDetails", "http://revbiosciences.com/20230930/taxonomy/role/DisclosureWarrantsTables", "http://revbiosciences.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfCashFlows", "http://revbiosciences.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": [ "r6", "r23", "r116", "r132", "r133", "r134", "r143", "r144", "r145", "r147", "r153", "r155", "r167", "r188", "r189", "r227", "r270", "r271", "r272", "r292", "r293", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r315", "r316", "r317", "r318", "r319", "r320", "r329", "r352", "r353", "r354", "r367", "r428" ] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesCurrent", "crdr": "credit", "calculation": { "http://revbiosciences.com/20230930/taxonomy/role/StatementConsolidatedBalanceSheets1": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/StatementConsolidatedBalanceSheets1" ], "lang": { "en-us": { "role": { "label": "Liabilities, Current", "totalLabel": "Total current liabilities", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": [ "r17", "r119", "r140", "r187", "r199", "r200", "r201", "r202", "r203", "r204", "r205", "r206", "r207", "r302", "r303", "r304", "r314", "r466", "r521", "r559", "r560" ] }, "us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromIssuanceOfConvertiblePreferredStock", "crdr": "debit", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DisclosurePreferredStockDetails" ], "lang": { "en-us": { "role": { "label": "Proceeds from Issuance of Convertible Preferred Stock", "terseLabel": "Net proceeds from issuance of preferred stock", "documentation": "The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock." } } }, "auth_ref": [ "r2" ] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetainedEarningsMember", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Retained Earnings [Member]", "terseLabel": "Accumulated Deficit", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r116", "r143", "r144", "r145", "r147", "r153", "r155", "r188", "r189", "r270", "r271", "r272", "r292", "r293", "r305", "r307", "r308", "r310", "r311", "r352", "r354", "r367", "r571" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Potential shares of common stock", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } }, "auth_ref": [ "r165" ] }, "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockCapitalSharesReservedForFutureIssuance", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DisclosureBusinessCombinationDetails", "http://revbiosciences.com/20230930/taxonomy/role/DisclosureCommonStockSummaryOfTotalSharesOfCommonStockReservedForIssuanceDetails", "http://revbiosciences.com/20230930/taxonomy/role/DisclosurePipeInvestmentDetails" ], "lang": { "en-us": { "role": { "label": "Common Stock, Capital Shares Reserved for Future Issuance", "terseLabel": "Common stock reserved for issuance", "verboseLabel": "Purchase of shares", "documentation": "Aggregate number of common shares reserved for future issuance." } } }, "auth_ref": [ "r22" ] }, "us-gaap_ClassOfWarrantOrRightTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightTable", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DisclosureWarrantsDetails", "http://revbiosciences.com/20230930/taxonomy/role/DisclosureWarrantsScheduleOfFairValueOfWarrantsEstimatedUsingBlackscholesOptionPricingModelDetails", "http://revbiosciences.com/20230930/taxonomy/role/DisclosureWarrantsTables" ], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right [Table]", "documentation": "Disclosure for warrants or rights issued, which includes the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable." } } }, "auth_ref": [ "r49" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DisclosureStockbasedCompensationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Awards outstanding", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number", "periodEndLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number, Ending Balance", "periodStartLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number, Beginning Balance", "documentation": "Number of equity instruments other than options outstanding, including both vested and non-vested instruments." } } }, "auth_ref": [ "r7", "r8" ] }, "us-gaap_ProceedsFromIssuanceInitialPublicOffering": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromIssuanceInitialPublicOffering", "crdr": "debit", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/Disclosure2022PublicOfferingDetails", "http://revbiosciences.com/20230930/taxonomy/role/Disclosure2023PublicOfferingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net proceeds received from public offering", "label": "Gross proceeds from initial public offering", "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public." } } }, "auth_ref": [ "r2" ] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "terseLabel": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "us-gaap_ProceedsFromConvertibleDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromConvertibleDebt", "crdr": "debit", "calculation": { "http://revbiosciences.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Proceeds from Convertible Debt", "terseLabel": "Proceeds from the Convertible Note", "documentation": "The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder." } } }, "auth_ref": [ "r24" ] }, "us-gaap_PropertyPlantAndEquipmentGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentGross", "crdr": "debit", "calculation": { "http://revbiosciences.com/20230930/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfPropertyAndEquipmentNetDetails": { "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfPropertyAndEquipmentNetDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Property, Plant and Equipment, Gross, Beginning Balance", "periodEndLabel": "Property, Plant and Equipment, Gross, Ending Balance", "label": "Property, Plant and Equipment, Gross", "terseLabel": "Total property and equipment, gross", "totalLabel": "Total property and equipment, gross", "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r85", "r121", "r347" ] }, "us-gaap_LongtermDebtTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongtermDebtTypeDomain", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/revb_r_CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "label": "Long-Term Debt, Type [Domain]", "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer." } } }, "auth_ref": [ "r19", "r40" ] }, "us-gaap_PrivatePlacementMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PrivatePlacementMember", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DisclosurePipeInvestmentDetails" ], "lang": { "en-us": { "role": { "label": "Private Placement [Member]", "netLabel": "Placement Agent Warrants [Member]", "verboseLabel": "Private Placement [Member]", "terseLabel": "Private Placement Warrants [Member]", "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts." } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "calculation": { "http://revbiosciences.com/20230930/taxonomy/role/StatementConsolidatedBalanceSheets1": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 1.0 }, "http://revbiosciences.com/20230930/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfPropertyAndEquipmentNetDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfPropertyAndEquipmentNetDetails", "http://revbiosciences.com/20230930/taxonomy/role/StatementConsolidatedBalanceSheets1" ], "lang": { "en-us": { "role": { "periodStartLabel": "Property, Plant and Equipment, Net, Beginning Balance", "periodEndLabel": "Property, Plant and Equipment, Net, Ending Balance", "label": "Property, Plant and Equipment, Net", "totalLabel": "Total property and equipment, net", "terseLabel": "Property and equipment, net", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r5", "r338", "r347", "r466" ] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesCurrentAbstract", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/StatementConsolidatedBalanceSheets1" ], "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current liabilities:" } } }, "auth_ref": [] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityComponentDomain", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/Disclosure2022PublicOfferingDetails", "http://revbiosciences.com/20230930/taxonomy/role/Disclosure2023PublicOfferingDetails", "http://revbiosciences.com/20230930/taxonomy/role/DisclosureBusinessCombinationDetails", "http://revbiosciences.com/20230930/taxonomy/role/DisclosureCommonStockDetails", "http://revbiosciences.com/20230930/taxonomy/role/DisclosureCommonStockSummaryOfTotalSharesOfCommonStockReservedForIssuanceDetails", "http://revbiosciences.com/20230930/taxonomy/role/DisclosureCommonStockSummaryOfTotalSharesOfCommonStockReservedForIssuanceParentheticalDetails", "http://revbiosciences.com/20230930/taxonomy/role/DisclosurePipeInvestmentDetails", "http://revbiosciences.com/20230930/taxonomy/role/DisclosureSubsequentEventsDetails", "http://revbiosciences.com/20230930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails", "http://revbiosciences.com/20230930/taxonomy/role/DisclosureUnitsDetails", "http://revbiosciences.com/20230930/taxonomy/role/DisclosureWarrantsDetails", "http://revbiosciences.com/20230930/taxonomy/role/DisclosureWarrantsScheduleOfFairValueOfWarrantsEstimatedUsingBlackscholesOptionPricingModelDetails", "http://revbiosciences.com/20230930/taxonomy/role/DisclosureWarrantsTables", "http://revbiosciences.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfCashFlows", "http://revbiosciences.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Equity Component [Domain]", "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": [ "r6", "r116", "r132", "r133", "r134", "r143", "r144", "r145", "r147", "r153", "r155", "r167", "r188", "r189", "r227", "r270", "r271", "r272", "r292", "r293", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r315", "r316", "r317", "r318", "r319", "r320", "r329", "r352", "r353", "r354", "r367", "r428" ] }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:" } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment, Policy [Policy Text Block]", "terseLabel": "Property and Equipment, Net", "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections." } } }, "auth_ref": [ "r5", "r109", "r112", "r345" ] }, "us-gaap_EquityMethodInvestmentOwnershipPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityMethodInvestmentOwnershipPercentage", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DisclosureBusinessCombinationDetails" ], "lang": { "en-us": { "role": { "label": "Equity Method Investment, Ownership Percentage", "verboseLabel": "Percentage of ownership", "terseLabel": "Ownership percentage", "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting." } } }, "auth_ref": [ "r184" ] }, "us-gaap_WarrantsAndRightsOutstandingMaturityDate": { "xbrltype": "dateItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WarrantsAndRightsOutstandingMaturityDate", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DisclosureWarrantsDetails" ], "lang": { "en-us": { "role": { "label": "Warrants and Rights Outstanding, Maturity Date", "terseLabel": "Warrant expiration date", "documentation": "Expiration date of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in YYYY-MM-DD format." } } }, "auth_ref": [ "r553" ] }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted-average shares used to compute net earnings per share, diluted", "label": "Weighted Average Number of Shares Outstanding, Diluted", "totalLabel": "Weighted Average Number of Shares Outstanding, Diluted, Total", "verboseLabel": "Weighted-average shares used to compute net (loss) earnings per share, diluted", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref": [ "r158", "r164" ] }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SignificantAccountingPoliciesTextBlock", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies1" ], "lang": { "en-us": { "role": { "label": "Significant Accounting Policies [Text Block]", "terseLabel": "Summary of Significant Accounting Policies", "documentation": "The entire disclosure for all significant accounting policies of the reporting entity." } } }, "auth_ref": [ "r83", "r138" ] }, "us-gaap_EarningsPerSharePolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerSharePolicyTextBlock", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "verboseLabel": "Basic and Diluted Net (Loss) Earnings per Share", "label": "Earnings Per Share, Policy [Policy Text Block]", "terseLabel": "Basic and Diluted Net Loss per Share", "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements." } } }, "auth_ref": [ "r33", "r34" ] }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DisclosureStockbasedCompensationTables" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]", "terseLabel": "Summary of Stock-Based Compensation Expense", "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement." } } }, "auth_ref": [ "r53" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DisclosureStockbasedCompensationAssumptionsUsedInEstimatingFairValueOfStockOptionsDetails", "http://revbiosciences.com/20230930/taxonomy/role/DisclosureWarrantsScheduleOfFairValueOfWarrantsEstimatedUsingBlackscholesOptionPricingModelDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term", "terseLabel": "Expected term (years)", "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r260" ] }, "us-gaap_DebtInstrumentPeriodicPaymentInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentPeriodicPaymentInterest", "crdr": "debit", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/revb_r_CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "label": "Debt Instrument, Periodic Payment, Interest", "terseLabel": "Monthly payable amount (in Dollars)", "documentation": "Amount of the required periodic payments applied to interest." } } }, "auth_ref": [ "r19" ] }, "us-gaap_DebtInstrumentPeriodicPayment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentPeriodicPayment", "crdr": "debit", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/revb_r_CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "label": "Debt Instrument, Periodic Payment", "terseLabel": "Monthly payments (in Dollars)", "totalLabel": "Debt Instrument, Periodic Payment, Total", "documentation": "Amount of the required periodic payments including both interest and principal payments." } } }, "auth_ref": [ "r19", "r63" ] }, "us-gaap_SegmentReportingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SegmentReportingPolicyPolicyTextBlock", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Segment Reporting, Policy [Policy Text Block]", "terseLabel": "Segment Reporting", "documentation": "Disclosure of accounting policy for segment reporting." } } }, "auth_ref": [ "r172", "r173", "r174", "r175", "r176", "r177", "r183", "r449" ] }, "us-gaap_UseOfEstimates": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UseOfEstimates", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Use of Estimates, Policy [Policy Text Block]", "terseLabel": "Use of Estimates", "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles." } } }, "auth_ref": [ "r35", "r36", "r37", "r106", "r107", "r110", "r111" ] }, "dei_AuditorLocation": { "xbrltype": "internationalNameItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditorLocation", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Auditor Location" } } }, "auth_ref": [ "r482", "r484", "r485" ] }, "dei_AuditorName": { "xbrltype": "internationalNameItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditorName", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Auditor Name" } } }, "auth_ref": [ "r482", "r484", "r485" ] }, "revb_ClassBPlacementAgentCommonStockWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://revbiosciences.com/20230930", "localname": "ClassBPlacementAgentCommonStockWarrantsMember", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/Disclosure2022PublicOfferingDetails", "http://revbiosciences.com/20230930/taxonomy/role/DisclosureCommonStockSummaryOfTotalSharesOfCommonStockReservedForIssuanceDetails", "http://revbiosciences.com/20230930/taxonomy/role/DisclosureCommonStockSummaryOfTotalSharesOfCommonStockReservedForIssuanceParentheticalDetails", "http://revbiosciences.com/20230930/taxonomy/role/DisclosureWarrantsDetails", "http://revbiosciences.com/20230930/taxonomy/role/DisclosureWarrantsScheduleOfFairValueOfWarrantsEstimatedUsingBlackscholesOptionPricingModelDetails", "http://revbiosciences.com/20230930/taxonomy/role/DisclosureWarrantsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Class B Placement Agent Common Stock Warrants [Member]", "label": "Class B Placement Agent Common Stock Warrants [Member]", "documentation": "Class B placement agent common stock warrants." } } }, "auth_ref": [] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsCurrentAbstract", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/StatementConsolidatedBalanceSheets1" ], "lang": { "en-us": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current assets:" } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/Disclosure2022PublicOfferingDetails", "http://revbiosciences.com/20230930/taxonomy/role/Disclosure2023PublicOfferingDetails", "http://revbiosciences.com/20230930/taxonomy/role/DisclosureCommonStockSummaryOfTotalSharesOfCommonStockReservedForIssuanceParentheticalDetails", "http://revbiosciences.com/20230930/taxonomy/role/DisclosurePipeInvestmentDetails", "http://revbiosciences.com/20230930/taxonomy/role/DisclosureWarrantsDetails" ], "lang": { "en-us": { "role": { "label": "Warrant exercise price, per share", "terseLabel": "Warrant exercise price (in Dollars per share)", "verboseLabel": "Purchase price, per share", "documentation": "Exercise price per share or per unit of warrants or rights outstanding." } } }, "auth_ref": [ "r226" ] }, "revb_AlternativeCashlessExerciseOfCommonStockWarrantsShares": { "xbrltype": "sharesItemType", "nsuri": "http://revbiosciences.com/20230930", "localname": "AlternativeCashlessExerciseOfCommonStockWarrantsShares", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "verboseLabel": "Alternative cashless exercise of common stock warrants", "terseLabel": "Alternative cashless exercise of common stock warrants (in Shares)", "label": "Alternative Cashless Exercise of Common Stock Warrants Shares", "documentation": "Alternative cashless exercise of common stock warrants shares." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "revb_OutstandingCommonStockPercentage": { "xbrltype": "percentItemType", "nsuri": "http://revbiosciences.com/20230930", "localname": "OutstandingCommonStockPercentage", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DisclosurePipeInvestmentDetails" ], "lang": { "en-us": { "role": { "label": "OutstandingCommonStockPercentage", "documentation": "Outstanding common stock, percentage.", "terseLabel": "Outstanding common stock, percentage" } } }, "auth_ref": [] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "crdr": "debit", "calculation": { "http://revbiosciences.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net increase in cash and cash equivalents", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect", "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r1", "r80" ] }, "revb_LesseeOperatingLeaseLiabilityBaseMonthlyRent": { "xbrltype": "monetaryItemType", "nsuri": "http://revbiosciences.com/20230930", "localname": "LesseeOperatingLeaseLiabilityBaseMonthlyRent", "crdr": "credit", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/revb_r_CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Base monthly rent", "label": "Lessee Operating Lease Liability Base Monthly Rent", "documentation": "Lessee operating lease liability base monthly rent." } } }, "auth_ref": [] }, "dei_AuditorFirmId": { "xbrltype": "nonemptySequenceNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditorFirmId", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Auditor Firm ID", "documentation": "PCAOB issued Audit Firm Identifier" } } }, "auth_ref": [ "r482", "r484", "r485" ] }, "revb_NumberOfUnitsSeperation": { "xbrltype": "sharesItemType", "nsuri": "http://revbiosciences.com/20230930", "localname": "NumberOfUnitsSeperation", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DisclosureUnitsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of units seperation", "label": "Number of Units Seperation", "documentation": "Number of units seperation." } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://revbiosciences.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash provided by financing activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": [ "r136" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DisclosureStockbasedCompensationDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage", "terseLabel": "Vesting percentage", "documentation": "Percentage of vesting of award under share-based payment arrangement." } } }, "auth_ref": [ "r525" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "Cash flows from financing activities:" } } }, "auth_ref": [] }, "revb_IncentiveStockOptionsMember": { "xbrltype": "domainItemType", "nsuri": "http://revbiosciences.com/20230930", "localname": "IncentiveStockOptionsMember", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DisclosureStockbasedCompensationDetails" ], "lang": { "en-us": { "role": { "documentation": "Incentive stock options.", "label": "Incentive Stock Options [Member]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://revbiosciences.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash used in investing activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": [ "r136" ] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "terseLabel": "Cash flows from investing activities:" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInOperatingActivities", "calculation": { "http://revbiosciences.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash used in operating activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": [ "r80", "r81", "r82" ] }, "revb_PlacementAgentCashFeeAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://revbiosciences.com/20230930", "localname": "PlacementAgentCashFeeAmount", "crdr": "debit", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/Disclosure2022PublicOfferingDetails", "http://revbiosciences.com/20230930/taxonomy/role/Disclosure2023PublicOfferingDetails" ], "lang": { "en-us": { "role": { "label": "Placement agent cash fee amount", "documentation": "Placement agent cash fee amount." } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Cash flows from operating activities:" } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightLineItems", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DisclosureWarrantsDetails", "http://revbiosciences.com/20230930/taxonomy/role/DisclosureWarrantsScheduleOfFairValueOfWarrantsEstimatedUsingBlackscholesOptionPricingModelDetails", "http://revbiosciences.com/20230930/taxonomy/role/DisclosureWarrantsTables" ], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "revb_WarrantsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://revbiosciences.com/20230930", "localname": "WarrantsTextBlock", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DisclosureWarrants1" ], "lang": { "en-us": { "role": { "documentation": "Warrants.", "label": "Warrants [Text Block]", "terseLabel": "Warrants" } } }, "auth_ref": [] }, "us-gaap_PaymentsOfStockIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsOfStockIssuanceCosts", "crdr": "credit", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DisclosurePipeInvestmentDetails" ], "lang": { "en-us": { "role": { "label": "Payments of Stock Issuance Costs", "verboseLabel": "Issuance costs", "terseLabel": "Issuance costs related to sale and issuance of common stock", "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security." } } }, "auth_ref": [ "r25" ] }, "us-gaap_SharesIssuedPricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharesIssuedPricePerShare", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/Disclosure2022PublicOfferingDetails", "http://revbiosciences.com/20230930/taxonomy/role/Disclosure2023PublicOfferingDetails", "http://revbiosciences.com/20230930/taxonomy/role/DisclosurePreferredStockDetails" ], "lang": { "en-us": { "role": { "label": "Shares Issued, Price Per Share", "terseLabel": "Price per units (in Dollars per share)", "verboseLabel": "Shares issued, price per share", "documentation": "Per share or per unit amount of equity securities issued." } } }, "auth_ref": [] }, "us-gaap_PreferredStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockSharesIssued", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DisclosurePreferredStockDetails", "http://revbiosciences.com/20230930/taxonomy/role/StatementConsolidatedBalanceSheetsParentheticals" ], "lang": { "en-us": { "role": { "label": "Preferred Stock, Shares Issued", "terseLabel": "Preferred stock, shares issued", "totalLabel": "Preferred Stock, Shares Issued, Total", "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt." } } }, "auth_ref": [ "r67", "r218" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Total", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "periodStartLabel": "Cash and cash equivalents at beginning of period", "periodEndLabel": "Cash and cash equivalents at end of period", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r28", "r80", "r137" ] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r488" ] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfStockholdersEquityAbstract", "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ClassOfStockDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfStockDomain", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DisclosureBusinessCombinationDetails", "http://revbiosciences.com/20230930/taxonomy/role/DisclosureCommonStockDetails", "http://revbiosciences.com/20230930/taxonomy/role/DisclosureCommonStockSummaryOfTotalSharesOfCommonStockReservedForIssuanceDetails", "http://revbiosciences.com/20230930/taxonomy/role/DisclosurePreferredStockDetails", "http://revbiosciences.com/20230930/taxonomy/role/DisclosureWarrantsDetails", "http://revbiosciences.com/20230930/taxonomy/role/StatementConsolidatedBalanceSheets1", "http://revbiosciences.com/20230930/taxonomy/role/StatementConsolidatedBalanceSheetsParentheticals", "http://revbiosciences.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfCashFlows", "http://revbiosciences.com/20230930/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquityDeficit", "http://revbiosciences.com/20230930/taxonomy/role/revb_r_CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "label": "Class of Stock [Domain]", "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock." } } }, "auth_ref": [ "r115", "r125", "r126", "r127", "r140", "r159", "r160", "r162", "r164", "r168", "r169", "r187", "r199", "r201", "r202", "r203", "r206", "r207", "r218", "r219", "r221", "r222", "r225", "r314", "r361", "r362", "r363", "r364", "r367", "r368", "r369", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r378", "r389", "r410", "r428", "r436", "r437", "r438", "r439", "r440", "r490", "r503", "r511" ] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "auth_ref": [] }, "us-gaap_PreferredStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockSharesAuthorized", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DisclosurePreferredStockDetails", "http://revbiosciences.com/20230930/taxonomy/role/StatementConsolidatedBalanceSheetsParentheticals" ], "lang": { "en-us": { "role": { "label": "Preferred Stock, Shares Authorized", "terseLabel": "Preferred stock, shares authorized", "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r67", "r389" ] }, "us-gaap_PreferredStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockSharesOutstanding", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/StatementConsolidatedBalanceSheetsParentheticals" ], "lang": { "en-us": { "role": { "label": "Preferred Stock, Shares Outstanding", "terseLabel": "Preferred stock, shares outstanding", "periodStartLabel": "Preferred Stock, Shares Outstanding, Beginning Balance", "periodEndLabel": "Preferred Stock, Shares Outstanding, Ending Balance", "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased." } } }, "auth_ref": [ "r67", "r389", "r407", "r571", "r572" ] }, "us-gaap_PreferredStockVotingRights": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockVotingRights", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DisclosurePreferredStockDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, votes", "label": "Preferred Stock, Voting Rights", "documentation": "Description of voting rights of nonredeemable preferred stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights." } } }, "auth_ref": [ "r45", "r67" ] }, "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DisclosureIncomeTaxesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Deferred Tax Assets", "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]", "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets." } } }, "auth_ref": [ "r97" ] }, "us-gaap_VestingAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "VestingAxis", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DisclosureStockbasedCompensationDetails" ], "lang": { "en-us": { "role": { "label": "Vesting [Axis]", "documentation": "Information by vesting schedule of award under share-based payment arrangement." } } }, "auth_ref": [ "r525", "r526", "r527", "r528", "r529", "r530", "r531", "r532", "r533", "r534", "r535", "r536", "r537", "r538", "r539", "r540", "r541", "r542", "r543", "r544", "r545", "r546", "r547", "r548", "r549", "r550" ] }, "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DisclosureIncomeTaxesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Provision for Income Taxes and Income Taxes Computed Using Effective U.S. Federal Statutory Rate", "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]", "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations." } } }, "auth_ref": [ "r96" ] }, "us-gaap_BusinessCombinationsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationsAbstract", "lang": { "en-us": { "role": { "label": "Business Combinations [Abstract]" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentTextBlock", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DisclosureBalanceSheetDetailsTables" ], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Table Text Block]", "terseLabel": "Schedule of Property and Equipment, Net", "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation." } } }, "auth_ref": [ "r5" ] }, "us-gaap_VestingDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "VestingDomain", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DisclosureStockbasedCompensationDetails" ], "lang": { "en-us": { "role": { "label": "Vesting [Domain]", "documentation": "Vesting schedule of award under share-based payment arrangement." } } }, "auth_ref": [ "r525", "r526", "r527", "r528", "r529", "r530", "r531", "r532", "r533", "r534", "r535", "r536", "r537", "r538", "r539", "r540", "r541", "r542", "r543", "r544", "r545", "r546", "r547", "r548", "r549", "r550" ] }, "us-gaap_ContractualObligation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ContractualObligation", "crdr": "credit", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/revb_r_CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Future obligations", "label": "Contractual Obligation", "totalLabel": "Contractual Obligation, Total", "documentation": "Amount of contractual obligation, including, but not limited to, long-term debt, lease obligation, purchase obligation, and other commitments." } } }, "auth_ref": [ "r506" ] }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockParOrStatedValuePerShare", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DisclosurePreferredStockDetails", "http://revbiosciences.com/20230930/taxonomy/role/StatementConsolidatedBalanceSheetsParentheticals" ], "lang": { "en-us": { "role": { "label": "Preferred Stock, Par or Stated Value Per Share", "terseLabel": "Preferred stock, par value (in Dollars per share)", "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer." } } }, "auth_ref": [ "r67", "r218" ] }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement [Policy Text Block]", "terseLabel": "Stock-based Compensation", "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost." } } }, "auth_ref": [ "r231", "r239", "r258", "r259", "r260", "r261", "r264", "r273", "r274", "r275", "r276" ] }, "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DisclosureBalanceSheetDetailsTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Accrued Liabilities [Table Text Block]", "terseLabel": "Schedule of Accrued Expenses", "documentation": "Tabular disclosure of the components of accrued liabilities." } } }, "auth_ref": [] }, "us-gaap_RestrictedStockUnitsRSUMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestrictedStockUnitsRSUMember", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DisclosureBusinessCombinationDetails", "http://revbiosciences.com/20230930/taxonomy/role/DisclosureStockbasedCompensationDetails", "http://revbiosciences.com/20230930/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockbasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restricted Stock Units (RSUs) [Member]", "verboseLabel": "Restricted Stock Units [Member]", "label": "Unvested RSU Awards [Member]", "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met." } } }, "auth_ref": [] }, "us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable", "presentation": [ "http://revbiosciences.com/20230930/taxonomy/role/DisclosurePipeInvestmentDetails" ], "lang": { "en-us": { "role": { "label": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]", "documentation": "Different names of stock transactions and the different attributes of each transaction." } } }, "auth_ref": [] } } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "13", "SubTopic": "10", "Topic": "480", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481766/480-10-25-13" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "4", "Subparagraph": "(SAB TOPIC 4.C)", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-4" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19-26)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.20)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.21)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.22)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.25)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.27(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.29)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.29-31)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-1" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-3" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-4" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-5" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481544/470-10-50-5" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "480", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(CFRR 211.02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480244/480-10-S99-1" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481142/505-10-45-2" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-10" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-11" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-4" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-5" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-8" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-1" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-12" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-13" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-3" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "820", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-2" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482949/835-30-55-8" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "210", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03.15(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "210", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03.17)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "470", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480848/942-470-50-3" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "825", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480981/942-825-50-1" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "985", "SubTopic": "20", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//205/tableOfContent" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r75": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r76": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r77": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r78": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.9)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r79": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13" }, "r80": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24" }, "r81": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r82": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r83": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "235", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//235/tableOfContent" }, "r84": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2" }, "r85": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r86": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "440", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//440/tableOfContent" }, "r87": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481284/470-20-25-10" }, "r88": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//505/tableOfContent" }, "r89": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6" }, "r90": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6" }, "r91": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-7" }, "r92": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r93": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "4", "Subparagraph": "(SAB Topic 4.C)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-4" }, "r94": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(e)(1)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r95": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(f)(2)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r96": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Paragraph": "12", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12" }, "r97": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2" }, "r98": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "805", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//805/tableOfContent" }, "r99": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//810/tableOfContent" }, "r100": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r101": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r102": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r103": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04.14)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r104": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "954", "SubTopic": "450", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480598/954-450-50-1" }, "r105": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2" }, "r106": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r107": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r108": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r109": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-1" }, "r110": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11" }, "r111": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12" }, "r112": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-6" }, "r113": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h))", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r114": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.22(a)(2))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r115": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(a)", "Publisher": "SEC" }, "r116": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6" }, "r117": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7" }, "r118": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r119": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5" }, "r120": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r121": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r122": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r123": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r124": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r125": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r126": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r127": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r128": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r129": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A" }, "r130": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B" }, "r131": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-1" }, "r132": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4" }, "r133": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5" }, "r134": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6" }, "r135": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r136": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24" }, "r137": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8" }, "r138": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-1" }, "r139": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r140": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r141": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r142": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3" }, "r143": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23" }, "r144": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24" }, "r145": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5" }, "r146": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r147": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r148": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r149": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r150": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3" }, "r151": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4" }, "r152": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r153": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r154": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8" }, "r155": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9" }, "r156": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 11.M.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480530/250-10-S99-5" }, "r157": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10" }, "r158": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16" }, "r159": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2" }, "r160": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-3" }, "r161": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r162": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r163": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7" }, "r164": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r165": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r166": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15" }, "r167": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1" }, "r168": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-1" }, "r169": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-3" }, "r170": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r171": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r172": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29" }, "r173": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29" }, "r174": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29" }, "r175": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482598/350-20-45-1" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//718/tableOfContent" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1D", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-1D" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-2" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-3" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(l)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.C.Q3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.1.Q5)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.2.Q6)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.3.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.F)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483044/730-10-05-1" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//740/tableOfContent" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-10B" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-25" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-28" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-14" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-19" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-20" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-21" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB TOPIC 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 11.C)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-2" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "270", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482526/740-270-50-1" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482603/740-30-50-2" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-5" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-5" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-2" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482900/835-30-50-1" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-1" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//855/tableOfContent" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "910", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(10)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-1" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-2" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(h)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-13" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-2" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "27", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-27" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483580/946-220-50-3" }, "r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r429": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r430": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r432": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r434": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r436": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-1" }, "r437": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r438": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r439": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r440": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r441": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "440", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1" }, "r442": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "976", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1" }, "r443": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "978", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1" }, "r444": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r445": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r446": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52" }, "r447": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r448": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31" }, "r449": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482785/280-10-55-47" }, "r450": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A" }, "r451": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482955/340-10-05-5" }, "r452": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482548/350-20-55-24" }, "r453": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r454": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B" }, "r455": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69C", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C" }, "r456": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69E", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69E" }, "r457": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69F", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69F" }, "r458": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r459": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-11" }, "r460": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-6" }, "r461": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8" }, "r462": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r463": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r464": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r465": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "53", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479589/842-20-55-53" }, "r466": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10" }, "r467": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F" }, "r468": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r469": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r470": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1" }, "r471": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1" }, "r472": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r473": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r474": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r475": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r476": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10" }, "r477": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11" }, "r478": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12" }, "r479": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r480": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r481": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r482": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r483": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r484": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r485": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r486": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r487": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r488": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r489": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" }, "r490": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-3" }, "r491": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-10" }, "r492": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-11" }, "r493": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-3" }, "r494": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12" }, "r495": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "SubTopic": "20", "Topic": "842", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3" }, "r496": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(1)", "SubTopic": "20", "Topic": "842", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r497": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//210/tableOfContent" }, "r498": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r499": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r500": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r501": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14" }, "r502": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r503": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r504": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(f))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r505": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r506": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3" }, "r507": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23" }, "r508": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24" }, "r509": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5" }, "r510": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4" }, "r511": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "55", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-55" }, "r512": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-18" }, "r513": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-13" }, "r514": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r515": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483032/340-10-45-1" }, "r516": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.A)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480341/340-10-S99-1" }, "r517": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r518": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r519": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10" }, "r520": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//450/tableOfContent" }, "r521": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r522": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r523": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r524": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2" }, "r525": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r526": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r527": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r528": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r529": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r530": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r531": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r532": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r533": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r534": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r535": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r536": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r537": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r538": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r539": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r540": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r541": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r542": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r543": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r544": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r545": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r546": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r547": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r548": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r549": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r550": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r551": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r552": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r553": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r554": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r555": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-4" }, "r556": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3" }, "r557": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3" }, "r558": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-2" }, "r559": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7" }, "r560": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7" }, "r561": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r562": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r563": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r564": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r565": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r566": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r567": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "912", "SubTopic": "730", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1" }, "r568": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(15)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r569": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4" }, "r570": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r571": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r572": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" } } }